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ABSTRACT  
   
Post Translational Modifications (PTMs) are a series of chemical modifications 
with the capacity to expand the structural and functional repertoire of proteins. PTMs can 
regulate protein-protein interaction, localization, protein turn-over, the active state of the 
protein, and much more. This can dramatically affect cell processes as relevant as gene 
expression, cell-cell recognition, and cell signaling. Along these lines, this Ph.D. thesis 
examines the role of two of the most important PTMs: glycosylation and 
phosphorylation.  
 In chapters 2, 3 and 4, a 10,000 peptide microarray is used to analyze the glycan 
variations in a series lipopolysaccharides (LPS) from Gram negative bacteria. This 
research was the first to demonstrate that using a small subset of random sequence 
peptides, it was possible to identify a small subset with the capacity to bind to the LPS of 
bacteria.  These peptides bound to LPS not only in the solid surface of the array but also 
in solution as demonstrated with surface plasmon resonance (SPR), isothermal titration 
calorimetry (ITC) and flow cytometry. Interestingly, some of the LPS binding peptides 
also exhibit antimicrobial activity, a property that is also analyzed in this work.  
In chapters 5 and 6, the role of protein phosphorylation, another PTM, is analyzed 
in the context of human cancer.  High risk neuroblastoma, a very aggressive pediatric 
cancer, was studied with emphasis on the phosphorylations of two selected oncoproteins: 
the transcription factor NMYC and the adaptor protein ShcC. Both proteins were isolated 
from high risk neuroblastoma cells, and a targeted-directed tandem mass spectrometry 
(LC-MS/MS) methodology was used to identify the phosphorylation sites in each protein. 
Using this method dramatically improved the phosphorylation site detection and 
  ii 
increased the number of sites detected up to 250% in comparison with previous studies. 
Several of the novel identified sites were located in functional domain of the proteins and 
that some of them are homologous to known active sites in other proteins of the same 
family. The chapter concludes with a computational prediction of the kinases that 
potentially phosphorylate those sites and a series of assays to show this phosphorylation 
occurred in vitro. 
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CHAPTER 1 
INTRODUCTION 
1  
From the sequencing of the human genome, we know that approximately 20 to 
25,000 genes can be found inside the human DNA(1). From this amount of material, it 
has been estimated that up to 100,000 different mRNA transcripts can be generated by 
means of different mechanism such as alternative promoters, differential transcription 
termination, alternative splicing of the transcripts, and others.(2) Human cells have the 
capacity of expanding this number even further to generate more than 1,000,000 different 
variations of proteins by using a series of chemical modifications known as Post 
Translational Modifications (PTMs)(3, 4). These modifications have the capacity of to 
expand not only the diversity but the functionality of the proteome as one single protein 
can be utilized for different purposes by means of these chemical changes.  
Some of these gained functions are, in fact, only possible because of specific 
characteristics of the modification. For example, the reversible addition of a phosphate, 
also known as phosphorylation, is the key mechanism behind intracellular cell 
communications. This process, which requires the fast transmission of chemical signals, 
is only possible because of the rapid addition and removal of phosphorylations by kinases 
and phosphatases.  
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Table 1.1. Some of the most common and relevant post translational modifications 
(adapted from Mann and Jensen 2003) 
PTM Function and notes 
Phosphorylation  Reversible, activation/inactivation of enzyme activity, modulation of 
molecular interactions, signaling 
Acetylation  Protein stability, protection of N terminus. Regulation of protein–DNA 
interactions (histones) 
Methylation Regulation of gene expression 
Glycosylation  Excreted proteins, cell–cell recognition/signaling O-GlcNAc, reversible, 
regulatory functions 
Sulfation Modulator of protein–protein and receptor–ligand interactions 
Disulfide bond 
formation 
Intra- and intermolecular crosslink, protein stability 
Deamination Possible regulator of protein–ligand and protein–protein  interactions, 
also a common chemical artifact 
Ubiquitination Destruction signal. After tryptic digestion, ubiquitination site is modified 
with the Gly-Gly dipeptide 
 
Some of the most common PTMs and their associated functions are presented in 
Table 1.1. From this variety of modifications, the present work focuses on two of them: 
glycosylations and phosphorylations.(5) 
Section 1.1 of this introduction focuses on the role of glycosylation in bacteria 
and its role as a determinant of bacterial serotype. It also covers the use of affinity-based 
technologies for the analysis of glycosylations.  This introduction forms the foundation 
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for Chapters 2, 3 and 4 where the analysis of glycans on the surface of gram negative 
bacteria is further expanded. 
Section 1.2 of this introduction focuses on the role of phosphorylation in the 
modulation of cell signaling with an emphasis on neuroblastoma, a severe type of 
pediatric cancer. The introduction preludes Chapters 5 and 6 where the development of a 
mass spectrometry methodology to identify novel phosphorylations in neuroblastoma 
proteins is presented. 
1.1 Glycans  
“Glycans” is the common designation of mono- or polysaccharides attached to 
proteins or lipids. In contrast to glyco-polymers, like glycogen that functions as energy 
storage, glycans perform multiple functions as structural units, enzymes, hormones, 
transporters, immunological agents, etc. Three major categories of glycans have been 
established: O-linked (i.e. bound to serine or threonine in proteins), N-Linked (i.e. bound 
to asparagine in proteins) and lipid bound. Glycans are structurally one of the most 
diverse molecules in biology. A typical glycan is composed of multiple carbohydrate 
moieties bound to each other through glycosidic linkage. This covalent binding can take 
place in multiple positions for each unit, which results in numerous possible 
combinations. Figure 1.1 presents a typical N-lined glycan visualized as a chemical 
structure, a word representation and a symbolic representation for simplicity.(6) 
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Figure 1.1. Representation of an N-linked glycan in its chemical, condense and symbolic 
form. (Taylor, Maureen E. Drickame. Kurt.  Introduction to Glycobiology, Oxford 
University Press, 2011) 
 
1.1.1 Glycosylation in Bacteria   
Glycosylation in bacteria can take place in different forms depending on the 
bacteria sub-type. 
Gram positive bacteria. The cell wall of gram positive bacteria is coated with 
teichoic acid. This polysaccharide provides structure and rigidity to the cell wall in the 
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absence of a second membrane, such as that present in gram negative bacteria.(7) The 
structure is illustrated in Figure 1.2. 
Gram negative bacteria. This type of bacteria has an inner and an outer cell 
membrane, and the space between them is connected by a dense peptidoglycan. The outer 
membrane is associated with capsular polysaccharides and  lipopolysaccharides(8,9). 
Mycobacteria. The cell membrane of this bacteria is composed of a thick layer of 
peptidoglycans interwoven with lipoarabinomannan and arabinogalactan and covered 
with trehalose-linked lipids(10) (Figure 1.2). This combination confers mycobacterium 
with unique permeability properties that allow them to elude a large set of antibiotic 
molecules.(11) 
The glycans on the surface of the three types of bacteria are closely linked to 
bacterial survival and pathogenicity. It has been observed that Gram positive bacteria 
lacking teichoic acid are also unable to colonize or infect their host(12). Gram negative 
bacteria with a truncated LPS lack the capacity to infect their host as they do not survive 
its immune system.(13). Gram (+) or gram (-) bacteria lacking peptide glycans do not 
survive osmotic changes(14). In a similar manner mycobacteria with a trehalose-deficient 
cell wall are unable to proliferate and enter the stationary phase, and they are also 
incapable of resisting thermic stress.(15)  
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Figure 1.2. Structure of the major glycolipids on the surface of bacteria. Gram positive 
bacteria contain teichoic acid and mycobacterium contain a trehalose-linked lipid. Gram 
negative bacteria contain a large lipopolysaccharide (LPS) of a more complex structure 
(presented in detail in the next figure).   
 
1.1.2 Lipopolysaccharides 
Bacterial lipopolysaccharides (LPS) are the major component of the outer 
membrane of gram negative bacteria(16). LPS has multiple functions: it protects bacteria 
from the immune system, it provides rigidity to the cell wall, and it induces host damage 
as a major component of toxic shock. 
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Figure 1.3. Lipopolysaccharide structure. From right to left, the innermost to the 
outermost components of LPS are the membrane embedded Lipid A, the core 
polysaccharide and the O-specific antigen. (From Alexander and Rietschel, 2001) 
 
As shown in Figure 1.3, LPS’s are constituted of 3 main units: 1) a lipid 
component embedded in the bacterial membrane that is commonly termed Lipid A. 2) a 
core region consisting of a polysaccharide unit of relatively conserved composition and 
3) a hyper variable polysaccharide region named O-antigen. Each of the three units has 
different characteristics and functions as detailed below:  
The lipid A is the main entity responsible of generating a strong immune 
response in humans. This response is mediated by Lipid A binding to Toll-like receptor 4, 
MD-2 and CD14. This event is the major component in the development of toxic shock 
syndrome.(17) 
The core carbohydrate unit, named core-antigen, is composed of 2 sections: the 
inner and the outer core. The inner core is the closest to the lipid A and is a much 
conserved unit composed of two uncommon pentoses: 3-deoxy-D-manno-octulosonic 
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acid (Kdo) and L-glycero-D-manno heptose (Hep). Kdo is an irreplaceable unit as it 
bridges the lipid A with the rest of the carbohydrates. The outer core is composed of 
more common hexoses and although its composition may change, it is mainly conserved 
between families of bacteria.(7)  
The O-antigen is the outer most section of LPS and is the most abundant 
component of the bacteria exposed to the outside. It is composed of multiple copies of a 
single polysaccharide unit that repeats up to 50 times.  The O-antigen is composed of 
multiple possible hexoses arranged in different combinations or modified by rings, 
substitutions or chemical linkage etc. Each strain of bacteria has a unique O-antigen 
composition but the divergence is smaller in strains belonging to the same families. In 
Figure 1.4, the O-antigen composition of three bacteria is compared side by side. Strains 
belonging to the same family (E coli) resemble each other in carbohydrate composition 
but differ in branching. In contrast P aeruginosa differ prominently in sugar 
composition.(18) 
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Figure 1.4. O-antigen composition of E. coli O111:B4, E. coli O55:B5 and P. aeruginosa 
10. The repeating unit of both E. coli is composed of five neutral monosaccharides: 
glucose (Glc), galactose (Gal), N-acetyl-galactosamine (GalNAc), N-acetylglucosamine 
(GlcNAc), and colitose (Col; 3,6-dideoxy-l-galactose). Both structures slightly vary in 
the branching but the overall sugar composition is the same.  The repeating unit of P. 
aeruginosa consists of three unusual sugars: 2-O-acetyl-l-rhamnose (RhaAc), 2-N-acetyl-
l-galacturonic acid (GalNA), and 2-N-acetyl-2,6-dideoxy-d-glucos-amine (QuiN). (From 
Morales Betanzos, C. et al 2009) 
 
The O-antigen has several unique characteristics and functions. It is essential for 
the survival of the bacteria in the host serum.(19) It protects the bacteria from phagocytes 
intake and from the activation of the complement system.(20,21) It protects the bacteria 
against bile acids and lipid A recognition antibodies.(22) In some commensal bacteria 
  10 
like H Pylori, N meningitis and H influenza, the O-antigen composition of the bacteria 
mimics the sugar composition of the host, which allows it to escape the immune 
system.(23-25) 
1.1.3 Glycosylation as a Serotyping Determinant in Bacteria 
 Serotypes are groups within a single species of bacteria that share distinctive 
surface antigens. The variety and composition of these antigens depends on the bacteria 
subtype. Some of the most common surface antigens are O-antigen (polysaccharide) and 
H antigen (flagella protein) in gram negative bacteria, and teichoic acid and other 
polysaccharides in gram positive bacteria. Serotypes are useful to differentiate different 
bacteria strains, for instance, highly pathogenic from non-pathogenic strains. For 
example, The Center for Control Disease has determined that from the 2,500 known 
serotypes of Salmonella, only 100 serotypes are infectious to humans. Serotyping is 
conducted through the use of antibodies recognizing specific antigens in the surface of 
bacteria. Glycans are the mayor determinants of bacterial serotypes. In gram negative 
bacteria, the antibody reaction to the O-antigens determine the serotype. In some cases 
the glycoproteins on the surface of the flagella (H-antigen) are used to complement the 
serotype distinction.  
1.1.4 Multiplexed Analysis of Glycan Variations 
Because polysaccharides are so diverse in composition and structural 
organization, the analysis of glycan variations is not an easy task. The structural analysis 
of glycans is conducted with a combination of enzymatic digestion and mass 
spectrometry. The first is directed to simplify the glycan into units of lower complexity 
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that can be then analyzed with MS. This process is, in the best case, laborious and 
requires the use of specialized enzymes for the different glycosydic bond types and the 
use of costly instrumentation. The data analysis is also hard as special attention should be 
taken to distinguish not only the components of the glycan but the structural information 
that accompanies the branching of the glycan as well. Because of the difficulties of this 
type of analysis, different techniques to approach glycan analysis have been pursued.  
Affinity based approaches have emerged as promising alternatives with higher 
throughput. In these approaches, a set of affinity reagents are immobilized in a solid 
platform (i.e. microarray) and use to interrogate glycol-conjugates of different 
composition or structures. The binding events between the affinity probes and the glycan 
are then quantified using fluorescence dyes, and the differences are catalogued. Different 
platforms containing lectins or antibodies have been created with this purpose.  
Lectin microarrays, illustrated in Figure 1.5, have been used successfully to 
analyze glycosylation patterns in glyco-proteins(26,27), to demonstrate changes in the 
glycoprotein composition during cell development and cancer (28-30) and to discriminate 
pathogenic from non-pathogenic bacteria(31). Antibody-based microarrays have been 
used to identify glycosylation changes in 2 serum proteins relevant for pancreatic 
cancer.(32) Some limitations of this approach are the small current repertoire of available 
lectins and carbohydrate binding antibodies. It has been estimated that although the 
number of glycan motifs range around 7000, only about 100 lectins are currently 
available.(27) The use of recombinant lectins, antibodies and other affinity reagents has 
been proposed as an alternative to cover this deficiency. 
 
  12 
 
Figure 1.5. Lectin microarray. A lectin microarray is interrogated with a labeled 
polysaccharide. Because of the promiscuous nature of lectins, several spots light up. 
Using a computational approach the binding affinities of the identified lectins are 
analyzed to deduce the identity of the polysaccharide. (From Rakus and Mahal, 2011) 
 
1.1.5 Peptide Microarray  
As an addition to the field of affinity-reagents-based platforms, the Center for 
Innovations in Medicine (CIM) at Arizona State University developed a novel peptide 
microarray. This platform consists of 10,000 random sequence peptide microarrays 
immobilized on a glass slide. The library of 20-mer peptides was synthesized using 
standard solid-phase methods utilizing 19 of the 20 natural amino acids, excluding 
cysteine. A terminal –GSC sequence was incorporated at the end of each peptide as a way 
to link the library to the glass slide using an NHS-ester and maleimide cross linker. 
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As part of the CIM-microarray program, we evaluated the capacity of the peptide 
microarray to discriminate small and large glycan variations. We utilized glycans from 
bacteria as an experimental model for 2 main reasons: 1) the biological key relevance of 
glycans for the pathogenicity and survival of bacteria. 2) The composition of glycans in 
the surface of bacteria is very similar between strains of the same family and diverges in 
members of different families. This property allowed us to study similar and very 
different glycan compositions by virtue of using close or distant family members of 
bacteria. 
1.1.6 Hypothesis 
The working hypothesis of this study was that owing to the large chemical 
diversity of the random peptide structures with no pre-conceived specificity, we could 
utilize the CIM-peptide microarray as an approach to identify novel lectin mimics with 
affinity toward bacterial glycans.  
As a proof of concept we labeled gram negative lipopolysaccharides (LPS) with 
highly fluorescent quantum nano-particles. Then we utilized these novel fluorescent 
probes to interrogate the peptide microarray in an attempt to identify novel LPS binding 
peptides. The synthesis of the novel LPS-nano particles is documented in Chapter 2 of 
this work, and the use of the fluorescent conjugates on the peptide microarray is 
presented in Chapter 3.  
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1.1.7 Specific Aims 
The specific aims of the project were:  
1. Synthesize a fluorescent probe using LPS from Gram negative bacteria 
and fluorescent nano particles.    
2. Using a 10,000 peptide microarray, identify a set of peptides that bind to 
three selected lipopolysaccharides from bacteria: two from E coli with 
similar glycan composition and one from a Pseudomonas Aeruginosa of 
divergent composition. 
3. Evaluate the binding affinity of the identified peptides using orthogonal 
binding assays (Surface Plasmon Resonance (SPR), isothermal 
calorimetry (ITC) and flow cytometry). 
4. Describe the biological properties of the selected list of peptides.  
1.2 Phosphorylations in Neuroblastoma 
1.2.1 Phosphorylation Chemistry 
Protein phosphorylation is one of the most important post-translational 
modifications. Phosphorylation is closely involved in the regulation of many cellular 
processes including growth, differentiation, apoptosis and several other signal 
transduction pathways. It has been calculated that as many as one third of the of the 
human proteins are phosphorylated at some point of their life cycle.(33) In eukaryotes 
reversible phosphorylation takes place in the side chain of three amino acids: Serine, 
Threonine and Tyrosine. All of them contain a nucleophilic group (-OH) that reacts with 
the terminal phosphate of ATP to transfer the phosphate into the amino acid residue. This 
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process is facilitated by protein kinases, which catalyze the reaction in the presence of 
magnesium (Figure 1.6).  
 
Figure 1.6. Protein phosphorylation reaction. The kinase initiates the reaction by 
transferring a proton to the Serine. Then the nucleophilic attack from the Serine group (-
OH) to the gamma-phosphate of ATP results in the phosphate transfer to the serine. ADP 
is produced as a by-product. 
 
The transfer of a phosphate group can results in a profound effect on the function 
of a protein. The addition of a double negative charge and the gained capacity to form 
hydrogen bonds are two of the major changes that this modification can produce. 
The results of this addition diverge greatly depending of the protein context. 
Phosphate groups can act as steric blocking groups(34,35), allosteric activators(36-38) or 
allosteric inhibitors(39,40). Phosphorylations can also regulate the protein recognition by 
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other protein domains such as SH2 or PTB (41,42) or induce the association(43,44) or 
dissociation(45,46) of protein-protein interactions. 
Phosphorylation addition is mediated by a group of proteins known as kinases that 
facilitate the transfer of the phosphate group from ATP to the proteins. To date, more 
than 500 human kinases have been identified. The collection of human kinases is 
commonly referred as the kinome has been divided in subfamilies, according to their 
catalytic domain. For example kinases phosphorylating tyrosine or serine/threonine 
residues(47). 
The counterpart to protein kinases are another group of proteins named 
phosphatases that are responsible for removing the phosphorylation group from selected 
protein residues. This group of approximately 150 proteins in humans takes the role of 
removing the phosphorylation from serine and threonine residues or from tyrosines using 
direct hydrolysis of the phosphorous atom by means of a Fe/Zn center (in Ser/Thr 
phosphatases) or using a covalent thiophosphoryl intermediate to facilitate the removal of 
the phosphate (in tyrosine phosphatases).(48-50)  
Kinases and phosphatases are thus the two balancing elements modulating the 
addition and removal of protein phosphorylation. Both of these reactions can occur at 
very fast rates, which makes protein phosphorylation a very dynamic process. (51-53)  
The versatility and the fast dynamics of protein phosphorylation make this post 
translational modification a recurring mechanism for the processing and communication 
of cell information, which is also designated as cell signal transduction.   
Signal transduction is characterized by a series of molecular events, commonly 
called cascades, which mediate the sensing and processing of cellular stimuli. These 
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molecular cascades detect, amplify and communicate diverse signals that result in cellular 
responses such as cell growth, gene expression, cell death and others.  The process 
typically starts when a sensing protein is activated by a stimulus (i.e. growth factor, 
hormone, drug, etc.) This initial signal is then communicated in the form of a kinase-
mediated phosphorylation, protein-protein interaction or dissociation that can activate 
even more downstream signals until the specific response is reached.  
This cascade of events can be rather complex as many cell events can be triggered 
by a single stimulus. For example, a single growth factor can initiate the activation of a 
whole cell proliferation program (54,55) or a single death factor can induce the release of 
an apoptosis program responsible for cell death(56-58). Figure 1.7 exemplifies the 
complexity of a single signaling pathway. In this case, the circuitry regulating the cell 
processes of growth and differentiation through the MAPK/ERK pathway is presented. 
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Figure 1.7. MAPK/ERK signaling pathway in cell growth and differentiation. The 
MAPK/Erk signaling cascade is activated by a wide variety of receptors involved in 
growth and differentiation including receptor tyrosine kinases (RTKs), integrins, and ion 
channels. The specific components of the cascade vary greatly among different stimuli, 
but the architecture of the pathway usually includes a set of adaptors (Shc, GRB2, Crk, 
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etc.) linking the receptor to a guanine nucleotide exchange factor (SOS, C3G, etc.) 
transducing the signal to small GTP-binding proteins (Ras, Rap1), which in turn activate 
the core unit of the cascade composed of a MAPKKK (Raf), a MAPKK (MEK1/2), and 
MAPK (Erk). An activated Erk dimer can regulate targets in the cytosol and also 
translocate to the nucleus where it phosphorylates a variety of transcription factors 
regulating gene expression. Illustration reproduced courtesy of Cell Signaling 
Technology, Inc. (www.cellsignal.com). 
 
The protein elements involved in the transduction of this signaling pathway can 
be categorized in several subtypes including receptors (brown), kinases (red), 
phosphatases (green), transcription factors (blue) and many other proteins covering 
multiple functions (grey). All of these elements interact in many different forms by 
inhibiting, activating or cooperating with each other.   
For the purpose of the present work, we focus on the role of two subtypes of cell 
signaling proteins: the transcription factors (i.e. c-MYC, NMYC, c-Fos, shown as blue in 
Figure 1.7) and the adaptor proteins (i.e. Shc, Grb2, shown as gray in Figure 1.7).  
Transcription factors (TF) are a group of proteins responsible for regulating 
gene expression. They do so by binding to DNA by themselves or as part of protein 
complexes and by promoting or repressing the binding of RNA polymerase to a specific 
gene sequence.  Transcription factors can be classified using their DNA binding 
motif(59). Large, well-established families include helix-turn-helix (HTH) proteins, 
homeodomains, zin finger proteins, leucine zipper proteins and helix-loop-helix (HLH) 
proteins. The regulation of TF takes place through several mechanisms including protein 
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synthesis, nuclear localization, ligand binding activation, phosphorylation, dimerization 
and others.(60,61) Cell signaling molecules commonly interact with TF to regulate their 
activity and though them induce a change in gene expression leading to a cell response.  
In Figure 1.8, the transcription factor TFIID binds to a promoter to start the formation of 
the transcription complex that in turn initiates gene expression (a). The initial step of the 
process is the binding of one of the TFIIB subunits: the TATA binding subunit (TBP) to 
DNA. This creates a morphological change of DNA that initiates the complex 
formation(b). It has been documented that the phosphorylation state of TBP is a potent 
regulator of TBP binding to DNA and of the overall transcription process.(62,63) 
 
a          b  
Figure 1.8. (a) After binding to the gene promoter, the transcription factor TFIID (green) 
triggers a large distortion of the DNA that serves as a physical landmark to assemble the 
transcription initiation complex. This assembly is composed of other transcription factors 
and the RNA polymerase. (b) TATA-Binding sub-unit (TBP) of the transcription factor 
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TFIID binding to DNA. Alberts, Bruce. Molecular Biology of the Cell. New York: 
Garland Science, 2008. 
 
Adaptor proteins are a group of molecules that participate in the midpoints of 
several cell signaling pathways. This group of proteins lacks in many cases enzymatic 
domains of their own. Instead, it contains several protein binding domains to support 
multiple protein-protein interactions. The main function of adaptor proteins is to interact 
with a cohort of multiple proteins to assemble an organized signaling complex.(64) These 
complexes can propagate and elicit appropriate responses that the individual members 
would not be able to do by themselves. The specificity of the signal is dictated by adaptor 
protein identity, its binding sequence, binding partners and cellular localization.(65) 
Adaptor proteins usually contain multiple binding domains within one single protein. 
These domains can bind to phosphorylated proteins like Phosphotyrosine Binding domain 
(PTB), Src Homology 2 and 3 (SH2, SH3), or to other molecules like Pleckstrin 
homology domain (PH) that binds to phosphatidylinositol in the cell membrane.(66) In 
addition to these common domains, several adaptor proteins contain other amino acid 
sequences and phosphorylation sites to harbor other protein interactions like SH3 and 
WW recognition sequences(64). In Figure 1.9, the adaptor protein Grb2 directs the 
interaction of three cell signaling proteins by means of its three binding domains. In 
addition to protein-protein interactions, Grb2 mediated cell signals can be modulated 
through phosphorylations.(67-69) 
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Figure 1.9. Adaptor protein Grb2 participates in the midst insulin cell signal. Grb2 
contains three distinctive domains that allow it to interact with IRS1 docking protein, 
GTPase-activating protein, Sos and a scaffold protein. Grb2 interactions can be also 
modulated via phosphorylation.  Alberts, Bruce. Molecular Biology of the Cell. New 
York: Garland Science, 2008. 
 
1.2.2 Abnormal Cell Signaling in Cancer 
Because cell signal transduction is involved in the regulation of the most 
important cellular processes, it should not be surprising to point out these signals are 
altered in cancer, a disease characterized by abnormal cell growth. The ways in which the 
cellular circuitry can be can be modified to induce tumors are relatively large. Abnormal 
cascades conferring self-sufficient cell growth are a classic example and a common find 
in several types of cancer(70-72).  Other signaling pathways commonly altered in cancer 
include apoptosis evasion, migration, limitless replication, and sustained 
angiogenesis.(73,74)   
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1.2.3 Neuroblastoma 
Neuroblastoma is a malignant tumor that arises from neural crest tissues, located 
mainly in the sympathetic chain and adrenal glands. It is the most common extracranial 
solid childhood tumor.  
Neuroblastoma is the most common extra cranial tumor in children. In the USA 
alone, it accounts for one case in every 70,000 live births.(75) According to the NCI the 
incidence of the disease is 10.54 cases per million per year in children younger than 15 
years.  
Neuroblastoma originates in early nerve cells called neuroblasts, which are part of 
the sympathetic nervous system (SNS). The SNS is part of the autonomous nervous 
system and includes:  
 The nerve fibers running along the spinal cord. 
 The clusters of nerves called ganglia present along the nerve fibers. 
 The inner nerve-like cells of the adrenal glands. These glands which 
produce a large number of hormones are located in the top of the kidneys.  
Neuroblastoma is accordingly found localized along any of these areas although, 
for the most aggressive cases, metastases are commonly found in other tissues. The 
image in Figure 1.10 shows one example of a localized neuroblastoma tumor as 
visualized by MIBG scan and CT scan.(76)  
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Figure 1.10. Supra-renal neuroblastoma tumor visualized with radio-labelled meta-
iodobenzylguanidine (MIBG) Scintigraphy (left) and with a CT scan (right). MIBG is 
commonly utilized for treatment and visualization of neuroblastoma. Copyright © 2014 
Raef Riad, Magdy Kotb, Walid Omar, Ahmed Zaher, Emad Ebied, Alexander Gregory 
Pitman, Hussein Abdel Dayem et al. This is an open access article distributed under the 
Creative Commons Attribution License, which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited. 
 
One of the hallmarks of Neuroblastoma is its heterogeneity. A patient with the 
disease can present very different scenarios ranging from a localized tumor that regresses 
spontaneously to a metastatic highly aggressive form that requires multi-modal treatment.  
Several studies have focused on understanding the molecular features that 
characterize the different forms of the disease. One of the most important markers of 
tumorigenicity was first identified by Kohl(77) and Schwab(78) in 1983 in the form of a 
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transcription factor named NMYC that was amplified in certain neuroblastomas. Soon 
after that, other groups linked the presence of the amplification with the most aggressive 
forms of the disease and this observation remains until now as the most important 
neuroblastoma marker.(79,80) Since then, the discovery of other pathological and 
molecular features have complemented NMYC and helped to stratify the diverse forms of 
the disease. The Children’s Oncology Group (COG) neuroblastoma risk stratification 
system is the scheme followed in North America for the classification of patients and 
selection of treatment.(81-84) This system takes into consideration the age of the patient, 
pathological evaluation (INPC), tumor extension (INSS), ploidy (number of 
chromosomes) and NMYC amplification to classify the neuroblastoma patients. The 
classification is defined in three groups, low, medium and high risk, which describes an 
increasing level of cancer aggressiveness and is treated more intensively.(85) Table 1.2 
shows the complete COG stratification system in low, medium and high risk 
neuroblastomas.(81-84) The International Neuroblastoma Staging System (INSS) score 
describes the propagation of the tumor in a range from 1 to 4 with the exception of 4S 
that represents a specific type of dissemination. The International Neuroblastoma 
Pathologic Classification (INPC) scores the tumor according to its degree of 
differentiation as evaluated by a pathologic examination. It is noticeable that from all the 
markers, NMYC amplification is the predominant factor that differentiates high risk 
neuroblastoma. This amplification invariably results in the most aggressive type of 
tumors, with the exception of a few localized tumors (see low risk INSS 1, 2 and 4S). 
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Table 1.2. Children’s Oncology Group (COG) Neuroblastoma risk stratification system.  
INPC = International Neuroblastoma Pathologic Classification; INSS = International 
Neuroblastoma Staging System. aDNA Ploidy: DNA Index (DI) > 1 is favorable, DI = 1 
is unfavorable; hypodiploid tumors (with DI < 1) will be treated as a tumor with a DI > 1 
(DI < 1 [hypodiploid] to be considered favorable ploidy) Stage 1 Localized tumor with 
complete gross excision, with or without microscopic residual disease. Stage 2A 
Localized tumor with incomplete gross excision; representative ipsilateral nonadherent 
lymph nodes negative for tumor microscopically. Stage 2B Localized tumor with or 
without complete gross excision, with ipsilateral nonadherent lymph nodes positive for 
tumor. Enlarged contralateral lymph nodes must be negative microscopically Stage 3 
Unresectable unilateral tumor infiltrating across the midline, with or without regional 
lymph node involvement; or localized unilateral tumor with contralateral regional lymph 
node involvement; or midline tumor with bilateral extension by infiltration (unresectable) 
or by lymph node involvement. The midline is defined as the vertebral column. Tumors 
originating on one side and crossing the midline must infiltrate to or beyond the opposite 
side of the vertebral column. Stage 4 Any primary tumor with dissemination to distant 
lymph nodes, bone, bone marrow, liver, skin, and/or other organs, except as defined for 
stage 4S. Stage 4S Localized primary tumor, as defined for stage 1, 2A, or 2B, with 
dissemination limited to skin, liver, and/or bone marrow (by definition limited to infants 
younger than 12 months). Marrow involvement should be minimal (i.e., <10% of total 
nucleated cells identified as malignant by bone biopsy or by bone marrow aspirate). More 
extensive bone marrow involvement would be considered stage 4 disease. The results of 
the mIBG scan, if performed, should be negative for disease in the bone marrow. 
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Low 
Risk  
INSS 
Stage   
Age   MYCN 
Status   
INPC 
Classification   
DNA Ploidya  
1 0–21 y Any Any Any 
2A/2B <365 d Any Any Any 
≥365 d–21 y Nonamplified Any - 
≥365 d–21 y Amplified Favorable - 
4S <365 d Nonamplified Favorable >1 
Medium 
Risk  
     
3 <365 d Nonamplified Any Any 
≥365 d–21 y Nonamplified Favorable - 
4 <548 d  Nonamplified Any Any 
4S <365 d Nonamplified Any =1 
<365 d Nonamplified Unfavorable Any 
High 
Risk 
     
2A/2B ≥365 d–21 y Amplified Unfavorable - 
3 <365 d Amplified Any Any 
≥365 d–21 y Nonamplified Unfavorable - 
≥365 d–21 y Amplified Any - 
4 <365 d Amplified Any Any 
≥548 d–21 y Any Any - 
4S <365 d Amplified Any Any 
 
High risk neuroblastoma. High risk neuroblastoma is the most aggressive form 
of neuroblastoma. In contrast to low and medium risk, which have a >95% survival rate 
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with minimum therapy, high risk neuroblastoma has a low survival rate and requires very 
intensive therapy.  
Therapy for high-risk neuroblastoma has 4 components: chemotherapy, local 
control with surgery and radiation therapy, consolidation chemotherapy with stem cell 
rescue and treatment of minimal residual disease with biologic agents. Despite this 
intensive therapy associated with significant side effects, the five-year event free survival 
for children with high-risk neuroblastoma is a dismal 20-30%.(86-89). New therapies are 
urgently needed. 
Target specific treatments for neuroblastoma. In the case of high risk 
neuroblastoma, therapeutic targets are starting to be identified. In a randomized trial 
conducted by the Children’s Oncology Group, patients treated with retinoic acid, a potent 
differentiating agent, had improvements in both event free survival and overall 
survival.(90-92) In another randomized trial conducted by the same group, patients 
treated with ch14.18 (a chimeric antibody to GD-2, an antigen found on neuroblastoma 
cells) had significantly better survival than patients who did not receive the antibody.(93) 
An understanding of the molecular biology of neuroblastoma will drive the rational 
development of new therapeutic agents to improve survival of this disease. 
The next frontier in oncologic therapy is the use of agents that target specific 
pathways of tumor growth and development. The classical example of this rational 
approach is imatinib, a tyrosine kinase inhibitor that revolutionized the treatment of 
Philadelphia positive acute lymphoblastic leukemia and chronic myeloid 
leukemia.(86,94) Imatinib (Gleevec) was discovered as a selective tyrosine kinase 
inhibitor of Bcr-Abl, a fusion protein that activates cell proliferation enzymes through 
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phosphorylation. This example illustrates the importance of target discovery as a prelude 
to finding new therapeutic agents.  
1.2.4 Molecular Factors Associated with Poor Prognosis in Neuroblastoma 
After more than 30 years of research since the identification of NMYC 
amplification, several other proteins have been correlated with the occurrence of high risk 
neuroblastoma; however NMYC has remained as the most important prognosis factor in 
neuroblastoma.  
Some of the most interesting proteins that have been identified as prognosis 
markers and/or potential therapeutic targets in neuroblastoma include the neutrophin 
receptor TrkA (NTRK1), the Anaplastic Lymphoma kinase (ALK), and (Src Homology 2 
Domain Containing) Transforming Protein 3 (ShcC).  
The expression of NTRK1 was correlated with good neuroblastoma prognosis. 
This receptor is believed to act through its involvement in apoptosis and cell 
differentiation.(95,96) In contrast, high expression of TrkB (NTRK2) correlated with 
poor prognosis and high risk neuroblastoma. TrkB is involved in the autocrine survival 
pathway.(97,98) 
ALK has been found either mutated or amplified in 10-15% of high risk 
neuroblastoma cancers. Its action mechanism in neuroblastoma has not been fully 
elucidated, but it has been hypothesized that it may act in a similar fashion to anaplastic 
large cell lymphoma (ALCL), where it is also amplified.(99,100)  
The expression of ShcC has been also correlated with poor outcome in high risk 
neuroblastoma.  ShcC inhibition in cells induced the differentiation of high risk 
neuroblastoma cells and decreased their growth rates. In addition, xerograph models of 
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ShcC neuroblastoma knockouts resulted in smaller tumors than wild type neuroblastoma 
cells. (101-103) 
In the present work, we focus our attention in the phosphorylation analysis of two 
of the aforementioned proteins: the transcription factor NMYC and the modulator protein 
ShcC. The selection of these two proteins was based in the following criteria: the 
expression of each protein correlates with the worst outcome cases of neuroblastoma, and 
both proteins have shown to be key modulators of neuroblastoma tumorigenicity.  
Additionally, both molecules belong to families of proteins where phosphorylation plays 
a central role in the regulation of their function. This is evident with the fact that several 
active phosphorylations have been identified in homologue proteins within their families. 
The characteristics of both families of proteins are described in the next sections.   
1.2.5 NMYC Transcription Factor   
The transcription factor NMYC (V-myc myelocytomatosis viral related 
oncogene) is a member of the MYC family of transcription factors that shares a common 
helix-loop-helix (bHLH) DNA binding domain. NMYC is localized in the nucleus of the 
cells and is highly expressed in neuronal tissue.  
NMYC amplification is the most important neuroblastoma oncoprotein. Its 
amplification was initially observed in 20% of neuroblastoma patients was soon linked to 
the most aggressive tumors (79,80). Since then, NMYC has been extensively described in 
literature as a major component of the tumorigenic cell signaling of 
neuroblastoma(104,105), medulloblastoma(106,107), rhabdomyosarcoma(108), 
neuroendocrine prostate cancer(109) and human acute myeloid leukemias(110). 
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MYC family of proteins. The MYC family of transcription factors is composed 
of three members: c-MYC, NMYC and MYCL1. The amplification of each of the three 
members of the family has been linked to different types of cancer. C-MYC amplification 
has been observed in colon cancer and leukemia cells (111,112). NMYC amplification is 
a notable hallmark of high risk neuroblastomas(113,114), and the MYCL1 amplification 
is consistent in lung cancer and ovarian carcinomas(115,116) .  
Mechanism of the MYC family of proteins. c-MYC is the prototypical MYC 
family member. Despite having been studied extensively for almost 30 years, the extent 
of its action mechanism was found to be very complex and is still being understood.  
Because c-MYC is the best described member of the MYC family, we use it to illustrate 
the most important features known to this group of proteins. It is currently well-
established that c-MYC can act as both a transcriptional activator and a repressor, 
although the former has been studied in more detail(117).  
As an activator of transcription, c-Myc depends on the formation of a protein 
complex with the protein binding partner MAX (Myc-associated factor X). c-MYC-MAX 
interaction takes place through the dimerization of the HLH-LZ domain present in the c-
terminal portion of both proteins. The MYC-MAX heterodimer has the capacity of 
binding to the CACGT E-box sequences found upstream of several promoter 
regions(118). The heterodimer binding to E-boxes is essential for the MYC mediated 
transformation (117) and generally (but not always) corresponds with the activation of 
gene expression(119). The c-MYC MAX complex activates transcription by different 
mechanisms that include several possible binding partners, with some of the most well-
described being TRRAP, INI1 and GCN-5.  TRRAP (Transformation/ transcription 
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domain associated protein) is an adapter protein essential for MYC transcription 
activation and concomitant cellular transformation(120). INI1(Integrase interactor 1), 
which is part of the SWI-SNF ATP-dependent chromatin remodeling model, also 
interacts with MYC-MAX and induces the ATP-dependent chromatin remodeling leading 
to changes in gene expression(121). C-MYC has been also identified to recruit GCN-5, 
which acetylates histone tails resulting in an open chromatin configuration and an 
increase in gene transcription(122).  MYC has also been found to directly promote the 
elevation of RNA polymerase II c-terminal domain levels, which may have also potential 
effects on gene transcription(123).    
As a transcriptional repressor, the MYC-MAX complex interacts with 
transcriptional activators bound directly to DNA and either recruits co-repressors or 
displaces co-activator proteins. Some of the known targets of this repression mechanism 
include nuclear factor Y (NFY)(124), the transcription factor SP1(125) and the MYC-
interacting zinc finger 1 (MIZ1) through the inhibition of nucleophosmin (NPM)(126).  
In contrast to other classical transcription factors that bind to a limited number of 
well-defined targets, c-MYC gene targets are broad. With the use of ChIP-PET and ChIP-
seq in combination with expression array data, several hundred MYC targets have been 
identified (127-130). It has been estimated that MYC can bind to approximately 10-15% 
of the genome and regulate encoding proteins and non-coding RNA products of several 
functions(127, 128). Several criteria have been stipulated to differentiate true MYC 
transcription targets from indirect binding targets. These results have been summarized 
by Dang et al in a MYC target database that utilizes those criteria and furthers separates 
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those MYC targets in functional classes, allowing the visualization of the whole MYC 
genetic program(131). 
MYC family function is mediated by phosphorylation. Of all the members of 
the MYC family, c-MYC is the protein that has been described in most detail. 27 
phosphorylation sites have been identified in c-MYC, and at least 15 of them have been 
linked to function(132). For example, In Burkitt’s lymphoma the phosphorylation of c-
MYC at T58 increases the half-time of the protein in two- to six-fold by inhibition of the 
ubiquitin-proteasome pathway(133). Phosphorylations at MYC-T58 and S62 also have 
been identified as essential for transactivation of gene expression by c-MYC, as mutation 
of these sites to alanine dramatically reduced transcription of downstream genes(134, 
135). Phosphorylations at MYC-S62 and S71 have been also identified as pro-apoptotic 
signals by JNK signaling(136). In leukemia, lymphoma prostate and pancreatic cancer c-
MYC is dramatically stabilized by Pim-1 and Pim-2. This stabilization takes places 
trough the phosphorylation at MYC-S329 by Pim-2 and at T58 by Pim-1(137). MYC-
S71, S81, T343, S344, S347 and S348 have been also identified as sites of negative 
regulation in c-MYC mediated cell transformation(138).  Pak-2 a Ser/Thr kinase that 
participates in cell stress interference with c-MYC binding to DNA by blocking the 
dimerization of c-MYC to MAX through MYC-S373 and T400 phosphorylation or by 
interfering with c-MYC binding to DNA trough T358 phosphorylation(139).   
Phosphorylation site comparison between MYC and NMYC. Although c-
MYC and NMYC share a 47% homology, hold the same protein domains and both are 
amplified in different cancer types(140-144), NMYC has not been studied in the same 
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detail. This difference is probably a result of the ubiquitous nature of c-MYC and the 
restricted expression of NMYC to few neuronal tissues.  
To date, only 6 phosphorylations sites have been identified in NMYC(132). From 
those, only two have been linked to function: NMYC-T58 and NMYC-S62 
phosphorylations increase the turn-over of NMYC in neuroblastoma cells by hindering 
the ubiquitin mediated degradation of the protein, thus stabilizing NMYC in 
neuroblastoma cells. This specific phosphorylation has been linked to the kinase Aurora 
A(145). 
Because several of the c-MYC phosphorylation sites have been directly linked to 
function in cancer and some of them even selected as therapeutic targets(138), it is very 
possible to imagine a similar scenario for NMYC where many other phosphorylation sites 
may be present in the protein with potential function in the tumorigenicity of neuronal 
cancers.   
1.2.6 ShcC Scaffold Protein  
ShcC has been recently associated with poor prognosis in neuroblastoma. ShcC is 
a scaffold protein normally involved in cell proliferation and development of normal 
neurons. In 2005, Terui et al. analyzed 52 neuroblastoma tumors from patients using 
semi-quantitative reverse transcription PCR and found that patients with high levels of 
ShcC mRNA had poor prognosis compared with patients with lower levels(103). In 2008, 
Miyake et al. also correlated the presence of ShcC with poor prognosis using western 
blot(102). The latter study evaluated the effect of ShcC knockdown in neuroblastoma 
differentiation and xenograft tumors in mice using RNA interference (RNAi) and showed 
that neuroblastoma cells treated with ShcC RNAi differentiated into neurites and were 
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less tumorigenic when injected into nude mice. This study suggests that ShcC inhibits 
neuroblastoma cell differentiation into neurites and may represent a potential target in the 
treatment of the disease.   
The Shc Family of Proteins. ShcC is one of the members of a family of 4 
scaffold proteins -- ShcA, ShcB, ShcC and ShcD -- that have very similar structures and 
functions but are present in different tissues. ShcA is ubiquitously expressed except in the 
central nervous system (CNS), whereas ShcB and ShcC are only found in the CNS. ShcD 
has been found only in adult brain and skeletal muscle.(146) 
Mechanism of the Shc Family of Proteins is Closely Mediated by Phosphorylation 
The Shc family of adaptor proteins connects and assembles the protein 
components of numerous signaling pathways. The individual members of the family 
ShcA, B, C or D may connect similar or totally different signaling cascades depending on 
the cell context. ShcA is the prototypical family member; it has been studied for almost 
20 years and is the member of the family for which the most signaling pathways have 
been described. Because the other family members have not been described in close 
detail, we utilize ShcA to exemplify the Shc family pathways; however, caution should 
be taken before extending these observations to the other family members. 
ShcA has been observed as a component of multiple signaling pathways, for 
example, the receptor tyrosine kinase signal (RTKs), specifically the EGFR/MAPK and 
the PI3K/AKT pathway. ShcA also mediates the EGFR independent activation of the 
RAS/MAPK in T-cells and B-lymphocytes. In a divergent side, ShcA is also involved in 
the signaling of Focal Adhesion Kinase (FAK) and the response of oxidative stress in 
apoptosis(147). 
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As part of the EGFR/MAPK, EGFR is auto-phosphorylated in less than 5 seconds 
of ligand stimulation(148). From the multiple resulting phosphorylations, EGFR-Y992, 
Y1148 and Y1173 interact with ShcA via its SH2 or PTB domains(149, 150). This 
interaction induces the phosphorylation of ShcA-Y317 that leads to the formation of a 
Grb2 binding motif (151). The ShcA-GrB2 complex then bind to SOS, a RAS exchange 
factor, via two SH3 domains and activates the MAPK cascade(152). ShcA also 
participates in a RAS independent activation of the MAPK pathways via 
phosphorylations at Y239/240, which stimulates the c-MYC transcription by an unknown 
mechanism (153). As an example of the non-EGFR activation of RAS cascade, ShcA 
connects the antigen recognition in T-cells to the RAS signaling pathway. This takes 
place after the T-cell receptor Complex (TCR) engages with antigen. CD3, a TCR 
subunit, phosphorylates and recruits the kinase ZAP-70. CD3 binds to the SH2 domain of 
ShcA while ZAP-70 binds the ShcA PTB domain, thus activating the RAS 
signaling(154). ShcA also participates in the signal transduction to MAPK induced by 
insulin in fibroblasts. This activity is mediated by ShcA binding to the PTP-_PEST 
phosphatase, which in turn is mediated by ShcA phosphorylation at Serine 129.(155). In a 
MAPK independent pathway, ShcA also participates in the pro-survival EGFR/ERK 
pathway in liver epithelia where it allows liver cells to survive under severe oxidative 
damage. This activity requires the phosphorylation of tyrosine ShcA residues Y349 and 
Y350 and is dominantly primarily regulated by the phosphorylation in the Serine 
36(156). 
Phosphorylation site comparison between ShcA and ShcC. The well-studied 
ShcA participates in several signaling pathways, and many of its phosphorylation sites 
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have been identified already. In contrast, much less is known about ShcC, for which only 
a few tyrosine phosphorylation sites have been identified. It is noticeable that no Serine 
or Threonine sites have been described yet. Presumably, the absence of good 
phosphoserine- or phosphothreonine-specific antibodies, compared to the availability of 
robust and specific phosphotyrosine antibodies, has made the study of these 
phosphorylation sites more difficult to study. It is for the same reason that the study of 
these two phosphorylation sites requires more sophisticated methods like mass 
spectrometry. Because ShcA and ShcC are very similar in structure (47% homology) and 
because they share similar functions as signal transducers, we propose that they may also 
share similar phosphorylation sites. Some of the most interesting phosphorylation sites in 
ShcA with sequence homologous is ShcC include ShcA S36 S54 Y315 S139 Y349 Y350 
(all of them with described function) which are homologous of S24, S35, S145, Y308 
Y341 Y342 (most of them not previously identified).  
Known ShcC phosphorylation sites. To date, several tyrosine phosphorylation 
sites in ShcC (Y341, Y342, Y379, Y380, Y406, Y424)(157, 158) and one kinase that 
phosphorylates them have been identified. This kinase, known as ALK, was measured in 
a set of 85 neuroblastoma samples but was only abnormally amplified in one of 
them(102). This finding suggests that other kinases may be involved in the activation of 
ShcC. In contrast to the tyrosine phosphorylations, the Serine and Threonine 
phosphorylation sites have not been studied in detail, homology studies between ShcA 
and ShcC suggest that there is still many possible active sites that remain unidentified, 
some of them located inside functional domains of the protein(132).  
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1.2.7 Hypothesis 
The working hypothesis of this work is that, similar to their well-described family 
members ShcA and c-MYC: 1) ShcC and NMYC are regulated by protein 
phosphorylations and that 2) by identifying these novel phosphorylation sites we can also 
identify novel mechanisms regulating high risk neuroblastoma. These mechanisms can in 
turn help to elucidate potential targets in the treatment of high risk neuroblastoma. To test 
our hypotheses, we divide our study into two specific aims: 
1.2.8 Specific Aim 1 
Specific Aim 1 is to identify all the amino acid sites in NMYC and ShcC that can 
be phosphorylated in high risk neuroblastoma human cells and tissue samples. We 
pursued this goal by using liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) to characterize and compare all the phosphorylation sites in 
the proteins extracted from neuroblastoma cells and human tissue samples.  
The mass spectrometry experiments consisted of two different approaches. In a 
general approach, all the phosphoproteins from high-risk neuroblastoma cells were 
separated and digested, and their phosphopeptides concentrated and analyzed. In a target 
specific approach, NMYC and ShcC were immunoprecipitated first and purified through 
SDS-PAGE. Gel bands were then digested and phosphopeptides enriched and analyzed. 
A schematic of both methods is presented in Figure 1.11.  
The description of the technical development of this method and its application to 
detect novel phosphorylations in NMYC and ShcC is presented in Chapter 6. 
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Figure 1.11. Mass spectrometry strategy used to identify NMYC and ShcC 
phosphorylation in high risk neuroblastoma cells. A general approach and a targeted 
approach are alternatively utilized. 
 
1.2.9 Specific Aim 2 
Specific Aim 2 of our project is to describe the biological relevance of each 
phosphorylation site identified in NMYC and ShcC. This was accomplished by means of 
a homology comparison between the novel identified phosphorylation sites and the well-
described family members ShcA and c-MYC.  The analysis of the novel phosphorylation 
sites identified in both proteins is described in the Chapter 6.  
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In Chapter 5 a more detailed analysis of the novel NMYC phosphorylations is 
presented. In the same chapter we also conducted a series of computational predictions 
complemented with in vitro assays to identify the kinases involved in the phosphorylation 
of the novel NMYC sites identified.  
 
1.3 References 
1. Human, International. "Finishing the Euchromatic Sequence of the Human 
Genome." Nature,  (2004). 
 
2. Ayoubi, T. A. and W. J. Van De Ven. "Regulation of Gene Expression by 
Alternative Promoters." FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 10, no. 4 (1996): 453-460. 
 
3. Kannicht, C. and B. Fuchs. "Post-Translational Modif Ications of Proteins." Post-
Translational Modif ications of Proteins,  (2008). 
 
4. Walsh, C. T. and S. Garneau‐Tsodikova…. "Protein Posttranslational 
Modifications: The Chemistry of Proteome Diversifications." Angewandte 
Chemie …,  (2005). 
 
5. Mann, M. and O. N. Jensen. "Proteomic Analysis of Post-Translational 
Modifications." Nature biotechnology,  (2003). 
 
6. Taylor, M. E. and K. Drickamer. "Introduction to Glycobiology." Introduction to 
glycobiology,  (2011). 
 
7. Tra, V. N. and D. H. Dube. "Glycans in Pathogenic Bacteria–Potential for 
Targeted Covalent Therapeutics and Imaging Agents." Chemical 
Communications,  (2014). 
 
8. Silhavy, T. J., D. Kahne and S. Walker. "The Bacterial Cell Envelope." … Harbor 
perspectives in biology,  (2010). 
 
  41 
9. Morrison, D.C. and J.L. Ryan. Bacterial Endotoxic Lipopolysaccharides: Taylor 
& Francis, 1992. 
 
10. Daffé, M. and G. Etienne. "The Capsule of Mycobacterium Tuberculosis and Its 
Implications for Pathogenicity." Tubercle and Lung Disease 79,  (1999). 
 
11. Delphi, Chatterjee. "The Mycobacterial Cell Wall: Structure, Biosynthesis and 
Sites of Drug Action." Current Opinion in Chemical Biology 1,  (1997). 
 
12. Christopher, Weidenmaier, Peschel Andreas, Xiong Yan‐Qiong, A. Kristian 
Sascha , Dietz Klaus, R. Yeaman Michael  and S. Bayer Arnold "Lack of Wall 
Teichoic Acids in Staphylococcus Aureus Leads to Reduced Interactions with 
Endothelial Cells and to Attenuated Virulence in a Rabbit Model of 
Endocarditis." The Journal of Infectious Diseases 191,  (2005). 
 
13. Dasgupta, T., T. R. de Kievit, H. Masoud, E. Altman, J. C. Richards, I. 
Sadovskaya, D. P. Speert and J. S. Lam. "Characterization of Lipopolysaccharide-
Deficient Mutants of Pseudomonas Aeruginosa Derived from Serotypes O3, O5, 
and O6." Infect Immun 62, no. 3 (1994): 809-17. 
 
14. Chatterjee, A. N. and F. E. Young. "Regulation of the Bacterial Cell Wall: 
Isolation and Characterization of Peptidoglycan Mutants of Staphylococcus 
Aureus." Journal of bacteriology,  (1972). 
 
15. Woodruff, P. J., B. L. Carlson, B. Siridechadilok, M. R. Pratt, R. H. Senaratne, J. 
D. Mougous, L. W. Riley, S. J. Williams and C. R. Bertozzi. "Trehalose Is 
Required for Growth of Mycobacterium Smegmatis." Journal of Biological 
Chemistry 279,  (2004). 
 
16. Alexander, C. and E. T. Rietschel. "Invited Review: Bacterial 
Lipopolysaccharides and Innate Immunity." Journal of endotoxin research,  
(2001). 
 
17. Gallay, P., D. Heumann and D. Le. "Lipopolysaccharide-Binding Protein as a 
Major Plasma Protein Responsible for Endotoxemic Shock." Proceedings of the 
…,  (1993). 
 
18. Morales Betanzos, Carlos, Maria J. Gonzalez-Moa, Kathryn W. Boltz, Brian D. 
Vander Werf, Stephen Albert Johnston and Sergei A. Svarovsky. "Bacterial 
  42 
Glycoprofiling by Using Random Sequence Peptide Microarrays." ChemBioChem 
10, no. 5 (2009): 877-888. 
 
19. Joiner, K. A., N. Grossman, M. Schmetz and L. Leive. "C3 Binds Preferentially to 
Long-Chain Lipopolysaccharide During Alternative Pathway Activation by 
Salmonella Montevideo." Journal of immunology (Baltimore, Md. : 1950) 136, 
no. 2 (1985): 710-715. 
 
20. Joiner, K. A. and M. M. Frank. "Mechanisms of Bacterial Resistance to 
Complement-Mediated Killing." The Pathogenesis of Bacterial Infections,  
(1985). 
 
21. Rautemaa, R. and S. Meri. "Complement-Resistance Mechanisms of Bacteria." 
Microbes and infection,  (1999). 
 
22. Gunn, J. S. "Mechanisms of Bacterial Resistance and Response to Bile." 
Microbes and infection,  (2000). 
 
23. Moran, A. P. and M. M. Prendergast. "Molecular Mimicry in< I> Campylobacter 
Jejuni</I> and< I> Helicobacter Pylori</I> Lipopolysaccharides: Contribution of 
Gastrointestinal Infections to Autoimmunity." Journal of autoimmunity,  (2001). 
 
24. Moran, A. P. and M. M. Prendergast…. "Molecular Mimicry of Host Structures 
by Bacterial Lipopolysaccharides and Its Contribution to Disease." FEMS 
Immunology & …,  (1996). 
 
25. Wim, C., B. C. Jacobs and J. D. Laman. "The Guillain–Barré Syndrome: A True 
Case of Molecular Mimicry." Trends in immunology,  (2004). 
 
26. Kuno, Atsushi, Noboru Uchiyama, Shiori Koseki-Kuno, Youji Ebe, Seigo 
Takashima, Masao Yamada and Jun Hirabayashi. "Evanescent-Field 
Fluorescence-Assisted Lectin Microarray: A New Strategy for Glycan Profiling." 
Nature methods 2, no. 11 (2005): 851-856. 
 
27. Rakus, J. F. and L. K. Mahal. "New Technologies for Glycomic Analysis: Toward 
a Systematic Understanding of the Glycome." Annual review of analytical 
chemistry,  (2011). 
 
  43 
28. Tao, Sheng-Ce C., Yu Li, Jiangbing Zhou, Jiang Qian, Ronald L. Schnaar, Ying 
Zhang, Irwin J. Goldstein, Heng Zhu and Jonathan P. Schneck. "Lectin 
Microarrays Identify Cell-Specific and Functionally Significant Cell Surface 
Glycan Markers." Glycobiology 18, no. 10 (2008): 761-769. 
 
29. Zheng, Ting, Dora Peelen and Lloyd M. Smith. "Lectin Arrays for Profiling Cell 
Surface Carbohydrate Expression." Journal of the American Chemical Society 
127, no. 28 (2005): 9982-9983. 
 
30. Chen, Siyuan, Ting Zheng, Michael R. Shortreed, Caroline Alexander and Lloyd 
M. Smith. "Analysis of Cell Surface Carbohydrate Expression Patterns in Normal 
and Tumorigenic Human Breast Cell Lines Using Lectin Arrays." Analytical 
chemistry 79, no. 15 (2007): 5698-5702. 
 
31. Hsu, Ku-Lung L., Kanoelani T. Pilobello and Lara K. Mahal. "Analyzing the 
Dynamic Bacterial Glycome with a Lectin Microarray Approach." Nature 
chemical biology 2, no. 3 (2006): 153-157. 
 
32. Chen, S., T. LaRoche, D. Hamelinck and D. Bergsma…. "Multiplexed Analysis 
of Glycan Variation on Native Proteins Captured by Antibody Microarrays." 
Nature …,  (2007). 
 
33. Cohen, P. "The Regulation of Protein Function by Multisite Phosphorylation–a 25 
Year Update." Trends in biochemical sciences,  (2000). 
 
34. Lin, K., V. L. Rath, S. C. Dai, R. J. Fletterick and P. K. Hwang. "A Protein 
Phosphorylation Switch at the Conserved Allosteric Site in Gp." Science,  (1996). 
 
35. Welburn, J. P. I., J. A. Tucker, T. Johnson and L. Lindert…. "How Tyrosine 15 
Phosphorylation Inhibits the Activity of Cyclin-Dependent Kinase 2-Cyclin A." 
Journal of biological …,  (2007). 
 
36. Ho, C. K. and S. Shuman. "Distinct Roles for Ctd Ser-2 and Ser-5 
Phosphorylation in the Recruitment and Allosteric Activation of Mammalian 
Mrna Capping Enzyme." Molecular cell,  (1999). 
 
37. Lee, H., H. Mun, N. Lewis, M. Crouch and E. Culverston…. "Allosteric 
Activation of the Extracellular Ca2+-Sensing Receptor by L-Amino Acids 
Enhances Erk1/2 Phosphorylation." Biochem. J,  (2007). 
  44 
 
38. Yarden, Y. and J. Schlessinger. "Self-Phosphorylation of Epidermal Growth 
Factor Receptor: Evidence for a Model of Intermolecular Allosteric Activation." 
Biochemistry,  (1987). 
 
39. Bender, E. and B. Kadenbach. "The Allosteric Atp-Inhibition of Cytochrome< I> 
C</I> Oxidase Activity Is Reversibly Switched on by Camp-Dependent 
Phosphorylation." FEBS letters,  (2000). 
 
40. Latsis, T., B. Andersen and L. Agius. "Diverse Effects of Two Allosteric 
Inhibitors on the Phosphorylation State of Glycogen Phosphorylase in 
Hepatocytes." Biochem. J,  (2002). 
 
41. Kaneko, Tomonori, Rakesh Joshi, Stephan M. Feller and Shawn S. Li. 
"Phosphotyrosine Recognition Domains: The Typical, the Atypical and the 
Versatile." Cell communication and signaling : CCS 10, no. 1 (2011): 32. 
 
42. Wagner, Melany J., Melissa M. Stacey, Bernard A. Liu and Tony Pawson. 
"Molecular Mechanisms of Sh2- and Ptb-Domain-Containing Proteins in 
Receptor Tyrosine Kinase Signaling." Cold Spring Harbor perspectives in 
biology 5, no. 12 (2013). 
 
43. Khokhlatchev, A. V., B. Canagarajah and J. Wilsbacher…. "Phosphorylation of 
the Map Kinase Erk2 Promotes Its Homodimerization and Nuclear 
Translocation." Cell,  (1998). 
 
44. Zhang, X., J. Blenis, H. C. Li, C. Schindler and S. Chen-Kiang. "Requirement of 
Serine Phosphorylation for Formation of Stat-Promoter Complexes." Science,  
(1995). 
 
45. Marx, S. O., S. Reiken, Y. Hisamatsu and T. Jayaraman…. "Pka Phosphorylation 
Dissociates Fkbp12. 6 from the Calcium Release Channel (Ryanodine Receptor): 
Defective Regulation in Failing Hearts." Cell,  (2000). 
 
46. Rao, R., S. Basuroy, V. Rao, K. Karnaky and A. Gupta. "Tyrosine 
Phosphorylation and Dissociation of Occludin–Zo-1 and E-Cadherin–Β-Catenin 
Complexes from the Cytoskeleton by Oxidative Stress." Biochem. J,  (2002). 
 
  45 
47. Manning, G., D. B. Whyte, R. Martinez and T. Hunter…. "The Protein Kinase 
Complement of the Human Genome." Science,  (2002). 
 
48. Ingebritsen, T. S. and P. Cohen. "The Protein Phosphatases Involved in Cellular 
Regulation." European Journal of …,  (1983). 
 
49. Ingebritsen, T. S. and P. Cohen. "Protein Phosphatases: Properties and Role in 
Cellular Regulation." Science,  (1983). 
 
50. Jackson, M. D. and J. M. Denu. "Molecular Reactions of Protein Phosphatases 
Insights from Structure and Chemistry." Chemical Reviews,  (2001). 
 
51. Heinrich, R., B. G. Neel and T. A. Rapoport. "Mathematical Models of Protein 
Kinase Signal Transduction." Molecular cell,  (2002). 
 
52. Hunter, T. "Protein Kinases and Phosphatases: The Yin and Yang of Protein 
Phosphorylation and Signaling." Cell,  (1995). 
 
53. Kholodenko, Boris N. "Cell-Signalling Dynamics in Time and Space." Nature 
reviews Molecular cell biology 7, no. 3 (2006): 165-176. 
 
54. Cattaneo, E. and R. McKay. "Proliferation and Differentiation of Neuronal Stem 
Cells Regulated by Nerve Growth Factor." Nature,  (1990). 
 
55. Guo, D., Q. Jia, H. Y. Song and R. S. Warren…. "… Cell Growth Factor 
Promotes Tyrosine Phosphorylation of Mediators of Signal Transduction That 
Contain Sh2 Domains Association with Endothelial Cell Proliferation." Journal of 
Biological …,  (1995). 
 
56. Chaudhary, P. M., M. Eby, A. Jasmin and A. Bookwalter…. "Death Receptor 5, a 
New Member of the Tnfr Family, and Dr4 Induce Fadd-Dependent Apoptosis and 
Activate the Nf-Κb Pathway." Immunity,  (1997). 
 
57. Lavrik, I., A. Golks and P. H. Krammer. "Death Receptor Signaling." Journal of 
Cell Science,  (2005). 
 
58. Thorburn, A. "Death Receptor-Induced Cell Killing." Cellular signalling,  (2004). 
  46 
 
59. Wingender, E., T. Schoeps and J. Dönitz. "Tfclass: An Expandable Hierarchical 
Classification of Human Transcription Factors." Nucleic acids research,  (2013). 
 
60. Brivanlou, A. H. and J. E. Darnell. "Signal Transduction and the Control of Gene 
Expression." Science,  (2002). 
 
61. Karin, M. and T. Hunter. "Transcriptional Control by Protein Phosphorylation: 
Signal Transmission from the Cell Surface to the Nucleus." Current Biology,  
(1995). 
 
62. Gottesfeld, J. M., V. J. Wolf, T. Dang, D. J. Forbes and P. Hartl. "Mitotic 
Repression of Rna Polymerase Iii Transcription in Vitro Mediated by 
Phosphorylation of a Tfiiib Component." Science,  (1994). 
 
63. Maldonado, E. and J. E. Allende. "Phosphorylation of Yeast Tbp by Protein 
Kinase Ck2 Reduces Its Specific Binding to DNA." FEBS letters,  (1999). 
 
64. Pawson, T. and J. D. Scott. "Signaling through Scaffold, Anchoring, and Adaptor 
Proteins." Science,  (1997). 
 
65. Flynn, D. C. "Adaptor Proteins." Oncogene 20, no. 44 (2001): 6270-6272. 
 
66. Salim, K., M. J. Bottomley, E. Querfurth and M. J. Zvelebil…. "Distinct 
Specificity in the Recognition of Phosphoinositides by the Pleckstrin Homology 
Domains of Dynamin and Bruton's Tyrosine Kinase." The EMBO …,  (1996). 
 
67. Li, S., A. D. Couvillon and B. B. Brasher…. "Tyrosine Phosphorylation of Grb2 
by Bcr/Abl and Epidermal Growth Factor Receptor: A Novel Regulatory 
Mechanism for Tyrosine Kinase Signaling." The EMBO journal,  (2001). 
 
68. Schlaepfer, D. D. and T. Hunter. "Evidence for in Vivo Phosphorylation of the 
Grb2 Sh2-Domain Binding Site on Focal Adhesion Kinase by Src-Family Protein-
Tyrosine Kinases." Molecular and cellular biology,  (1996). 
 
69. Skolnik, E. Y., A. Batzer, N. Li, C. H. Lee and E. Lowenstein…. "The Function 
of Grb2 in Linking the Insulin Receptor to Ras Signaling Pathways." Science,  
(1993). 
  47 
 
70. Bollag, G., D. W. Clapp, S. Shih, F. Adler and Y. Y. Zhang…. "Loss of Nf1 
Results in Activation of the Ras Signaling Pathway and Leads to Aberrant Growth 
in Haematopoietic Cells." Nature …,  (1996). 
 
71. Normanno, N., A. De, C. Bianco and L. Strizzi…. "Epidermal Growth Factor 
Receptor (Egfr) Signaling in Cancer." Gene,  (2006). 
 
72. Yang, X., L. Long and M. Southwood…. "Dysfunctional Smad Signaling 
Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial 
Pulmonary Arterial Hypertension." Circulation …,  (2005). 
 
73. Hanahan, D. and R. A. Weinberg. "The Hallmarks of Cancer." cell,  (2000). 
 
74. Hanahan, D. and R. A. Weinberg. "Hallmarks of Cancer: The Next Generation." 
Cell,  (2011). 
 
75. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary 
CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, 
Cronin KA (eds). , "Seer Cancer Statistics Review, 1975-2011, National Cancer 
Institute.", National Cancer Institute. http://seer.cancer.gov/csr/1975_2011/, 
(accessed May 2014). 
 
76. Raef, Riad. "I-131 Mibg Therapy for Advanced Stage Iii & Iv Neuroblastoma." 
Journal of Cancer Therapy 02,  (2011). 
 
77. Kohl, N. E., N. Kanda, R. R. Schreck, G. Bruns, S. A. Latt, F. Gilbert and F. W. 
Alt. "Transposition and Amplification of Oncogene-Related Sequences in Human 
Neuroblastomas." Cell 35, no. 2 Pt 1 (1983): 359-367. 
 
78. Schwab, M., K. Alitalo, K. H. Klempnauer, H. E. Varmus, J. M. Bishop, F. 
Gilbert, G. Brodeur, M. Goldstein and J. Trent. "Amplified DNA with Limited 
Homology to Myc Cellular Oncogene Is Shared by Human Neuroblastoma Cell 
Lines and a Neuroblastoma Tumour." Nature 305, no. 5931 (1982): 245-248. 
 
79. Brodeur, G., R. Seeger, M. Schwab, H. Varmus and J. Bishop. "Amplification of 
N-Myc in Untreated Human Neuroblastomas Correlates with Advanced Disease 
Stage." Science,  (1984). 
  48 
 
80. Robert, C. Seeger, M. Brodeur Garrett, Sather Harland, Dalton Andree, E. Siegel 
Stuart, Y. Wong Kwan and Hammond Denman. "Association of Multiple Copies 
of the N-Myconcogene with Rapid Progression of Neuroblastomas." New 
England Journal of Medicine,  (1985). 
 
81. Cotterill, S. J., A. D. J. Pearson, J. Pritchard and A. B. M. Foot…. "Clinical 
Prognostic Factors in 1277 Patients with Neuroblastoma: Results of the European 
Neuroblastoma Study Group 'Survey'1982–1992." European journal of …,  
(2000). 
 
82. Look, A. T., F. A. Hayes, J. J. Shuster, E. C. Douglass, R. P. Castleberry, L. C. 
Bowman, E. I. Smith and G. M. Brodeur. "Clinical Relevance of Tumor Cell 
Ploidy and N-Myc Gene Amplification in Childhood Neuroblastoma: A Pediatric 
Oncology Group Study." Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 9, no. 4 (1991): 581-591. 
 
83. Monclair, T., G. M. Brodeur and P. F. Ambros…. "The International 
Neuroblastoma Risk Group (Inrg) Staging System: An Inrg Task Force Report." 
Journal of Clinical …,  (2009). 
 
84. Moroz, V., D. Machin, A. Faldum, B. Hero and T. Iehara…. "… over Three 
Decades in Outcome and the Prognostic Influence of Age-at-Diagnosis in Young 
Patients with Neuroblastoma: A Report from the International Neuroblastoma 
…." European journal of …,  (2011). 
 
85. Garrett, M. Brodeur. "Neuroblastoma: Biological Insights into a Clinical 
Enigma." Nature Reviews Cancer,  (2003). 
 
86. Druker, Brian J., François Guilhot, Stephen G. O'Brien, Insa Gathmann, Hagop 
Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John 
M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard 
L. Powell, Janice L. Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. 
Cornelissen, Timothy Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, 
John Shepherd, Giuseppe Saglio, Alois Gratwohl, Johan L. Nielsen, Jerald P. 
Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie 
Letvak, Richard A. Larson and Iris Investigators. "Five-Year Follow-up of 
Patients Receiving Imatinib for Chronic Myeloid Leukemia." The New England 
journal of medicine 355, no. 23 (2006): 2408-2417. 
 
  49 
87. Frappaz, D., J. Michon, C. Coze, C. Berger, E. Plouvier, C. Lasset, J. L. Bernard, 
J. L. Stephan, E. Bouffet, M. Buclon, V. Combaret, A. Fourquet, T. Philip and J. 
M. Zucker. "Lmce3 Treatment Strategy: Results in 99 Consecutively Diagnosed 
Stage 4 Neuroblastomas in Children Older Than 1 Year at Diagnosis." Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 
18, no. 3 (2000): 468-476. 
 
88. Garaventa, A., B. De Bernardi, C. Pianca, A. Donfrancesco, L. Cordero di 
Montezemolo, M. T. Di Tullio, S. Bagnulo, A. Mancini, M. Carli and A. Pession. 
"Localized but Unresectable Neuroblastoma: Treatment and Outcome of 145 
Cases. Italian Cooperative Group for Neuroblastoma." Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 11, no. 9 
(1993): 1770-1779. 
 
89. Garaventa, A., R. Rondelli, E. Lanino, S. Dallorso, G. Dini, F. Bonetti, A. 
Arrighini, N. Santoro, F. Rossetti, R. Miniero, M. Andolina, A. Amici, P. Indolfi, 
M. Lo Curto, C. Favre, P. Paolucci, A. Pession and B. De Bernardi. 
"Myeloablative Therapy and Bone Marrow Rescue in Advanced Neuroblastoma. 
Report from the Italian Bone Marrow Transplant Registry. Italian Association of 
Pediatric Hematology-Oncology, Bmt Group." Bone marrow transplantation 18, 
no. 1 (1996): 125-130. 
 
90. Matthay, Katherine K., C. P. Reynolds, Robert C. Seeger, Hiroyuki Shimada, E. 
S. Adkins, Daphne Haas-Kogan, Robert B. Gerbing, Wendy B. London and 
Judith G. Villablanca. "Long-Term Results for Children with High-Risk 
Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy 
Followed by 13-Cis-Retinoic Acid: A Children's Oncology Group Study." 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 27, no. 7 (2009): 1007-1013. 
 
91. Matthay, K. K., J. G. Villablanca, R. C. Seeger, D. O. Stram, R. E. Harris, N. K. 
Ramsay, P. Swift, H. Shimada, C. T. Black, G. M. Brodeur, R. B. Gerbing and C. 
P. Reynolds. "Treatment of High-Risk Neuroblastoma with Intensive 
Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-
Cis-Retinoic Acid. Children's Cancer Group." The New England journal of 
medicine 341, no. 16 (1999): 1165-1173. 
 
92. Villablanca, J. G., A. A. Khan, V. I. Avramis, R. C. Seeger, K. K. Matthay, N. K. 
Ramsay and C. P. Reynolds. "Phase I Trial of 13-Cis-Retinoic Acid in Children 
with Neuroblastoma Following Bone Marrow Transplantation." Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 
13, no. 4 (1995): 894-901. 
  50 
 
93. Yu, Alice L., Andrew L. Gilman, Fevzi M. Ozkaynak, Wendy B. London, Susan 
G. Kreissman, Helen X. Chen, Malcolm Smith, Barry Anderson, Judith G. 
Villablanca and Katherine K. Matthay. "Anti-Gd2 Antibody with Gm-Csf, 
Interleukin-2, and Isotretinoin for Neuroblastoma." New England Journal of 
Medicine 363, no. 14 (2010): 1324-1334. 
 
94. Ottmann, O. G. and H. Pfeifer. "Management of Philadelphia Chromosome–
Positive Acute Lymphoblastic Leukemia (Ph+ All)." ASH …,  (2009). 
 
95. Nakagawara, A. and M. Arima-Nakagawara…. "Association between High 
Levels of Expression of the Trk Gene and Favorable Outcome in Human 
Neuroblastoma." … England Journal of …,  (1993). 
 
96. Souza, D. R. V., S. S. Sanabani and Acmf Souza…. "Prognostic Impact of Mycn, 
Ddx1, Trka, and Trkc Gene Transcripts Expression in Neuroblastoma." Pediatric 
blood & …,  (2011). 
 
97. Light, J. E., H. Koyama, J. E. Minturn and R. Ho…. "Clinical Significance of 
Ntrk Family Gene Expression in Neuroblastomas." Pediatric blood & …,  (2012). 
 
98. Schramm, A., J. H. Schulte, K. Astrahantseff and O. Apostolov…. "Biological 
Effects of Trka and Trkb Receptor Signaling in Neuroblastoma." Cancer letters,  
(2005). 
 
99. Chen, Qing-Rong, Young K. Song, Li-Rong Yu, Jun S. Wei, Joon-Yong Chung, 
Stephen M. Hewitt, Timothy D. Veenstra and Javed Khan. "Global Genomic and 
Proteomic Analysis Identifies Biological Pathways Related to High-Risk 
Neuroblastoma." Journal of proteome research 9, no. 1 (2009): 373-382. 
 
100. Cole, K. A. and J. M. Maris. "New Strategies in Refractory and Recurrent 
Neuroblastoma: Translational Opportunities to Impact Patient Outcome." Clinical 
Cancer Research,  (2012). 
 
101. Miyake, Izumi, Yuko Hakomori, Yoko Misu, Hisaya Nakadate, Nobuo 
Matsuura, Michiie Sakamoto and Ryuichi Sakai. "Domain-Specific Function of 
Shcc Docking Protein in Neuroblastoma Cells." Oncogene 24, no. 19 (2005): 
3206-3215. 
 
  51 
102. Miyake, I., M. Ohira, A. Nakagawara and R. Sakai. "Distinct Role of Shcc 
Docking Protein in the Differentiation of Neuroblastoma." Oncogene 28, no. 5 
(2009): 662-673. 
 
103. Terui, Elena, Tadashi Matsunaga, Hideo Yoshida, Katsunori Kouchi, 
Hiroaki Kuroda, Tomoro Hishiki, Takeshi Saito, Shin-Ichi Yamada, Hiroshi 
Shirasawa and Naomi Ohnuma. "Shc Family Expression in Neuroblastoma: High 
Expression of Shcc Is Associated with a Poor Prognosis in Advanced 
Neuroblastoma." Clinical cancer research : an official journal of the American 
Association for Cancer Research 11, no. 9 (2005): 3280-3287. 
 
104. Huang, Miller and William A. Weiss. "Neuroblastoma and Mycn." Cold 
Spring Harbor Perspect. Med. 3, no. 10 (2013): A014415/1-A014415/22. 
 
105. Gustafson, W. C. and W. A. Weiss. "Myc Proteins as Therapeutic 
Targets." Oncogene 29, no. 9 (2010): 1249-1259. 
 
106. Heine, Vivi M., Markus Priller, Jason Ling, David H. Rowitch and Ulrich 
Schüller. "Dexamethasone Destabilizes Nmyc to Inhibit the Growth of Hedgehog-
Associated Medulloblastoma." Cancer research 70, no. 13 (2010): 5220-5225. 
 
107. Kenney, Anna M., Michael D. Cole and David H. Rowitch. "Nmyc 
Upregulation by Sonic Hedgehog Signaling Promotes Proliferation in Developing 
Cerebellar Granule Neuron Precursors." Development (Cambridge, England) 130, 
no. 1 (2002): 15-28. 
 
108. Barr, Frederic G. "New Treatments for Rhabdomyosarcoma: The 
Importance of Target Practice." Clin. Cancer Res. 18, no. 3 (2012): 595-597. 
 
109. Mosquera, Juan M., Himisha Beltran, Kyung Park, Theresa Y. 
MacDonald, Brian D. Robinson, Scott T. Tagawa, Sven Perner, Tarek A. Bismar, 
Andreas Erbersdobler, Rajiv Dhir, Joel B. Nelson, David M. Nanus and Mark A. 
Rubin. "Concurrent Aurka and Mycn Gene Amplifications Are Harbingers of 
Lethal Treatment-Related Neuroendocrine Prostate Cancer." Neoplasia (New 
York, N.Y.) 15, no. 1 (2012): 1-10. 
 
110. Kawagoe, H., A. Kandilci, T. A. Kranenburg and G. C. Grosveld. 
"Overexpression of N-Myc Rapidly Causes Acute Myeloid Leukemia in Mice." 
Cancer Res 67, no. 22 (2007): 10677-85. 
  52 
 
111. Alitalo, K., M. Schwab, C. C. Lin, H. E. Varmus and J. M. Bishop. 
"Homogeneously Staining Chromosomal Regions Contain Amplified Copies of 
an Abundantly Expressed Cellular Oncogene (C-Myc) in Malignant 
Neuroendocrine Cells from a Human Colon Carcinoma." Proceedings of the 
National Academy of Sciences of the United States of America 80, no. 6 (1983): 
1707-1711. 
 
112. Collins, Steven and Mark Groudine. "Amplification of Endogenous Myc-
Related DNA Sequences in a Human Myeloid Leukaemia Cell Line." Nature 
Publishing Group,  (1982). 
 
113. Bartram, C. R. and F. Berthold. "Amplification and Expression of the N-
Myc Gene in Neuroblastoma." European journal of pediatrics,  (1987). 
 
114. Kohl, N. E., N. Kanda, R. R. Schreck, G. Bruns and S. A. Latt…. 
"Transposition and Amplification of Oncogene-Related Sequences in Human 
Neuroblastomas." Cell,  (1983). 
 
115. Nau, M. M., B. J. Brooks, J. Battey, E. Sausville and A. F. Gazdar…. "L-
Myc, a New Myc-Related Gene Amplified and Expressed in Human Small Cell 
Lung Cancer." Nature,  (1985). 
 
116. Wu, R., L. Lin, D. G. Beer, L. H. Ellenson and B. J. Lamb…. 
"Amplification and Overexpression of the L-< I> Myc</I> Proto-Oncogene in 
Ovarian Carcinomas." The American journal of …,  (2003). 
 
117. Meyer, Natalie and Linda Z. Penn. "Reflecting on 25 Years with Myc." 
Nature reviews. Cancer 8, no. 12 (2008): 976-990. 
 
118. Fisher, F., D. H. Crouch, P. S. Jayaraman and W. Clark…. "Transcription 
Activation by Myc and Max: Flanking Sequences Target Activation to a Subset of 
Cacgtg Motifs in Vivo." The EMBO …,  (1993). 
 
119. Eilers, M. and R. N. Eisenman. "Myc's Broad Reach." Genes & 
development,  (2008). 
 
  53 
120. McMahon, S. B., H. A. Van and K. A. Dugan…. "The Novel Atm-Related 
Protein Trrap Is an Essential Cofactor for the C-Myc and E2f Oncoproteins." Cell,  
(1998). 
 
121. Cheng, S. W. G., K. P. Davies, E. Yung, R. J. Beltran and J. Yu…. "C-
Myc Interacts with Ini1/Hsnf5 and Requires the Swi/Snf Complex for 
Transactivation Function." Nature …,  (1999). 
 
122. McMahon, S. B., M. A. Wood and M. D. Cole. "The Essential Cofactor 
Trrap Recruits the Histone Acetyltransferase Hgcn5 to C-Myc." Molecular and 
cellular biology,  (2000). 
 
123. Cowling, V. H. and M. D. Cole. "The Myc Transactivation Domain 
Promotes Global Phosphorylation of the Rna Polymerase Ii Carboxy-Terminal 
Domain Independently of Direct DNA Binding." Molecular and cellular biology,  
(2007). 
 
124. Wanzel, M., S. Herold and M. Eilers. "Transcriptional Repression by 
Myc." Trends in cell biology,  (2003). 
 
125. Kleine-Kohlbrecher, D., S. Adhikary and M. Eilers. "Mechanisms of 
Transcriptional Repression by Myc." … Myc/Max/Mad Transcription …,  (2006). 
 
126. Lüscher, B., E. A. Kuenzel, E. G. Krebs and R. N. Eisenman. "Myc 
Oncoproteins Are Phosphorylated by Casein Kinase Ii." The EMBO journal 8, no. 
4 (1989): 1111-1119. 
 
127. Patel, J. H., A. P. Loboda, M. K. Showe and L. C. Showe…. "Analysis of 
Genomic Targets Reveals Complex Functions of Myc." Nature Reviews …,  
(2004). 
 
128. Dang, C. V., K. A. O'Donnell, K. I. Zeller and T. Nguyen…. "The C-Myc 
Target Gene Network." Seminars in cancer …,  (2006). 
 
129. Levens, D. L. "Reconstructing Myc." Genes & development,  (2003). 
 
  54 
130. Zeller, K. I., X. D. Zhao and C. W. H. Lee…. "Global Mapping of C-Myc 
Binding Sites and Target Gene Networks in Human B Cells." Proceedings of the 
…,  (2006). 
 
131. Zeller, K. I., A. G. Jegga, B. J. Aronow and K. A. O'Donnell…. "An 
Integrated Database of Genes Responsive to the Myc Oncogenic Transcription 
Factor: Identification of Direct Genomic Targets." Genome …,  (2003). 
 
132. Hornbeck, Peter V., Jon M. Kornhauser, Sasha Tkachev, Bin Zhang, 
Elzbieta Skrzypek, Beth Murray, Vaughan Latham and Michael Sullivan. 
"Phosphositeplus: A Comprehensive Resource for Investigating the Structure and 
Function of Experimentally Determined Post-Translational Modifications in Man 
and Mouse." Nucleic acids research 40, no. Database issue (2011): 70. 
 
133. Gregory, M. A. and S. R. Hann. "C-Myc Proteolysis by the Ubiquitin-
Proteasome Pathway: Stabilization of C-Myc in Burkitt's Lymphoma Cells." 
Molecular and cellular biology,  (2000). 
 
134. Gupta, S., A. Seth and R. J. Davis. "Transactivation of Gene Expression 
by Myc Is Inhibited by Mutation at the Phosphorylation Sites Thr-58 and Ser-62." 
Proceedings of the National …,  (1993). 
 
135. Seo, H. R., J. Kim, S. Bae, J. W. Soh and Y. S. Lee. "Cdk5-Mediated 
Phosphorylation of C-Myc on Ser-62 Is Essential in Transcriptional Activation of 
Cyclin B1 by Cyclin G1." Journal of Biological Chemistry,  (2008). 
 
136. Noguchi, K., C. Kitanaka, H. Yamana and A. Kokubu…. "Regulation of 
C-Myc through Phosphorylation at Ser-62 and Ser-71 by C-Jun N-Terminal 
Kinase." Journal of Biological …,  (1999). 
 
137. Zhang, Y., Z. Wang, X. Li and N. S. Magnuson. "Pim Kinase-Dependent 
Inhibition of C-Myc Degradation." Oncogene 27, no. 35 (2008): 4809-4819. 
 
138. Wasylishen, Amanda R., Michelle Chan-Seng-Yue, Christina Bros, 
Dharmendra Dingar, William B. Tu, Manpreet Kalkat, Pak-Kei K. Chan, Peter J. 
Mullen, Ling Huang, Natalie Meyer, Brian Raught, Paul C. Boutros and Linda Z. 
Penn. "Myc Phosphorylation at Novel Regulatory Regions Suppresses 
Transforming Activity." Cancer research 73, no. 21 (2013): 6504-6515. 
 
  55 
139. Huang, Z., J. A. Traugh and J. M. Bishop. "Negative Control of the Myc 
Protein by the Stress-Responsive Kinase Pak2." Molecular and cellular biology,  
(2004). 
 
140. Dang, C. V. "Therapeutic Targeting of Myc-Reprogrammed Cancer Cell 
Metabolism." Cold Spring Harbor Symp. Quant. Biol. 76, no. Metabolism and 
Disease (2011): 369-374. 
 
141. Li, Bo and M. Celeste Simon. "Molecular Pathways: Targeting Myc-
Induced Metabolic Reprogramming and Oncogenic Stress in Cancer." Clin. 
Cancer Res. 19, no. 21 (2013): 5835-5841. 
 
142. Luescher, Bernhard and Joerg Vervoorts. "Regulation of Gene 
Transcription by the Oncoprotein Myc." Gene 494, no. 2 (2012): 145-160. 
 
143. Miller, Donald M., Shelia D. Thomas, Ashraful Islam, David Muench and 
Kara Sedoris. "C-Myc and Cancer Metabolism." Clin. Cancer Res. 18, no. 20 
(2012): 5546-5553. 
 
144. Swami, Meera. "Oncogenes: Adding More to the Myc Story." Nat. Rev. 
Cancer 10, no. 7 (2010): 455. 
 
145. Otto, T., S. Horn, M. Brockmann, U. Eilers and L. Schüttrumpf…. 
"Stabilization of N-Myc Is a Critical Function of Aurora a in Human 
Neuroblastoma." Cancer cell,  (2009). 
 
146. Jones, Nina, W. R. Hardy, Matthew B. Friese, Claus Jorgensen, Matthew 
J. Smith, Neil M. Woody, Steven J. Burden and Tony Pawson. "Analysis of a Shc 
Family Adaptor Protein, Shcd/Shc4, That Associates with Muscle-Specific 
Kinase." Molecular and cellular biology 27, no. 13 (2007): 4759-4773. 
 
147. Wills, Melanie K. and Nina Jones. "Teaching an Old Dogma New Tricks: 
Twenty Years of Shc Adaptor Signalling." The Biochemical journal 447, no. 1 
(2012): 1-16. 
 
148. Dengjel, Joern, Vyacheslav Akimov, Jesper V. Olsen, Jakob Bunkenborg, 
Matthias Mann, Blagoy Blagoev and Jens S. Andersen. "Quantitative Proteomic 
Assessment of Very Early Cellular Signaling Events." Nature biotechnology 25, 
no. 5 (2007): 566-568. 
  56 
 
149. Sakaguchi, K., Y. Okabayashi, Y. Kido, S. Kimura, Y. Matsumura, K. 
Inushima and M. Kasuga. "Shc Phosphotyrosine-Binding Domain Dominantly 
Interacts with Epidermal Growth Factor Receptors and Mediates Ras Activation 
in Intact Cells." Molecular endocrinology (Baltimore, Md.) 12, no. 4 (1998): 536-
543. 
 
150. Batzer, A. G., P. Blaikie, K. Nelson, J. Schlessinger and B. Margolis. "The 
Phosphotyrosine Interaction Domain of Shc Binds an Lxnpxy Motif on the 
Epidermal Growth Factor Receptor." Molecular and cellular biology 15, no. 8 
(1995): 4403-4409. 
 
151. Salcini, A. E., J. McGlade, G. Pelicci, I. Nicoletti and T. Pawson…. 
"Formation of Shc-Grb2 Complexes Is Necessary to Induce Neoplastic 
Transformation by Overexpression of Shc Proteins." Formation of Shc-Grb2 
complexes is necessary to induce neoplastic transformation by overexpression of 
Shc proteins,  (1994). 
 
152. Egan, S. E., B. W. Giddings, M. W. Brooks and L. Buday…. "Association 
of Sos Ras Exchange Protein with Grb2 Is Implicated in Tyrosine Kinase Signal 
Transduction and Transformation." Association of Sos Ras exchange protein with 
Grb2 is implicated in tyrosine kinase signal transduction and transformation,  
(1993). 
 
153. Gotoh, N., M. Toyoda and M. Shibuya. "… Sites at Amino Acids 239 and 
240 of Shc Are Involved in Epidermal Growth Factor-Induced Mitogenic 
Signaling That Is Distinct from Ras/Mitogen-Activated Protein Kinase …." 
Molecular and cellular biology,  (1997). 
 
154. Finetti, F., M. T. Savino and C. T. Baldari. "Positive and Negative 
Regulation of Antigen Receptor Signaling by the Shc Family of Protein 
Adapters." Immunological reviews,  (2009). 
 
155. Faisal, Amir, Mahmoud el-Shemerly, Daniel Hess and Yoshikuni 
Nagamine. "Serine/Threonine Phosphorylation of Shca. Regulation of Protein-
Tyrosine Phosphatase-Pest Binding and Involvement in Insulin Signaling." The 
Journal of biological chemistry 277, no. 33 (2002): 30144-30152. 
 
156. Arany, I., A. Faisal, Y. Nagamine and R. L. Safirstein. "P66shc Inhibits 
Pro-Survival Epidermal Growth Factor Receptor/Erk Signaling During Severe 
  57 
Oxidative Stress in Mouse Renal Proximal Tubule Cells." Journal of Biological 
…,  (2008). 
 
157. Heinrich, J. N., S. P. Kwak, D. S. Howland, J. Chen and S. Sturner…. 
"Disruption of Shca Signaling Halts Cell Proliferation—Characterization of Shcc 
Residues That Influence Signaling Pathways Using Yeast." Cellular signalling,  
(2006). 
 
158. Pelicci, G., F. Troglio, A. Bodini and R. M. Melillo…. "The Neuron-
Specific Rai (Shcc) Adaptor Protein Inhibits Apoptosis by Coupling Ret to the 
Phosphatidylinositol 3-Kinase/Akt Signaling Pathway." … and cellular biology,  
(2002). 
 
  58 
CHAPTER 2 
FACILE LABELING OF LIPOGLYCANS WITH QUANTUM DOTS 
 
Carlos Morales Betanzos, Maria Gonzalez-Moa, Stephen Albert Johnston, Sergei 
A. Svarovsky 
 
Reprinted from Biochemical and Biophysical Research Communications, 380, 
Carlos Morales Betanzos, Maria Gonzalez-Moa, Stephen Albert Johnston, Sergei A. 
Svarovsky, Facile labeling of lipoglycans with quantum dots, 1 - 4, Copyright (2009), 
with permission from Elsevier. 
 
2  
 
  
  59 
2.1 Contributions 
The following chapter describes the synthesis of a novel fluorescent conjugate of 
Lipopolysaccharides and Quantum dots.  Carlos Morales Betanzos designed the strategy 
for the conjugation of LPS-Quantum dots based on the in-situ formation of a ternary 
solvent system to allow the interaction between hydrophobic Quantum dots and 
hydrophilic LPS. Maria Gonzalez-Moa conducted the micelle size characterization by 
means of Dynamic Light Scattering (DLS). Carlos Morales Betanzos conducted the 
monocytes binding assays. Dr. David Lowry from the School of Life Sciences 
Bioimaging Facility obtained all the TEM images. Dr. Sergei Svarovsky and Dr. Stephen 
Johnston advised in the conduction of the experiments. Dr. Svarovsky , Dr. Gonzalez and 
Mr. Morales Betanzos wrote the manuscript. The results of this work were published in 
Biochemical and Biophysical Research Communications.  
2.2 Abstract 
Bacterial endotoxins or lipopolysaccharides (LPS) are among the most potent 
activators of the innate immune system, yet mechanisms of their action and in particular 
the role of glycans remain elusive. Efficient non-invasive labeling strategies are 
necessary for studying interactions of LPS glycans with biological systems. Here we 
report a new method for labeling LPS and other lipoglycans with luminescent quantum 
dots. The labeling is achieved by partitioning of hydrophobic quantum dots into the core 
of various LPS aggregates without disturbing the native LPS structure. The 
biofunctionality of the LPS–Qdot conjugates is demonstrated by the labeling of mouse 
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monocytes. This simple method should find broad applicability in studies concerned with 
visualization of LPS biodistribution and identification of LPS binding agents.  
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2.3 Introduction 
Bacterial lipopolysaccharides (LPS), also known as endotoxins, are the major 
constituents of the outer surface of Gram-negative bacteria [1]. They occupy up to 90% 
of the bacterial cell surface and are responsible for septic shock that kills nearly 200,000 
of critically ill patients in the US alone [2]. Not surprisingly, there is a great deal of 
interest in understanding mechanisms of LPS action for the developing of antisepsis 
drugs. The development of such agents depends on the availability of efficient labeling 
strategies for LPS molecules [3]. Ideally such labeling should be the least disruptive to 
the LPS functionality. 
LPSs are complex, negatively charged lipoglycans composed of three distinct 
regions: (a) a fatty acid region called Lipid A; (b) a core region oligosaccharide 
composed of approximately 10 monosaccharides; and (c) a highly variable O-antigenic 
polysaccharide responsible for much of the bacterial pathogenicity and 
immunospecificity. Most labeling strategies rely on chemical modification of LPS 
molecules with organic dyes and normally require complex manipulations and 
purification steps [4,5] due to the aggregative tendencies of LPS molecules [6]. The 
chemical modification is not site-specific and depends on the availability of reactive 
groups that are not always accessible or available in LPS [1]. If such groups are not 
present, they are chemically introduced by oxidation of the Oantigenic glycans [5,7]. By 
introducing additional moieties to the LPS molecule these methods perturb its physical 
properties and biomolecular recognition events [8], making such probes unlikely 
candidates for elucidating the roles of glycan interactions. 
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Nanometer-sized crystals of semiconductors known as quantum dots (Qdots) have 
recently emerged as useful luminescent labeling agents [9]. These nanoprobes have 
significant benefits over organic dyes including long-term photostability, high 
luminescent intensity, and multiple colors with single-wavelength excitation that open up 
possibilities for multiplex detection. Coating of hydrophobic quantum dots with 
phospholipids [10] and synthetic amphiphilic polymers have been described [11]. Both 
methods rely on phase transfer of hydrophobic quantum dots from an organic solvent to 
an aqueous solution of amphiphilic molecules. Here, we report an application of 
hydrophobic quantum dots to non-covalent labeling of LPS and its derivatives. We show 
that this method may be broadly applicable to other lipoglycans as well. This method 
takes advantage of the universal amphiphilic nature of lipoglycans and does not introduce 
any chemical modalities to the LPS structure, making it ideally suitable for studying 
glycan interactions. 
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2.4 Materials and Methods 
Unless otherwise noted, all chemicals were purchased from Sigma, Inc. 
(Milwaukee, WI) and used without further purification. Smooth type LPS from 
Escherichia coli (serotypes O111:B4 and O55:B5) and Pseudomonas aeruginosa (type 
10) were supplied by Sigma, Inc. (Milwaukee, WI). Lipid A was purchased from Avanti 
Polar Lipids (Alabaster, AL). FITC-labeled LPS from E. coli O111:B4 was from Sigma 
(cat# F3665). (Caution! LPS and Lipid A are pyrogens that may cause fever. It may be 
harmful if inhaled, ingested, or absorbed through skin. Good laboratory practice should 
be employed. Wear a lab coat, gloves, safety glasses and a respirator mask). Deionized 
water was obtained from a Millipore ultrapure water filtration unit. Organic Qdots were 
purchased from Invitrogen (Carlsbad, CA). Sepharcyl HiPrep 16/60 (S-200 HR) was 
from GE Healthcare. Transmission electron microscopy (TEM) was done on a Philips 
CM12S electron microscope operated at an accelerating voltage of 80 kV. Samples were 
deposited onto carbon-formvar mesh grids and images were recorded using a Gatan 
model 791 digital camera. In solution nanosizing and zeta potential measurements were 
done on Zetasizer® Nano-ZS instrument (Malvern Instruments, UK). Spectrophotometric 
measurements were carried out on NanoDrop® ND-1000 instrument. 
Labeling LPS with Qdots. The supplied solution of organic Qdots (QDot® 605 
ITK™, catalog #Q21701MP, Invitrogen, Inc.) in decane (1 μM) was evaporated to 
dryness on SpeedVac at room temperature and re-dissolved in equal amount of 
chloroform. A 100 μL aliquot of the chloroform solution was diluted to 500 μL with 
chloroform and mixed with 100 μL of 10 mg/mL aqueous solution of corresponding 
lipoglycan (E. coli O111:B4, E. coli O55:B5, P. aeruginosa 10, or Lipid A). Methanol 
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was added dropwise with occasional vortexing until complete mixing of both phases was 
achieved (400 μL of MeOH). This homogeneous mixture of 5/4/1 
chloroform/methanol/water was then evaporated to dryness on a SpeedVac and the solid 
residue was re-suspended in 100 μL of ddH2O. A saturated solution of 
tetramethylammonium hydroxide pentahydrate (Me4N
+OH-5H2O) was added until pH 11 
(ca. 25 μL). The solution was sonicated for 30 min and then passed through two 
consecutive Zeba columns (2 mL, Pierce) to remove salts and excess of free LPS. We 
further purified the LPS-coated Qdots by size-exclusion chromatography on Sepharcyl 
HiPrep 16/ 60 (S-200 HR) column (50 x 1 cm). The LPS–Qdots eluted in a narrow color 
band and were stored in the dark at 4 ˚C. Under these conditions, the LPS–Qdots are 
stable for at least one month without any visible signs of flocculation or deterioration in 
fluorescent intensity. In a control experiment, the above procedure was repeated without 
a lipoglycan; no solubilization of organic Qdots was observed in this case. 
Preparation of control PEG20K-QDots. 17.2 μL of 8 μM solution of amino 
QDots (QDot® 605 ITK™ amino(PEG) Quantum Dots, catalog #Q21501MP, Invitrogen, 
Inc.) were diluted with 200 μL of 100 mM sodium borate buffer pH = 8.5. To this 
solution, 27.5 μg of Traut’s reagent were added and the mixture was shaken at 750 rpm 
for 2 h at rt. Then, the buffer was exchanged with 300 μL of 1 x PBS by using a Zeba 
column (2 ml, Pierce). To the solution obtained, 2 mg of mPEG-maleimide 20 K 
(NEKTAR) was added and the mixture was reacted overnight at room temperature. 
Excess of mPEGmaleimide was eliminated by filtering the mixture through an Amicon 
Ultra-4 100 K centrifugal filter and washing two times with 1 x PBS. The solution 
obtained was used immediately as a control to label monocytes. 
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Monocytes culture. Mouse monocytes from the cell line RAW 264.7 (American 
Type Culture Collection, ATCC) were provided by Dr. Yung Chang from the Center of 
Infectious Diseases and Vaccinology at The Biodesign Institute at ASU. Monocytes were 
cultured in DMEM (Dulbecco Modified Eagle medium; GIBCO, Grand Island, NY, 
USA) with 10% (v/v) Fetal Calf Serum (FCS) at 37 ˚C in a 5% CO2 atmosphere and 95% 
humidity until confluence. 
Monocytes labeling. Monocytes were detached using non-enzymatic cell 
dissociation agent, (Cellstripper™ Cat # 25-056-CI, Mediatech Inc.) and washed twice 
with 1 x PBS. Elutriated monocytes (1 x 106) were incubated in polypropylene tubes with 
100 μg/mL of FITC conjugated E. coli O111:B4 LPS or the LPS equivalent of 
Biomimetic probe or QDots-PEG20K control, suspended in a final volume of 300 μL of 
HBSS (Hank’s Balanced Salt Solution, GIBCO, Grand Island, NY, USA). Incubation 
time was 1 h at 37 ˚C [12]. After incubation cells were washed twice, fixed with 1% 
paraformaldehyde solution and analyzed by flow cytometry (FACS Caliber, BD 
Biosciences Inc.). The same cell suspension was poured on to a poly(L-lysine)-coated 
glass slide, incubated 30 min at room temperature and analyzed using a fluorescence 
microscope (BX51, Olympus America Inc.). 
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2.5 Results and Discussion 
2.5.1 Labeling of Smooth-Type LPS 
Due to its amphipathic nature, LPS has strong tendency to form aggregates in 
solution [13]. The aggregation behavior depends on the concentration and the nature of 
the LPS molecule. Smooth-type LPS is believed to self-assemble into micellar structures 
of over 1 MDa [6]. This self-aggregation behavior is a function of the lipid A component 
of LPS molecule that also confers its ability to bind to hydrophobic surfaces. We 
exploited this ability for labeling LPS with luminescent quantum dots (Qdots) as shown 
schematically in Figure 2.1. 
 
 
Figure 2.1. (A) Lipid A-Qdots; (B) LPS–Qdots. m designates number of O-antigen 
repeating units; n, number of LPS molecules encapsulating the Qdot. 
 
Aqueous solution of LPS was mixed with a solution of organic Qdots in 
chloroform-methanol-water, evaporated, and re-suspended in basic aqueous solution. 
These steps resulted in the homogenous mixing of the hydrophobic constituents and 
incorporation of the Qdots into the LPS micelles. We followed the formation of Qdot–
LPS conjugates by the Dynamic Light Scattering (DLS). As an example, Figure 2.2 
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shows the size distribution during the labeling process of smooth-type LPS from E. coli 
O55:B5. The size of LPS micelles prior to labeling is represented by a broad peak with a 
hydrodynamic diameter of 100 nm, which agrees with previously reported values [13]. 
After mixing with Qdots and adding the base, the size of the newly formed Qdots–LPS 
aggregates is reduced to 50 nm. The basification process makes the LPS monomeric [4] 
favoring the access of the Qdots to the lipidic part of the LPS. Under the UV light, the 
Qdot particles can be seen quickly transitioning into the aqueous solution, which is only 
possible if the particles are taken up by the amphiphilic LPS. No luminescence is 
observed in solution in the absence of LPS even after sonication. The sonication of the 
mixture of Qdot–LPS for 30 min makes the aggregate more compact as the diameter is 
reduced to 38 nm and the size distribution becomes narrower, indicating increasing 
homogeneity of the Qdot–LPS conjugates. 
 
 
Figure 2.2. Size distribution by number of particles obtained from the DLS analysis of the 
LPS E. coli O55:B5 serotype labeling process. Three key steps in the labeling process are 
included in the DLS study: (A) Qdots alone; (B) LPS alone; (C) after basification step, 
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and (D) after sonication step. X-axis shows the diameter in nanometer and the Y-axis 
shows the percentage of particles of each specific diameter. 
 
The Qdot–LPS conjugates were purified by size-exclusion chromatography and 
studied by Transmission Electron Microscopy (TEM). Figure 2.3 shows the sizes of the 
Qdots (ca. 5 nm) and the purified Qdot–LPS conjugates (ca. 50 nm) obtained in the TEM 
experiment. No free Qdots were observed in the aqueous solution of Qdot–LPS conjugate 
by TEM. These results agree with the data obtained by DLS shown in Figure 2.2. 
 
 
Figure 2.3. Transmission Electron Microscopy image of (A) the organic Qdots from 
CHCl3 solution; and (B) the purified Qdot-LPS E. coli O55:B5 conjugates in water. 
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2.5.2 Labeling of Other Lipoglycans 
Similarly, we labeled Lipid A, LPS from P. aeruginosa, E. coli O111:B4, and 
lipoteichoic acid (LTA)—a LPS equivalent in gram-positive bacteria. Interestingly, 
despite differences in molecular sizes, all of these conjugates had similar hydrodynamic 
diameters (centered around 30 nm) after conjugation to the Qdots (Supplementary Fig. 
S1). Even the complex formed by the smallest Lipid A molecule presents a size 
comparable to the one formed by the much larger smooth-type LPS. Since similar 
responses to basification and sonication were observed with the LPS alone, we conclude 
that presence of Qdots in the lipophilic core of the lipoglycans causes minimal 
disturbance to their native micellar structures. This highlights an important advantage of 
our labeling strategy over conventional labeling of individual LPS molecules in the 
developing assays for the binding analysis of endotoxin-receptor interactions. While in 
the case of individually labeled LPS molecules a possibility for false-positive binding, 
e.g. via membrane incorporation [14], is high, this is not the case with the Qdot-labeled 
LPS micelles since any molecule detached from the micelles is photosilent. Hence, only 
relevant saccharidic interactions can be detected with the Qdot–LPS probes. 
2.5.3 Biological Functionality of Qdot–LPS Probes 
To demonstrate that the Qdot labeled LPS keeps the integrity and biofunctionality 
of the bacterial LPS, and that it can bind as efficiently as the conventional FITC labeled 
LPS, we studied the recognition of LPS from E. coli O111:B4 by its natural cellular 
membrane receptors. A number of mammalian cells respond to LPS stimulation, with 
mononuclear phagocytes (monocytes) being the primary targets of the LPS action [15]. 
Although the exact mechanism of this interaction is not fully understood, it is evident that 
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in order to elicit a response, LPS must first bind to the surface of the cells. We used 
monocytes as a model to study the interaction of Qdot-labeled LPS and compare it to the 
commercially available FITC-labeled LPS [8]. Also, to determine if that the LPS part of 
the complex is responsible for monocytes binding, we used Qdot-PEG20K as a control, 
where the Qdots were conjugated to a linear 20 kDa polyethyleneglycol (PEG) molecule. 
Figure 2.4 shows fluorescent microscope images of the monocytes treated with the 
different probes, using two different filter sets for each. Figure 2.4A and Figure 2.4B 
correspond to FITC–LPS labeling, Figure 2.4C and Figure 2.4D depict the Qdot–LPS 
labeling, and Figure 2.4E and Figure 2.4F relate to the Qdot- PEG20K labeling. The LPS 
labeled with FITC and Qdots show binding to the surface of the monocytes, whereas no 
binding is observed with PEG20K QDots. The monocytes labeling was also followed by 
flow cytometry to get a more complete picture of the binding process (Supplementary 
Fig. S2). Both FITC- and Qdot-labeled LPS efficiently stained the monocytes, while the 
control Qdot-PEG20K did not. 
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Figure 2.4. Fluorescent microscope images of the labeling of mouse monocytes with (A, 
B) FITC-LPS; (C, D) Qdot-LPS; (E, F) Qdot-PEG20K. The top panel shows images 
taken using a filter with a wavelength range of 480–600 nm. The bottom panel shows 
images taken using a filter with a wavelength range of 530–650 nm. 
 
In summary, we developed a new unobtrusive method for labeling lipoglycans 
with luminescent quantum dots. The labeling takes place by incorporation of lipophilic 
quantum dots into the native LPS aggregates. These highly luminescent LPS–Qdot 
complexes were formed and found to be stable in aqueous solution. Since the lipid 
functionality is concealed, LPS–Qdot constructs are ideally suited for studying 
interactions of the polysaccharide moiety of LPS in micellar presentation. 
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2.7 Appendix A. Supplementary Data 
Supplementary data associated with this article can be found, in the online 
version, at doi: 10.1016/j.bbrc.2008.12.167. 
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3.1 Contributions  
The following chapter describes the use of fluorescent conjugates of 
Lipopolysaccharides and Quantum dots to interrogate a 10,000 peptide microarray with 
the objective of identifying peptides binding to the glycans on the surface of bacteria. 
Carlos Morales Betanzos and Dr. Maria Gonzalez-Moa conducted the screening of the 
LPS-Qdots on the peptide microarray and conducted the analysis of the information. 
Together with Dr. Sergei Svarovsky, they identified the best peptide candidates. Using a 
protein blast tool, Mr. Morales Betanzos identified the sequence homology of target to 
natural occurring antimicrobial peptides and performed all the inhibitory assays. Dr. 
Kathryn Boltz performed the ITC experiments. Dr. Svarovsky performed the ITC data 
analysis. Mr. Brian Vander Werf performed the SPR experiments and data analysis. Mr. 
Morales Betanzos conducted the flow cytometry experiments and data analysis. Dr. 
Gonzalez-Moa conducted the DLS experiments and data analysis. Dr. Svarovsky , Dr. 
Gonzalez and Mr. Morales Betanzos wrote the manuscript. Dr. Svarovsky and Dr. 
Stephen Johnston oversaw the research methods and advised in the conduction of the 
project. The results of this work were published in Chembiochem: a European Journal of 
Chemical Biology.  
3.2 Abstract 
Current analytical methods have been slow in addressing the growing need for 
glyco-analysis. A new generation of more empirical high-throughput (HTP) tools is 
needed to aid the advance of this important field. To this end, we have developed a new 
HTP screening platform for identification of surface-immobilized peptides that 
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specifically bind O-antigenic glycans of bacterial lipopolysaccharides (LPS). This 
method involves screening of random sequence peptide libraries in addressable high-
density microarray format with the newly developed luminescent LPS–quantum dot 
micelles. Screening of LPS fractions from O111:B4 and O55:B5 serotypes of E. coli on a 
microarray consisting of 10 000 20-mer peptide features revealed minor differences, 
while comparison of LPS from E. coli O111:B4 and P. aeruginosa produced sets of 
highly specific peptides. Peptides strongly binding to the E. coli LPS were highly 
enriched in aromatic and cationic amino acids, and most of these inhibited growth of E. 
coli. Flow cytometry and isothermal titration calorimetry (ITC) experiments showed that 
some of these peptides bind LPS in-solution with a Kd of 1.75 μM. Peptide selections 
against P. aeruginosa were largely composed of hydrogen-bond forming amino acids in 
accordance with dramatic compositional differences in O-antigenic glycans in E. coli and 
P. aeruginosa. While the main value of this approach lies in the ability to rapidly 
differentiate bacterial and possibly other complex glycans, the peptides discovered here 
can potentially be used off-array as antiendotoxic and antimicrobial lead compounds, and 
on-array/on-bead as diagnostic and affinity reagents. 
3.3 Introduction 
The increasing awareness of the importance of glycosylation to biological systems 
has led to recognition of the need to develop better tools for the analysis of protein–
carbohydrate interactions. In contrast to template-driven nucleic acid and protein 
sequences, which aid function assignments, the need for a more empirical, high-
throughput analysis of potential carbohydrate patterns has resulted in a variety of 
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approaches.[1] The two key newcomers in the area of functional glycomics thus far have 
been glycan[2] and lectin microarrays,[3] in which glycans or lectins are immobilized on 
glass slides for investigating the specificity of glycan-binding proteins or 
glycoconjugates, respectively. In lectin microarrays, carbohydrate-binding proteins, such 
as lectins and anticarbohydrate antibodies, are immobilized on a solid support in high 
spatial density. Interrogation of these arrays with fluorescently-labeled samples creates 
binding patterns (glycosignatures) that depend on the carbohydrate structures present, and 
provide a method for rapid characterization of glycans on glycoproteins,[4] bacteria,[5] 
or mammalian cells.[6] The microarray format allows rapid parallel analysis of multiple 
carbohydrate–protein interactions with a minimal amount of sample. Notwithstanding the 
advantages, lectin microarrays are intrinsically handicapped by restricted availability,[3] 
and the limited and often unexpected specificities of natural lectins.[7] Only about 60 
lectins are commercially available, and they have the ability to recognize only a fraction 
of glycans present on mammalian and especially on microbial cells.[3] The common 
problems inherent to other protein arrays,[8] such as linking chemistry, orientation-
dependent binding activity, and storability, are also important factors that strongly argue 
in favor of alternative approaches.  
Proteins are not the only molecules that bind carbohydrates. Cyclic tricatechol[9] 
and terphenyl[10] constructs, acyclic pyridine, pyrimidine, and naphthyridine units,[11] 
self-assembled structures and various boronic acid derivatives[12, 13] have been 
described. Also, aptamers and peptides have been explored.[14] Synthetic peptides have 
long been known as highly versatile molecules for a variety of biological applications. 
Unlike proteins, which unfold readily and subsequently lose their biological activities, 
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peptides are functionally stable and capable of retaining their activities under most 
reaction conditions; this makes them the preferred molecules for facile and robust 
screening assays, especially in microarray-based formats.  
We have an ongoing program applying addressable random sequence peptide 
microarrays, as an alternative to phage display, to the analysis of various biomolecular 
interactions. As a part of this program, we have tested these microarrays for their ability 
to detect carbohydrate interactions. We hypothesized that owing to the large chemical 
diversity of peptide structures with no preconceived specificity, the microarray could 
provide an expedient approach to de novo discovery of artificial lectin mimics with 
engineered specificities towards glycans of interest. As a proof-of-concept, we chose to 
use the microarray to analyze the saccharidic portion of bacterial lipopolysaccharides 
(LPS). The reason for choosing such a complex target was threefold. First, the diversity 
of glycan structures unique to bacteria would allow the widest dynamic range of 
molecules to be tested and therefore let us evaluate the limitations of this approach. 
Second, from a practical standpoint LPS have been implicated in the systemic 
inflammatory response and septic shock, which have claimed more than 200 000 lives 
each year in the U.S. alone.[15] Hence, there is a great deal of interest in developing 
therapeutic agents that can efficiently bind LPS.[16] Third, whereas the therapeutic 
strategy directed against viral glycans was a success, a similar approach to antibacterial 
therapies has not been systematically explored due to difficulties in finding molecules 
that can selectively bind to bacterial glycans.[17]  
Herein, we report our findings in screening of 10 000 random 20-mer peptide 
sequences printed on a glass slide with newly developed luminescent LPS glycoprobes 
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for potential lectinomimetic activity. A set of specific lectinomimetic antagonists of LPS 
molecules have been discovered that can be used as a new class of diagnostic, 
antiendotoxic, and antimicrobial peptide leads in both on- and off-array formats. To our 
knowledge, this is the first application of peptide microarrays to studying carbohydrate 
interactions. 
3.4 Results and Discussion 
3.4.1 General Experimental Set-Up 
The peptide microarrays were constructed by spotting 10 000 random 20-mer 
sequences in duplicates on a maleimide-functionalized microscope glass slide by using a 
robotic pin spotter. The random peptide library was produced by conventional solid-
phase synthesis based on computer-generated random sequences of 19 amino acids, 
excluding cysteine, for the first 17 amino acids. A C-terminal –GSC sequence was 
incorporated into each peptide to facilitate coupling to the array surface. These arrays 
were probed directly with fluorescently labeled LPS. 
3.4.2 General Considerations in the Design of LPS Glycoprobes 
LPS is a complex, negatively charged lipoglycan composed of three distinct 
regions: 1) a fatty acid region called lipid A that has very low variability ; 2) a conserved 
glycosidic “core” consisting of approximately ten monosaccharides; and 3) a highly 
variable region called O-antigen, consisting of repetitive sub-units of one to eight 
monosaccharides repeated up to 100 times.[18] The O-antigen region defines the strain, 
serotype, and even the virulence of the bacteria; this makes it a very attractive target to 
study. Probing the peptide microarray with directly labeled LPS allowed us to avoid the 
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use of secondary detection reagents, which complicate the interpretation and later 
deconvolution of the data. This consideration is especially important for the random 
peptide microarrays because each peptide on the array de facto is not specific and serves 
as a putative ligand for any target of choice. Not only can the secondary probe bind to the 
array, but it could also compete with the primary probe. In the case of carbohydrates, the 
binding affinities of which are typically weak, the latter can present a serious problem. 
For these reasons, the arrays were probed directly with conventional organic dye-labeled 
and the newly developed quantum dot (Qdot)-labeled LPS in order to specifically single 
out carbohydrate interactions.  
3.4.3 LPS Labeling with Qdots 
The existing LPS labeling strategies rely on chemical modification of LPS 
molecules with organic dyes (Figure 3.1A). This method requires complex manipulation 
and purification steps, is not site-specific, and depends on the availability of reactive 
groups in the LPS molecule.[19] When such groups are unavailable, an extra 
functionality is introduced into the saccharidic branch of LPS, which might affect its 
physical properties and biomolecular recognition events; thus it is not ideally suitable for 
the purposes of this study. For this reason, we have developed an alternative labeling 
strategy that takes advantage of the amphipathic nature of LPS molecule and does not 
introduce any new chemical modalities into the structure. 
We used nanometer-sized crystals of semiconductors known as quantum dots 
(Qdots) that have recently emerged as useful luminescent labeling agents.[20] Coating of 
hydrophobic Qdots with phospholipids[21] and synthetic amphiphilic polymers have 
been previously described.[22] Both methods rely on phase transfer of hydrophobic 
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Qdots from organic solvent to an aqueous solution of an amphiphile. Using a similar 
approach, we conjugated smooth-type LPS from E. coli and P. aeruginosa to hydrophobic 
Qdots (Figure 3.1B). In this case, the lipid A, which is responsible for self-aggregation, 
also confers the ability of LPS to bind to hydrophobic surfaces of Qdots. Since the lipid 
functionality is attached directly to the label, Qdot–LPS constructs are especially useful 
for studying the saccharidic moiety of LPS. 
 
 
Figure 3.1.A cartoon depicting: A) organic dye labeled LPS; B) Qdots-labeled 
LPS; m designates the number of O-antigen repeating units, n designates 
the number of LPS molecules attached to the Qdot.  
 
3.4.4 Comparison of Qdot- and Organic Dye-Labeled LPS 
Although many peptides have been shown to bind LPS in solution,[23] at the 
outset of this work it was not clear if peptides in the microarray format would also be 
able to bind LPS specifically and reproducibly. In order to demonstrate that the peptides 
on the microarray indeed bind LPS and the interaction is not dye- or lipid-induced, we 
conducted several experiments. In the first of these experiments, identical concentrations 
of LPS from E. coli O111:B4 (ECO111) labeled with FITC (FITC–ECO111) and with Qdots 
(QDot–ECO111) were used to probe the microarray slides. The “unblocked” sample was 
used as is, while the “blocked” sample was spiked with 100-fold excess of unlabeled 
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ECO111 during the binding step. For both FITC–ECO111 and QDot– ECO111 probes (Figure 
S1 in the Supporting Information) blocking with unlabeled LPS localized the specific 
interactions, as most of the top binders to LPS become low binders when excess 
unlabeled LPS is used to inhibit the specific peptide– LPS interactions. This simple test 
effectively eliminated any unspecific dye-induced interactions. The same test was applied 
to all binding experiments described below.  
To test the applicability of the Qdot–LPS probes for specifically detecting 
carbohydrate-binding events, we used scatter plots as previously reported by Reddy and 
Kodadek,[24] and compared the results with those obtained with conventionally labeled 
LPS. This representation helped us to focus our attention only on peptides with high 
expression profile for both experiments (FITC–ECO111 and Qdot–ECO111). Figure 3.2 
shows reasonable correlation (R=0.824) between the two experiments. Although some 
unique hits were present both in Qdot–LPS and FITC–LPS binding peptides, they can be 
attributed to differences in the probe construction and photophysical properties of the 
labels. The LPS is presented on the multivalent Qdots in a defined orientation, since the 
hydrophobic Qdots only exist in aqueous solution when they are enclosed in the 
hydrophilic environment created by the lipid portion of the LPS molecules. This 
orientation exposes the saccharidic branch of the LPS, similar to their orientation in the 
micellar (or cellular) state of LPS. In contrast the monovalent FITC–LPS probe can 
potentially detect saccharidic-, dye-, and lipid-induced interactions. It has been found that 
aggregated micellar FITC– LPS has strongly diminished fluorescence due to quenching, 
while the disaggregation of single FITC–LPS molecules from micelles leads to 
enhancement in fluorescence.[25] So, it is likely that oriented micellar LPS molecules 
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would not be observable, and the most significant signal detected would come from the 
single LPS molecules, which include nonsaccharidic components. Due to the well-known 
cluster glycoside effect,[26] the interaction of multiple sugars is also stronger than a 
single LPS molecule. These observations highlight the utility of Qdot–LPS for studying 
variable saccharidic components. 
 
 
Figure 3.2. FITC-labeled versus Qdot-labeled E. coli O111:B4 LPS correlation 
(R=0.824). Annotated black dots indicate selected LPS-binding peptides shown in Table 
1. Both axes show normalized signal in a logarithmic (log2) scale. Blue lines delimit the 
twofold change.  
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3.4.5 Selection of Peptides Binding the Saccharidic Branch of LPS 
Since the Qdot labels were novel for LPS, we argued that only peptides that bind 
both FITC–LPS and Qdot–LPS with high intensity were the most reliable saccharidic 
LPS-binding peptides. Such peptides were identified by statistical analysis by using 
image-processed data, and visualized as a scatter plot.[24] We have selected only high 
intensity binders with a minimal standard deviation (s<0.2) that were present in both 
Qdot– LPS and FITC–LPS experiments (Figure 3.2). Autofluorescent peptides were 
filtered as described in the Experimental Section and each hit was independently 
confirmed by careful visual inspection of the slides. 
The data revealed 16 peptides, QF1–QF16, that bound with high affinity to E. coli 
O111:B4 LPS (Table 3.1). Most of these peptides contain noticeably abundant cationic 
arginine, lysine, and histidine, along with clusters of aromatic hydrophobic tryptophan 
and phenylalanine and/or tyrosine. Since many of the existing LPS-binding peptides are 
also antimicrobial,[ 27] we hypothesized that if our selections were valid then at least 
some of the peptides should share sequence similarity with the existing antimicrobial 
peptides (AMPs). To test this hypothesis, we compared the selected sequences against 
several AMP databases. In particular, we found that the above amino acids were also 
abundant in indolicidin- like AMPs.[28] Moreover, using the Antimicrobial Peptide 
Database,[29] we found that some of these peptides (QF1–8) shared 30 to 40% similarity 
to human histatins-2, -6, or -9, which are histidine-rich AMPs found in oral cavities. 
Finally, we applied a recently developed algorithm that predicts antibacterial sequences 
based on similarity to the existing 486 AMPs.[30] The higher the antibacterial peptides 
prediction (APP) score, the more probable the antibacterial activity, while negative scores 
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suggest no antibacterial activity. The APP scores shown in Table 3.1 predicted that 11 out 
of 16 selected peptides had potential antibacterial properties. 
 
Table 3.1. E. coli O111:B4 LPS binding peptides arranged by isoelectric point (pI), 
number of negative residues (NR), number of positive residues (PR), aliphatic index (AI), 
and antibacterial peptides prediction score (APP).[27] 
 
 
3.4.6 Antimicrobial Properties of the LPS Binding Peptides 
We assayed the ability of the LPS-binding peptides to inhibit E. coli growth, and 
compared them to 142 LPS nonbinding peptides (Table S1). Figure 3.3 shows that nearly 
70% of the LPS-binding peptides demonstrated some growth inhibition activity against E. 
coli DH10B, while none of the 142 nonbinding peptides inhibited growth by more than 
20% (Figure S2). Interestingly, the peptides QF12, -13, -14, and -16 demonstrated 
enhancement of bacterial growth (Figure 3.3). In agreement with the APP scores peptides 
QF1–10 displayed antibacterial activity (Table 3.1). An evident outlier, QF15, which 
departs from the conventional cationic amphipathic motifs associated with AMPs, was 
also identified. Further testing through kinetic growth curves showed that these peptides 
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are bacteriostatic, not bactericidal. This agrees with recent work demonstrating that the 
biophysical properties required to kill bacteria differ from those to bind LPS.[31] In 
addition to affinity for LPS, bactericidal activity requires the abilities to traverse the LPS 
layer and to disaggregate LPS micelles. Our concentration-dependent studies (data not 
shown) demonstrated that even at 10 mm concentration, peptides QF7, -8, and -10 
retained their ability to inhibit up to 50% of E. coli growth. 
 
 
Figure 3.3. Relative growth inhibition activities of peptides QF1–16 tested against E. coli 
DH10B. The error bars are standard deviations of triplicate measurements; Neg1 is a 
negative control peptide. 
 
3.4.7 Flow Cytometry Studies of the LPS-Binding Peptides 
Intrigued by the high incidence of antimicrobial activity of the selected peptides, 
we conducted flow cytometry studies to quantify the in vivo binding abilities of the 
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selected peptides to E. coli, and the ability of preincubation with LPS to block 
binding.[32] The LPS nonbinding peptide, Neg1, was used as a negative control. The 
peptides were biotinylated and their specificities were compared through quantifying the 
cell surface staining of E. coli DH10B cells with AlexaFluor488-labeled streptavidin. 
Cells labeled only with streptavidin were used as controls, and fluorescent intensity 
greater than that associated with streptavidin only labeled cells was quantified as the M1 
region. Peptides QF1 through QF10 bound the cells almost completely in the M1 region; 
this indicates that these peptides bound the cells with higher affinity than would be 
expected from streptavidin-only binding (Table S2). The results for streptavidin, the 
negative control peptide Neg1, QF5, and QF8 are summarized in Figure 3.4. Both QF5 
and QF8 bound to DH10B cells, and their cell-surface binding was nearly eliminated 
after preincubation with ECO111 LPS. While these results do not elucidate the nature of 
the target on the DH10B cell surface, they do show that the peptides bind to and are 
sequestered by the interaction with their target ECO111 LPS. 
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Figure 3.4. Flow cytometry of AlexaFluor488-labeled streptavidin, Neg1 control peptide, 
QF5, QF8, and QF5 and QF8 after 1 h preincubation with 100-fold excess of E. coli 
O111:B4 LPS. The y axes show the cell count, and the x axes show the AlexaFluor488 
intensity. 
 
3.4.8 Surface Plasmon Resonance (SPR) 
High resolution differential SPR was used to compare the binding of QF5, QF8, 
and Neg1 to ECO111 (Figure 3.5 and S3). This technique has sufficient sensitivity to detect 
direct binding of free glycans to lectins immobilized on a sensor chip and allows the 
evaluation of sugar–lectin dissociation constants in the nm range.[33] Both QF5 and QF8 
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are strong antimicrobial candidates, while Neg1—a peptide showing no binding to LPS 
on the peptide microarrays—was used as a negative control. The relative responses of 
these peptides were compared by using normalization based on the immobilization 
density and molecular weight of the respective peptides. Both QF5 and QF8 peptides had 
similar abilities to bind LPS, while Neg1 had negligible binding (Figure S3 A). 
 
 
Figure 3.5. A) High resolution differential (HRD) SPR responses of peptides Neg1, QF5, 
and QF8 to E. coli O111:B4 LPS. B) ITC titration curve of the LPS ECO111 with peptide 
QF8. 
 
3.4.9 Isothermal Titration Calorimetry (ITC) 
To estimate the ability of peptide QF8, which exhibited maximal antimicrobial 
activity, to bind LPS in solution, we conducted the microcalorimetry titration of LPS 
ECO111 with QF8. The integrated heats in Figure 3.5B represent the net heats of each 
injection after subtraction of the heat of dilution of QF8 into pure buffer. The upward 
position of the ITC titration peaks (Figure S3 B) and the resultant positive integrated 
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heats indicate that the association between QF8 and LPS is an endothermic process.[34] 
With a single site independent binding model, the enthalpy (ΔH) of association between 
QF8 peptide and LPS is 7.8 kcalmol-1 with an equilibrium association constant (Ka) of 
568 731M-1 (Kd=1.75 μM) and a stoichiometry of 0.2–0.4 QF8/LPS (due to heterogeneity 
of LPS) obtained at pH 7.4. This ratio likely corresponds to the net charge compensation 
between anionic LPS (2–4 negative charges) and cationic QF8 (seven positive 
charges).[35] The free energy (ΔG) and entropy (ΔS) changes of binding are estimated to 
be -7.8 kcalmol-1 and 52.6 calmol-1 deg-1, respectively. 
3.4.10 Differentiation of E. coli Serotypes 
Gram-negative bacteria are classified by serological types (serotypes) based on 
the composition of the LPS O-antigen domains. Thus, the O-antigen, which is responsible 
for much of the immunospecificity of the bacterial cells, essentially serves as the 
“glycosignature” of a bacterium.[18] To test whether we can distinguish among different 
serotypes of a bacterium using the peptide microarray, we screened Qdot-labeled LPS 
derived from two different serotypes of E. coli: O111:B4 (ECO111) and O55:B5 (ECO55). 
Figure 3.6 shows the 2D scatter plot corresponding to these experiments. Overall, an 
excellent correlation (R=0.907) was observed between the two serotypes; this indicates 
that there are only marginal differences detectable by the microarray. The high 
correlation coefficient is in agreement with the compositional similarity of the LPS 
molecules derived from the two serotypes (Figure 3.7). The O-antigen repeating units of 
ECO111 [36] and ECO55 [37] LPS are composed of five neutral monosaccharides, which 
include glucose (Glc), galactose (Gal), N-acetyl-galactosamine (GalNAc), N-
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acetylglucosamine (GlcNAc), and colitose (Col; 3,6-dideoxy-L-galactose). Although both 
structures differ in branching and sequence, the overall sugar content remains similar.  
 
 
Figure 3.6. E. coli O111:B4 versus E. coli O55:B5 Qdot–LPS correlation for triplicate 
experiments of each (R=0.907). The black dot corresponds to the ECO111 specific peptide 
FPKDQW (shown in the insert, with ECO111 on the left and ECO55 on the right). Both 
axes show normalized signal in a logarithmic (log2) scale. Blue lines delimit the twofold 
change. Insert shows close-up of the peptide microarray binding patterns of: A) ECO111 
and B) ECO55. The first six (of 20) amino acids are shown. (For a full sequence see the 
Supporting Information.) 
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Despite the negligible statistical differences, a close visual inspection of the slides 
revealed several distinct hits that are unique to ECO111 (Figure 3.6, insert) and to ECO55. 
In all the cases, for a hit to be statistically significant it must be reproduced in all replicate 
slides with a standard deviation of less than 0.2. 
 
 
Figure 3.7. Chemical structures of the repeating units of LPS used in this work.[36–38] 
3.4.11 Differentiation Between E. coli and P. aeruginosa 
While the two E. coli serotypes have subtle compositional differences, more 
prominent differences are apparent when the LPS structures of P. aeruginosa 10 (PA10) 
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and ECO111 are compared (Figure 3.7). The repeating unit of PA10 consists of three 
unusual sugars: 2-O-acetyl-L-rhamnose (RhaAc), 2-N-acetyl-L-galacturonic acid 
(GalNA), and 2-N-acetyl-2,6-dideoxy-D-glucosamine (QuiN).[38] One of these sugars 
(GalNA) contains a carboxylic acid group that can carry negative charge and form strong 
hydrogen bonds. Screening of the PA10 LPS labeled with Qdots and statistical correlation 
of the results with ECO111 revealed a number of distinct hits for ECO111 and PA10. Indeed, 
even a superficial visual inspection of the slides immediately shows differences in 
binding patterns between the two experiments (Figure 3.8). 
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Figure 3.8. LPS binding patterns (“glycosignatures”) on the microarray of: A) P. 
aeruginosa 10 LPS and B) E. coli O111:B4 LPS. Sequences in yellow indicate peptides 
unique to P. aeruginosa; sequences in green are unique to E. coli; sequences in white are 
common binders. Only the first six (of 20) amino acids are shown. (For a full sequence 
see the Supporting Information.) 
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Figure 3.9 shows the statistical correlation between Qdot–PA10 and Qdot–ECO111 
experiments as a scatter plot.[24] The correlation coefficient is far lower (R=0.630) than 
in the case of ECO111 versus ECO55 (R=0.907; Figure 3.7). Peptides EC1–8 (Table 3.2), 
which specifically bind ECO111 but not PA10, were identified by minimizing the error 
(standard deviation σ < 0.2) while maximizing the ratio of normalized ECO111 to PA10 
signals. These comparisons independently validate the first selection of ECO111 binding 
peptides QF1–16 (Table 3.1) which are annotated in blue in Figure 3.9. A similar 
selection strategy seeking peptides that specifically bind PA10 but not ECO111 yielded 
peptides PA1–8 (Table 3.2). The heat map shown in Figure 3.9 graphically demonstrates 
the expression levels of each of the EC1–8 and PA1–9 peptides in Qdot–PA10 and Qdot–
ECO111 experiments. All EC peptides present a high expression in the ECO111 experiment, 
while the expression in the PA10 experiment is low. The opposite is true for PA peptides, 
which have high expression in the PA10 experiment, but low in the ECO111 experiment. 
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Figure 3.9. A) E. coli O111:B4 versus P. aeruginosa 10 LPS correlation (R=0.630). 
Annotated blue dots correspond to peptides shown in Table 3.1; annotated black dots 
correspond to the peptides shown in Table 3.2. Both axes show normalized fluorescence 
signal at 605 nm on a logarithmic scale. Blue lines delimit the twofold change. B) Heat 
map compares the level of expression (luminescent intensity, log2) for the EC and PA 
peptides (green: low; red: high). 
 
3.4.12 Structural Considerations 
As seen in Table 3.2, most of the peptides unique to ECO111 are enriched in 
aromatic tryptophan and cationic arginine, lysine, and histidine, while peptides specific to 
PA10 tend to contain aliphatic amino acids, anionic aspartic, and glutamic acids, and 
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especially hydrogen bond forming glycine, proline, serine, and threonine (Figure S4). 
These differences are reflected in the consistent differences in pI values and aliphatic 
indices (AI) of the selected peptides (Table 3.2). This can be explained by the prominent 
compositional differences between ECO111 and PA10 LPS. Interestingly, Cherkasov et 
al.[39] recently found the same kind of amino acid distribution by using artificial 
intelligence in the design of peptide antibiotics. 
 
Table 3.2. Peptides specific to EC LPS versus PA10 LPS. Column headings indicate the 
isoelectric point (pI), negative residues (NR), positive residues (PR), and aliphatic index 
(AI). 
 
 
As shown in Figure 3.7, the O-antigens of ECO111 and ECO55 LPS are dominated 
by neutral galactose-like structures, such as colitose, galactose, and galactosamine. The 
aromatic amino acids, W, F, or Y, are known to interact with the nonpolar b-face of 
galactose to provide a common binding motif residue for most galactose-binding 
proteins.[40, 41] So, it is not unusual that the ECO111 binding peptides show a high 
incidence of aromatic amino acids, such as tryptophan, phenylalanine, and tyrosine. 
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These observations are further supported by two independent investigations. In one study, 
peptides were selected to bind components of the bacterial cell membrane devoid of 
polysaccharides. This selection led to peptides containing only cationic arginine and 
lysine, but no aromatic residues.[42] In a second study, peptides that bind LPS from S. 
enterica (LPSs from E. coli and S. enterica are closely related)[37] were identified by 
screening phage displayed peptide libraries against bead-immobilized LPS.[43] All of 
these peptides were found to be enriched in aromatic hydrophobic residues, such as 
tryptophan and phenylalanine, along with cationic residues. These peptides were capable 
of discriminating between various bacterial species, which strongly supports their ability 
to target the distinctly variable O-antigenic domains. 
In contrast to the neutral ECO111 and ECO55 repeating units, the repeating unit of 
PA10 consists one third of negatively charged galacturonic acid (Figure 3.7), which can 
form strong hydrogen bonds with the aspartic and glutamic acids,[44] as well as with 
hydrophilic glycine, proline, serine, and threonine, which are prominently over-
represented in the selected PA10- specific peptides (Figure S4). 
3.4.13 Electrostatic Contributions 
To test the contribution of electrostatic interactions to LPS binding to microarray 
peptides, we measured the zeta potential (ζ-potential) of ECO111 and PA10 LPS. The zeta 
potential is the overall charge a particle acquires in a specific medium and is a measure of 
the potential at the slipping plane, which is the layer just past the bulk solution layer of 
ions surrounding the particle. Under conditions identical to those used in the microarray 
probing experiments, the ECO111 LPS had a charge of ζ =(-6.7±1.4) mV, while the PA10 
LPS was also negative and of significantly greater magnitude at ζ =(-25.7±3.1) mV, 
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which is consistent with the presence of negatively charged galacturonic acid. Since the 
ECO111 LPS has only hydroxyls in the structure and thus lacks the ability to form strong 
hydrogen bonds in aqueous solutions,[45] its interactions are dominated by CH–π 
interactions[45] and by electrostatic attraction, which drive the selection towards 
hydrophobic aromatic and cationic amino acids. On the other hand, the galacturonic acid 
in the repeating unit of PA10 LPS has a strong propensity to form hydrogen bonds, which 
overpowers the electrostatic forces and drives the selection towards hydrogenbond- 
forming amino acids. 
We conclude that specific interactions of peptides with LPS on microarrays are 
not driven by electrostatic forces alone, but involve far more specific molecular 
interactions, such as hydrogen bonds and hydrophobic forces. This makes the peptide 
microarray a suitable tool for studying carbohydrate interactions.  
3.5 Conclusions 
In summary, we have developed a LPS screening technology to quickly identify 
LPS binding peptides that are specific to the variable saccharidic branch of LPS. We 
demonstrated that such a platform, which consists of only 10 000 random 20-mer 
sequences, is capable of differentiating between Gram-negative bacterial strains based on 
differences in their LPS structures. We also demonstrated that the parallel analysis 
platform, inherent to the microarray format, allows rapid and, most important, direct 
identification of multiple LPS interactions at the same time. In contrast to screening of 
phage displayed or other solution-based combinatorial peptide libraries, microarray 
format allows systematic analysis and statistical deconvolution of postselection data. In 
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the future, as peptide microarray technology matures and the number of features 
increases, this platform could enable direct discovery of high-affinity and protease- 
resistant peptidomimetics since peptides can be readily synthesized with unnatural 
functionalities, for example, damino acids, cyclic structures, and unnatural side chains, to 
facilitate the transition of discovered leads into the clinic. Finally, this technology paves 
the way for systematic investigation of disease-associated changes in other poorly 
defined complex glycobiomolecules, such as mucins and glycosylaminoglycans that 
currently present insurmountable challenges to the available analytical methods.  
3.6 Experimental Section 
Materials and methods: Smooth-type LPS from E. coli serotype O111:B4 was 
obtained from Fluka (Cat# 62325), serotype O55:B5 was from Sigma (Cat# 62326); P. 
aeruginosa 10 was from Sigma (Cat# L8643). FITC-labeled LPS from E. coli O111:B4 
was from Sigma (Cat# F3665). CAUTION! LPS molecules are highly pyrogenic and can 
cause severe fever in humans if inhaled, ingested, or absorbed through skin. Good 
laboratory practices should be employed. Wear a lab coat, gloves, safety glasses, and a 
respiratory mask while handling LPS. 
Unless noted otherwise, all chemicals were purchased from Sigma– Aldrich, Inc. 
(Milwaukee, WI, USA) and used without further purification. Deionized water was 
obtained from a Millipore ultrapure water filtration unit. PEPscreen® peptides were 
synthesized by Sigma–Genosys, Inc., with 100% quality control and used as received for 
initial screens. Lead peptides were resynthesized inhouse by using Fmoc chemistry and 
purified to 95% by HPLC. Organic Qdots® were purchased from Invitrogen (Carlsbad, 
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CA, USA; Cat# Q21701MP). Sephacryl HiPrep 16/60 (S-200 HR) was from GE 
Healthcare. In-solution nanosizing and zeta potential was measured by using a Zetasizer 
Nano-ZS instrument (Malvern Instruments, Worcestershire, UK). Spectrophotometric 
measurements were carried out by using a NanoDrop® ND-1000 instrument.  
Labeling LPS with Qdots: The supplied solution of organic Qdots (QDot 605 
ITK™, Cat# Q21701MP, Invitrogen, Inc.) in decane (1 μM) was evaporated to dryness 
by using a SpeedVac® at room temperature and redissolved in equal amount of 
chloroform. An aliquot (100 μL) of the chloroform solution was diluted to 500 μL with 
chloroform and mixed with an aqueous solution of corresponding LPS (100 μL of 
10mgmL-1; E. coli O111:B4, E. coli O55:B5, and P. aeruginosa 10). Methanol was added 
dropwise and the sample was occasionally vortexed until both phases were completely 
mixed (about 400 μL of MeOH). The mixture was then evaporated to dryness by using a 
SpeedVac and the solid residue was suspended in ddH2O (100 μL). A saturated solution 
of tetramethylammonium hydroxide pentahydrate (Me4NOHx5H2O) was added until the 
mixture was at pH 11–12 (about 25 μL). The latter basification step is critical as it allows 
the transfer of the Qdots into the aqueous phase; no transfer occurs in nonbasified 
solutions. The mixture was sonicated for 30 min, and the colored solution was then 
passed through two consecutive Zeba columns (2 mL; Pierce) to remove salts and excess 
free LPS. We further purified the LPScoated Qdots by size-exclusion chromatography 
using Sephacryl HiPrep 16/60 (S-200 HR) column (50x1 cm). The Qdot–LPS constructs 
eluted in a narrow color band and were stored in the dark at 4 ˚C. Under these conditions, 
the Qdot–LPS are stable for at least one month without any visible signs of deterioration. 
In a control experiment, the above procedure was repeated without LPS. No 
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solubilization of Qdots was observed without LPS as determined by measuring 
absorbance of Qdots in the supernatant. 
Peptide microarray design and construction: The peptide microarray consisted 
of 10000, 20-residue peptides of random sequence, with a C-terminal linker of -Gly-Ser-
Cys-COOH. All peptides were synthesized by Alta Biosciences Ltd. (Birmingham, UK) 
based on amino acid sequences provided by in-house custom software (Hunter, Preston, 
and Uemura, Yusuke, CIM, The Biodesign Institute). Nineteen amino acids (cysteine was 
excluded) were selected at random for each of the first seventeen positions with -GSC as 
the carboxy-terminal linker. The synthesis scale was 2–5 mg total at ≥ 70% purity and 
2% of the peptides were tested at random by mass spectrometry as quality control. Dry 
peptides were dissolved in N,N’-dimethylformamide (100 %), then diluted 1:1 with 
purified water at pH 5.5 to a master concentration (2 mgmL-1). The original 96-deep-well 
plates were robotically transferred to 384-well spotting plates, and the peptides were 
diluted to a final spotting concentration (1 mgmL-1) in phosphate buffered saline at pH 
7.2. High-quality precleaned Gold Seal glass microscope slides were obtained from 
Fisher (Fair Lawn, NJ, USA; Cat# 3010). Each slide was treated with amino-silane, 
activated with sulfo-SMCC (Pierce Biotechnology, Rockford, IL, USA; Cat# 22622) to 
create a maleimideactivated surface, and the quality was checked for coating efficiency. 
During spotting, we employed a Telechem Nanoprint 60 using 48 Telechem series SMP2 
style titanium pins. Each pin spots approximately 500 pL of peptide (1 mgmL-1) per 
spot—an estimate based on pin trajectory, surface dwell time, and the amount of liquid 
each pin holds. The spotting environment was at 25 ˚C and 55% humidity. The 
maleimide-activated surface reacts with the sulfhydryl group on the peptide’s terminal 
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cysteine. Each peptide was spotted twice per array. The arrays were spotted in an 
orangecrate packing pattern to maximize spot density. Six fiducials were applied 
asymmetrically by using AlexaFluor647, -555, and -488 labeled peptides. The fiducials 
were used to align each subarray during image processing. The printed slides were stored 
under an argon atmosphere at 4˚C until used. Quality control included imaging the arrays 
by laser scanner (Perkin–Elmer ProScanArray HT, Perkin–Elmer, Wellesley, MA, USA) 
at 647 nm to image the spot morphology. If the batch passed this test, further testing of 
randomly selected slides with known proteins and antibodies was carried out for the 
quality control of precision spot intensity. Array batches that failed to meet an array-to-
array variability of 30% CV (coefficient of variation) were discarded. 
Microarray probing: Each microarray probing was performed in triplicate. The 
slides were placed in a humidified chamber and blocked for 1 h at room temperature with 
BSA (650 μL of 3% solution) and methoxytetraethyleneglycol thiol (mPEG4-SH; 1 
mM)[46] in 1xPBS with Tween-20 (TBS-T; 0.05 %). The slides were washed with 
1xTBS-T (3x30 inversion in a Coupling jar) and ddH2O (3x30 inversion in a Coupling 
jar). The slides were then dried by centrifugation at 1500 rpm for 3 min, with the barcode 
label at the bottom to avoid the spread of the label glue onto the slide surface. The slides 
were then scanned at the appropriate wavelength to note any peptide autofluorescence. 
An AbGene frame was then attached to the surface of each slide to confine the solution 
(260 μL) of labeled LPS in 1xPBS (0.154 mgmL-1 for FITC–LPS or AF488–LPS and 
0.630 mgmL-1 for Qdot–LPS) that was added to the printed area. A plastic coverslip was 
used to spread the solution on the surface of the slide and seal the frame while avoiding 
bubbles. The slides were incubated for 1 h in the dark at room temperature in a 
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humidified chamber. The coverslips and AbGene frames were then removed, and the 
slides were washed by being dipped two times in ddH2O, then incubated for 5 min in 
ddH2O, and then dipped two more times in ddH2O; the solution was changed each time. 
Finally the slides were dried by centrifugation at 1500 rpm for 3 min at room temperature 
and scanned. 
Microarray scanning and image analysis: Microarrays were scanned by using a 
Perkin–Elmer ProScanArray HT Microarray Scanner with the 488 and 543 nm excitation 
lasers at 100% power and 70% photomultiplier tube gain. Detection was done at 605 nm 
for Qdot probes and at 543 nm for FITC probes. All scanned images were analyzed by 
using GenePix Pro 6.0 software (Axon Instruments, Union City, CA, USA). Upon careful 
visual inspection, bad spots were eliminated by flagging them “absent”. Median spot 
intensities were used in further analyses. Statistical analysis comparison of microarray 
data was done with GeneSpring 7.2 (Agilent, Inc., Palo Alto, CA, USA) by importing 
image-processed data from GenePix Pro 6.0 (Molecular Devices, Inc.). Median signal 
intensities were used in the calculations. For statistical comparisons, each slide was 
normalized to 50th percentile. Measurements of less than 0.01 were set to 0.01; per 
“gene” normalization were not included since it tends to overemphasize differences in 
peptide expression, even when the intensity value is almost negligible for all the 
experiments. However, the goal of this work is to differentiate peptides that show a 
distinct behavior towards different probes, not only by statistical means, but also by 
visual inspection of the slides. Autofluorescent peptides were identified by scanning the 
slides prior to binding with LPS, peptides which had fluorescent intensities comparable to 
the postbinding intensity were eliminated from the final selections. The results collected 
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for each experiment were represented by using scatter plots as previously reported by 
Reddy and Kodadek.[24] This representation helped us focus our attention only on 
peptides with the right expression profile, that is, either with high expression against one 
of the LPSs tested and low expression for the other LPS, or with high expression for both.  
Antimicrobial assays: DH10B E. coli cells (MAX Efficiency® DH10BTM 
Competent Cells, Cat# 18297-010, Invitrogen Inc.) were grown, overnight, at 37˚C at 270 
rpm rotation in LB medium with streptomycin (0.1%) to a cell density of 2000x106 
CFUmL-1. An aliquot (1 μL) of these cultured cells was then mixed with fresh medium (1 
mL) containing an individual peptide at concentrations of 25, 50 and 100 μM, and 
allowed to grow, overnight. The McFarland turbidity scale for E. coli[47, 48] was used to 
quantify the overnight growth of the cells by comparing the optical density of the cells at 
600 nm to the turbidity equivalent of BaCl2 (1%)/H2SO4 (1%) in the microplate reader 
(Spectra MAX 190, Molecular Devices, Inc.). In control experiments, the above 
procedure was repeated with no peptide in the culture and with nonbinding peptide 
(Neg1, sequence EFSNPTAQVFPDFWMSDGSC) as a negative control. 
Flow cytometry: Peptides were conjugated to biotin by incubation with 
heterobifunctional maleimide-PEO2-biotin linker (Pierce Biotechnology, Inc.; Cat# 
21901) in 1xPBS at pH 7.2, overnight, at room temperature. Excess biotin was removed 
by overnight dialysis by using 1 kDa cutoff membrane (Spectrum Laboratories, Inc.). E. 
coli DH10B (MAX Efficiency® DH10B™ Competent Cells, Cat# 18297-010, Invitrogen 
Inc.) were cultured under routine conditions, pelleted by centrifugation and washed 
(3x1xPBS) to remove traces of media. The harvested cells were resuspended in blocking 
buffer (1xPBS, 0.05% FBS). Experiments with LPS preincubation involved mixing 
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biotinylated peptide solution (400 μM; 10 μL) with LPS solution (200 μM; 20 μL) for 1 h 
at room temperature. Then, 10x106 cells were mixed with biotinylated peptides (400 μM; 
10 μL), biotinylated peptides preincubated with LPS, or biotinylated wheat germ 
agglutinin (WGA) lectin (EY Laboratories, Inc.; 10 μL of 1 mgmL-1 solution) and 
incubated for 1 h on ice. The cells were then washed three times with blocking buffer (1 
mL) to remove unbound peptides or lectins. For detection of bound peptides and lectins, 
streptavidin–AlexaFluor488 (4 μgmL-1, 100 μL; Invitrogen, Inc., Cat# S-11223) was 
added to the cells and incubated for 1 h. Cells were washed three times in blocking 
buffer, resuspended in blocking buffer (300 μL) and analyzed for cell-surface staining by 
using the FACS Caliber machine (BD Biosciences, Inc.). Cells stained with streptavidin–
AlexaFluor488 only, were used as controls. 
Surface plasmon resonance: Bare gold SPR sensor chips (Biosensing 
Instruments, Tempe, AZ, USA) were functionalized by adding 8- amino-1-octanethiol (1 
mM; Dojindo Molecular Technologies, Inc., Cat# A424) in ddH2O to the ethanol 
prewashed gold surface and incubating for 2 h at room temperature in a humidified 
chamber. The surface was then washed with ddH2O and dried by using ultrapure argon 
gas. A solution of sulfo-SMCC linker (1 mM; bio- WORLD, Dublin, OH, USA) in 
1xPBS was added to the gold surface, incubated for 30 min at room temperature in a 
humidified chamber, then washed and dried as above. The SPR instrument sensitivity 
was calibrated by using the response from ethanol (1%) in water on a bare gold sensor 
chip as a standard. The AOT/sulfo- SMCC modified chip was mounted on the 
instrument, and the peptide was immobilized in the sample channel by injecting a 
solution of peptide (100 μM) in TBS-T. A solution of sodium dodecylsulfate (0.01 %; 
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SDS) in TBS-T was injected to dissociate any peptide aggregates. The SPR response after 
the SDS wash was used to calculate the immobilization density, where 1 RU=1 pgmm-2. 
To abrogate possible unspecific interactions, a solution of mPEG4-SH (1 mM)[46] was 
used to block unreacted maleimide groups on the sample channel and to act as a 
nonbinding control on the reference channel. A solution of LPS (1 mgmL-1) from E. coli 
serotype O111:B4 was injected at 20 μLmin-1 flow rate in the TBS-T analyte solution. 
Regeneration was accomplished by using SDS (0.05%) followed by an injection of 
glycine (10 mM; pH 2.5). 
LPS zeta potential (ζ-potential) and size measurements: The zeta potential of 
the LPS was determined by electrophoretic mobility by using a Zetasizer Nano-ZS 
(Malvern Instruments). Measurements were performed at 25˚C in clear disposable Zeta 
cells (Malvern Instruments). LPS concentrations were the same as the ones used in the 
microarray probing experiments. All measurements were done in triplicate.  
ITC measurements:[34] LPS was dissolved in PBS, pH 7.4, to give a 75 μM 
solution (assumed MW=10000 kDa) equilibrated by dialysis, overnight, and degassed 
under vacuum. The QF8 peptide was dissolved in the same buffer at 1 mM and degassed 
under vacuum. Isothermal calorimetric titrations were performed by using the Nano ITC 
(TA Instruments, New Castle, DE, USA) at 23.5 ˚C. Degassed LPS (0.075 mM) was 
loaded into the sample cell (volume 950 μL), the reference cell was filled with water, and 
the degassed QF8 peptide (1 mM) was loaded into the injection syringe. Aliquots of QF8 
(20x5 μL) were titrated into the LPS in the reaction cells at an interval of 300 s while 
being stirred at 150 rpm. Raw data were corrected for the heat of dilution of QF8 into 
buffer and integrated by using NanoAnalyze 1.1.0 software. The independent binding 
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model allowed the determination of the binding stoichiometry (n), association constant 
(Ka), and enthalpy change (ΔH). The free energy (ΔG) and enthalpy (ΔS) changes were 
calculated through the fundamental equations of thermodynamics: ΔG=-RT ln Ka and 
ΔS=(ΔH-ΔG)T-1, respectively. All titration curves were repeated at least three times. 
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4.1 Contributions 
The following chapter is a book chapter by invitation originally published in 
Methods in Molecular Biology. The goal of the chapter was to describe in detail the 
synthesis of fluorescent conjugates of Lipopolysaccharides and Quantum Dots with 
emphasis on the experimental protocol. Carlos Morales Betanzos and Dr Maria Gonalez-
Moa prepared the LPS-Qdot micelles. Dr. Gonzalez- Moa characterized them by DLS. 
Mr. Morales Betanzos conducted the experiments with monocytes and conducted the 
fluorescent imaging. Mr. Morales Betanzos, Dr. Sergei Savrosky and Dr. Maria 
Gonzalez-Moa prepared the manuscript. 
4.2 Abstract 
Bacterial endotoxins or lipopolysaccharides (LPS) are among the most potent 
activators of innate immune system, yet mechanisms of their action and, in particular, the 
role of the glycans remains elusive. Efficient noninvasive labeling strategies are 
necessary for studying interactions of LPS glycans with biological systems. Here, we 
describe a new method for labeling LPS and other lipoglycans with luminescent quantum 
dots (QDots). The labeling is achieved by the partitioning of hydrophobic quantum dots 
into the core of various LPS aggregates without disturbing the native LPS structure. The 
biofunctionality of the LPS-QDot conjugates is demonstrated by labeling of mouse 
monocytes. This simple method will find broad applicability in studies concerned with 
visualization of LPS biodistribution and identification of LPS-binding agents. 
Key Words: Endotoxin, Lipopolysaccharide, Labeling, Monocytes, Quantum 
dots, Fluorescence imaging. 
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4.3 Introduction  
Bacterial lipopolysaccharides (LPS), also known as endotoxins, are the major 
constituents of the outer surface of Gram-negative bacteria [1]. They occupy up to 90% 
of the bacterial cell surface and are responsible for septic shock, which kills nearly 
200,000 critically ill patients in the USA alone [2].  Not surprisingly, there is a great deal 
of interest in understanding mechanisms of LPS action for the developing of antisepsis 
drugs. The development of such agents depends on the availability of efficient labeling 
strategies for LPS molecules [3]. Ideally, such labeling should not be disruptive to the 
LPS functionality. 
LPS are complex, negatively charged lipoglycans composed of three distinct 
regions: (a) a fatty acid region called Lipid A; (b) a core region oligosaccharide 
composed of up to 15 monosaccharides; and (c) a highly variable O-antigenic 
polysaccharide responsible for much of the bacterial pathogenicity and 
immunospecificity. Most labeling strategies rely on chemical modification of LPS 
molecules with organic dyes and normally require complex manipulations and 
purification steps [4, 5] due to the aggregative tendencies of LPS molecules [6]. The 
chemical modification is not site-specific and depends on the availability of reactive 
groups that are not always accessible or available in LPS [1]. If such groups are not 
present, they are chemically introduced by oxidation of the O-antigenic glycans [5, 7]. By 
introducing additional moieties to the LPS molecule, these methods perturb its physical 
properties and biomolecular recognition events [8], making such probes unlikely 
candidates for elucidating the roles of glycan interactions. 
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Nanometer-sized crystals of semiconductors known as quantum dots (QDots) 
have recently emerged as useful luminescent labeling agents [9]. These nanoprobes have 
significant benefits over organic dyes including long-term photostability, high 
luminescent intensity, and multiple colors with single-wavelength excitation that opens 
up possibilities for multiplex detection. Coating of hydrophobic QDots with 
phospholipids [10] and synthetic amphiphilic polymers have been described [11]. Both 
methods rely on phase transfer of hydrophobic QDots from an organic solvent to an 
aqueous solution of amphiphilic molecules. Here, we describe an application of 
hydrophobic QDots to non-covalent labeling of LPS and its derivatives. We show that 
this method may be broadly applicable to other lipoglycans as well. This method takes 
advantage of the universal amphiphilic nature of lipoglycans and does not introduce any 
chemical modifications to the LPS structure, making it ideally suitable for studying 
glycan interactions.  
4.4 Materials  
4.4.1 Labeling of LPS with QDots 
1. Organic Quantum Dots (QDot® 605 ITK™, Invitrogen, Inc) (see Note 1). 
2. Smooth-type LPS from Escherichia coli serotypes O111:B4 and O55:B5 (Sigma Inc.) 
and Pseudomonas Aeruginosa (Sigma Inc.), as well as Lipid A (Avanti Polar Lipids, 
Inc.), Kdo2-lipid A (Avanti Polar Lipids, Inc.), and lipoteichoic acid (LTA) from 
Bacillus subtilis (Sigma, Inc.) (see Note 2) (Fig. 1).  
3. Chloroform and methanol. 
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4. A saturated solution of tetramethylammonium hydroxide pentahydrate 
(Me4NOH+5H2O) 
5. Deionized water (18 mΩ) was obtained from a Millipore ultrapure water filtration 
unit.   
6. Zeba desalting spin columns (Pierce Inc.).  
7. Speed Vacuum concentrator (Thermo Scientific, Inc.).  
4.4.2 Cell Culture  
1. Mouse monocytes (ATCC RAW 264.7, American Type Culture Collection, 
Manassas, VA). 
2. Dulbecco’s modified Eagle medium (DMEM, GIBCO, Grand Island, NY) 
supplemented with 10% fetal calf serum (FCS).     
3. Dulbecco’s phosphate-buffered saline 1x (DPBS, GIBCO, Grand Island, NY). 
4. Nonenzymatic cell dissociation agent (CellstripperTM Mediatech Inc.). 
5. Hank’s Balanced Salt Solution (HBSS, GIBCO, Grand Island, NY). 
6. Fixing solution - paraformaldehyde 1% in PBS (Invitrogen Inc.). 
4.4.3 Flow Cytometry  
1. Flow cytometer (FACS Caliber, BD Biosciences Inc) (see Note 3) . 
2. 5 mL polystyrene round-bottom tube 12 x 75 mm style. 
4.4.4 Fluorescence Microscope  
1. Fluorescence microscope (for example, BX51, Olympus America Inc) (see Note 4). 
2. Poly(L-lysine)-coated glass slides (see Note 5). 
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4.4.5 Dynamic Light Scattering 
1. Zetasizer NanoZS (Malvern Instruments). 
2. 100 L disposable plastic cuvettes (Malvern Instruments, model ZEN0117). 
4.4.6 Transmission Electron Microscopy 
1. Electron microscope (Philips CM12S) operated at an accelerating voltage of 80 kV. 
2. Carbon-formvar mesh grids. 
3. Digital camera (e.g., Gatan model 791). 
 
4.5 Methods  
The described method for LPS labeling is compatible with several types of LPS 
varying in the glycan component, as well as for other lipoglycans with a similar 
amphipatic behavior. The resulting bioluminescent probes in the form of micelles are 
better evaluated by dynamic light scattering (DLS) and transmission electron microscopy 
(TEM).  Although the protocol as described was designed for complete LPS, we have 
also used it for labeling monophosphoryl Lipid A, which is the amphipatic component of 
LPS responsible for its toxicity, Kdo2-lipid A and LTA. Although Lipid A does not 
contain the glycan elements present in complete LPSs, it also forms micelles in solution, 
which prove to be necessary for our labeling method.  
4.5.1 Labeling of LPS in suspension  
1. Evaporate the solution of the Organic QDots (Invitrogen, Inc) until dry using the 
Speed Vac at room temperature (23˚C).   Resuspend the solid residue in equal amount 
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of chloroform. In our knowledge, the QDs suspended in chloroform are stable for 
several months without any visible sign of flocculation.  
2. Take a 100 µL aliquot of the chloroform solution and dilute it to 500 µL with 
chloroform. Prepare 100 µL of a 10mg/mL aqueous solution of the corresponding 
lipoglycan (i.e. E. coli 0111:B4, E. coli 055:B5, P. aeruginosa LPS, or Lipid A).  
3. Mix together the QDots in chloroform and the lipoglycan solution. At this point a 
very distinctive two-layer water-chloroform system will be formed. Add methanol 
dropwise with occasional vortexing until complete mixing of the two phases (ca. 
400µL of methanol). The homogeneous mixture chloroform/methanol/water will have 
an approximate ratio of 5:4:1 (see Note 6). 
4. Evaporate the homogeneous mixture until dry and resuspend the solid residue in 100 
µL of ddH2O. Add dropwise tetramethylammonium hydroxide pentahydrate 
(Me4NOH.5H2O) solution until pH 11 (ca. 25 µL). The latter basification step is 
critical as it allows transfer of the QDots into the aqueous phase.  No transfer occurs 
when no lipoglycan is present in the mixture. 
5. Then, sonicate the solution for 30 min. Pass the solution through two consecutive 
Zeba columns to remove salts and excess of free LPS (see Note 7). 
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Fig. 1. Schematic of the lipoglycans-QDot micelles formed with (a) lipid A, (b) Kdo2-
lipid A, and (c) LPS. 
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4.5.2 DLS Analysis of Lipoglycan-QDot Micelles 
1. Place 100L of the labeled LPS solution in a plastic disposable cuvette.  
2. Load the cuvette in the Zetasizer, close the lid, and run the size measurement of the 
lipoglycans-QDot micelles (see Note 8) (Fig. 2).  
 
 
Fig. 2. Size distribution by number of particles obtained from the DLS analysis of the 
LPS-QDot nanoprobes. The x-axis shows the particles diameter in nm, and the y-axis 
shows the percentage of particles of each specific diameter. (a) Isolated Qdots and 
lipoglycans (without Qdots) showing various sizes due to unilamellar and multilamellar 
arrangements in aqueous solution. (b) Isolated QDots and QDots complexed with LPS 
from P. aeruginosa 10, E. coli O111:B4, E. coli O55:B5, and lipid A are included. After 
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mixing with QDots and adding base, the size of the newly formed QDots-LPS aggregates 
is around 50 nm. The basification process makes the LPS monomeric, favoring the access 
of the QDots to the lipid part of the LPS. Under UV light, the QDot particles are seen in 
the aqueous solution, which is only possible if the particles are taken up by the 
amphiphilic LPS. No luminescence is observed in solution prior to adding the base. The 
sonication of the mixture of QDots-LPS for 30 minutes makes the aggregate more 
compact as the diameter is reduced to 38 nm and the peak distribution becomes narrower, 
indicating increasing homogeneity of the QDot-LPS conjugates. The excess of non-
solubilized QDots can be observed under UV light on the walls of the flask.  
 
4.5.3 TEM Analysis of Lipoglycan-QDot Micelles 
1. 2 µl of the labeled LPS solution was applied to a glow-discharged mesh copper grid 
coated with carbon-formvar.  
2. The sample was allowed to adhere for 1 min and excess liquid was removed. 
Contrasting stain was not required due to the inherent electron density of the QDots 
(Fig. 3). 
3. The sample was analyzed at an accelerating voltage of 80kV in the TEM, and images 
were recorded using magnification-calibrated digital acquisition.    
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Fig. 3. (a) Schematic of PS-QDot miscelles and (b) TEM image of the LPS-QDot 
micelles synthesized using this protocol. 
 
4.5.4 QD-LPS Labeling of Monocytes.   
1. Culture mouse monocytes until confluence in DMEM supplemented with 10% FCS at 
37°C in a 5% CO2 atmosphere and 95% humidity.  
2. Detach the monocytes from the flask using Cellstripper™ and wash twice with 1 x 
PBS. Resuspend the pellet in HBSS 1x. Count the monocytes in the solution and 
separate them in aliquots of 1 x 106 CFU in 5-mL polypropylene round-bottom tubes. 
Add LPS pre-labeled with QDots to a final concentration of 100 µg LPS/mL, for a 
final volume of 300 µL. Incubate for 30 min at 37°C. 
3. After incubation, wash the cells twice with PBS and fix them in 1% 
paraformaldehyde solution; wash two more times with PBS to remove the excess of 
fixing solution (Fig. 4). 
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4.5.5 Flow Cytometry  
1. Place an aliquot of 1 x 106 CFU pre-labeled and fixed in a 5-mL polypropylene 
round-bottom tube. Place the tube in the flow cytometer’s sample injection port.  
2. Set the appropriate beam laser for your sample (see Note 4). Set the appropriate filter 
for the emission of your QDots (see Note 3). 
3. Adjust the FSC and SSC detector levels to position the population properly on the 
graph.  
4. Adjust the threshold to eliminate low-level signals.  
5. Use the gate tool to draw a region around the cell population of interest.  
6. Adjust the fluorescence detector voltage for the channel (color) of interest.  
7. Acquire data. 
4.5.6 Fluorescence Microscopy 
1. Place 60L of the fixed cells solution on a poly-L-lysine-coated glass slide and set a 
cover slide on top. Allow the cells to attach for 30 minutes at room temperature 
(23˚C).  
2. Use the fluorescence microscope to visualize the cells:  Set the laser beam and filter 
in a short visible wavelength, such as blue or green, and view the cells using the 
corresponding filter for the emission of your QDots (see Note 4). Adjust the exposure 
time to maximize the signal above the background and acquire images. 
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Fig. 4. Fluorescence microscope image of mouse monocytes labeled with QDot-LPS. (a) 
Image taken using a filter with range 480-600 nm. (b) Image taken using a filter with a 
wavelength range of 539-650. QDot 605 nm labeling is only observed in (b).  
 
4.6 Notes 
1. We used QDot® 605 ITKTM organic quantum dots from Invitrogen with a peak 
emission wavelength of 605 nm. These QDots have a lipophilic coating required for 
this protocol. Alternatively, other organic QDots can be used with a different 
emission wavelength (Invitrogen offers organic QDots with 7 different emission 
wavelengths: 545, 565, 585, 605, 655, 705, 800 nm) 
2. Note that LPS, lipid A, Kdo2-lipid A, and LTA are pyrogens that may cause fever.  It 
may be harmful if inhaled, ingested, or absorbed through skin.  Good laboratory 
practice should be employed.  Wear a lab coat, gloves, safety glasses and a respirator 
mask.  LPSs from numerous Gram-negative bacteria are available from a large 
number of vendors. In the method described here, LPS from three different bacteria 
was used. Additionally, other lipoglycans with a similar amphipatic behavior can be 
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used with our method.  For example, monophosphoryl Lipid A (PHAD, Avanti Inc.) 
was used to synthesize labeled micelles with similar properties to the LPSs.  
3. We used a Flow Cytometer (FACS Caliber, BD Biosciences Inc) equipped with a 488 
nm Argon laser. The Instrument has three band-pass emission filters. FL1: 530 ± 30 
nm (green), FL2: 585 ± 42 nm (yellow - orange), FL3> 650 nm (red). Since the 
emission of the QDots we used is 605nm, FL2 was used.  
4. We used a Fluorescence microscope (BX51, Olympus America Inc) equipped with a 
100-W mercury lamp, two separate filter wheels for fluorescence and excitation 
emission, and an Olympus DP70 12.5 megapixel cooled digital camera (Olympus 
America Inc). The samples labeled with QDot® 605 ITKTM were exited using a 
488nm beam, and emission was registered through an orange filter. (QDots are 
characterized by a broad excitation band that precedes the emission peak and are 
better excited using UV light. However, for cell samples, it is recommended to use 
short visible wavelengths such as blue or green to avoid damaging the samples.)  
5. Poly-L-lysine-coated glass slides were prepared as described elsewhere by incubating 
acid-washed slides in poly-L-lysine 0.1% solution for 30 min and drying them at 
115°C for 30 min. Alternatively poly-L-lysine-coated  slides and cover slides can be 
purchased from different vendors (Polysciences Inc, BD Biosciences).  
6. Although the 5:4:1 ratio works well for most LPSs, Lipid A solution attained 
homogenization with less methanol. In general, the predominant factor to observe is 
the complete mixing of the phases independently of the ratio of solvents.  
7. If necessary, further purification can be achieved through size exclusion 
chromatography. We used a Sephacryl HiPrep 16/60 (S-200 HR) column (50 x 1 cm) 
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(GE Healthcare) for this purpose.  The LPS-QDots conjugate was eluted in a narrow 
color band and stored in the dark at 4 ºC. Under these conditions, the LPS-QDots are 
stable for at least one month without any visible signs of flocculation or deterioration 
of fluorescent intensity. If such flocculation occurs, the constructs can be 
reconstituted by sonication. 
8. DLS measures the size of particles, emulsions and molecules in suspension, by means 
of the fluctuation of their Brownian motion when the particles or molecules are 
illuminated with a laser. The intensity of the scattered light fluctuates at a rate that is 
dependent upon the size of the particles. Analysis of these intensity fluctuations 
yields the velocity of the Brownian motion and hence, the particle size using the 
Stokes-Einstein relationship.  
 
Figure 2 shows the size distribution during the labeling process of smooth-type LPS from 
E. coli O55:B5, measured at 173° scattering and at room temperature (23ºC). The 
experiment was performed with the following settings: material profile “protein”, 
refractive index = 1.450, absorption = 0.001; dispersant water: temperature = 25°C, 
viscosity = 0.8872 cP, and refractive index = 1.330. The Mark-Houwink parameters are 
as follows: A parameter = 0.428, K parameter (cm2/s) = 7.65.10-5; equilibration time = 2 
min, and cell: ZEN0117-disposable micro-cuvette (100L). 
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CHAPTER 5 
IDENTIFICATION AND ANALYSIS OF NOVEL NMYC 
PHOSPHORYLATION SITES IN HIGH RISK NEUROBLASTOMA 
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5.1 Abstract  
The transcription factor NMYC is a proto-oncogene associated with several types 
of cancer, of which the most notable are neuroblastomas. Amplification of NMYC is the 
most important feature of high risk neuroblastoma, the most aggressive form of this 
disease. Despite the central role of NMYC in neuroblastoma tumorigenicity, its 
biochemical regulation is still incomplete. To date, only 6 NMYC phosphorylation sites 
have been found, which contrasts dramatically with the 27 sites identified in c-MYC, 
another member of the MYC family and a close homologue that also regulates cancer. In 
this paper, we describe the purification of endogenous NMYC from five high risk 
neuroblastoma cell lines and the use of a 3-step LC-MS/MS methodology to identify 11 
NMYC phosphorylations, including 8 novel sites. The new phosphorylations shared an 
almost identical sequence homology and relative position to other active sites within the 
MYC family responsible for regulating cell transformation, increasing protein stability 
and protein turn-over in cancer. We conducted a bioinformatics analysis using the amino 
acid sequence of the novel phosphorylation sites and identified Chk1, CK1 and CK2 as 
plausible upstream kinases of the novel phosphorylations. We then confirmed the 
capacity of the three kinases to phosphorylate NMYC using in vitro assays, which 
suggests that those kinases may be important in regulating NMYC in high risk 
neuroblastoma through the novel identified sites. 
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5.2  Introduction  
Neuroblastoma accounts for 7.5% of all cancers in children younger than 15 years 
old and 15% of all pediatric oncology deaths.(1) It is the most common extra cranial solid 
tumor in childhood affecting 1 case per 7,000 live births in the USA.(2) 
Neuroblastoma is very heterogeneous, with a wide spectrum of clinical 
presentations and outcomes depending on several factors including age at the time of 
diagnosis, extent and biology of the tumor. Using a combination of these factors, 
neuroblastoma is clinically classified into three distinctive risk levels: low, medium and 
high risk (LR-, MR- and HR-NB). Each level describes increasing cancer aggressiveness 
and is treated more intensively.(3) LR-NB has a very good prognosis with a 5-year 
survival rate of > 95%. MR-NB is treated with surgery and chemotherapy with generic 
cancer agents (carboplatin, cyclophosphamide, doxorubicin or etoposide) and has a 5-
year survival rate of 90-95%. In striking contrast, HR-NB is treated in a very intense, 3-
step treatment consisting of: (a) Induction, which aims to destroy as much of the tumor as 
possible using chemotherapy and surgery; (b) Consolidation with high doses of chemo- 
and radiotherapy, which is followed in many cases follow by stem cell transplantation to 
help patients recover; and (c) Maintenance, which focuses on decreasing the chances of 
recurrence. This is accomplished using retinoic acid and the only known target-specific 
agent for neuroblastoma, the antibody ch14.18 directed toward GD-2, a ganglioside 
highly expressed in neuroblastoma. Despite the very intensive treatment, the 5-year 
survival for HR-NB is only 40-50%.(4) New treatments for HR-NB that are more 
effective and less intense for the patients are urgently needed.  
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One attractive area to explore in the search for treatments for HR-NB is the 
identification and targeting of abnormal cell signals in the tumor. This approach, which 
has been successfully used to treat 80% of children with acute lymphoblastic leukemia(5, 
6), aims to inhibit the key protein phosphorylations that modulate the abnormal cell 
signals in tumors. The target of such approaches should be proteins that are key for the 
tumorigenicity of the cancer and whose mechanism of action relies on the 
phosphorylation state of the protein. 
The transcription factor NMYC is the most important neuroblastoma oncoprotein 
known to date. It was first linked to neuroblastoma by Kohl(7) and Schwab(8) in 1983 
when multiple copies of the gene were identified in certain neuroblastoma cases. It was 
soon after this discovery that amplification of the gene was linked to the worse prognosis 
in 20% of patients (9, 10). Since then, NMYC has been extensively described in literature 
as a major component of the tumorigenic cell signaling of neuroblastoma(11, 12), 
medulloblastoma(13, 14), rhabdomyosarcoma(15), neuroendocrine prostate cancer(16) 
and human acute myeloid leukemias(17). 
Despite its relevance in several neuronal tumors, NMYC-mediated cell signaling 
has not been described to nearly the same extent as its non-neuronal counterpart c-MYC, 
which is also a well-documented proto-oncogene that shares 47% sequence homology 
with NMYC. C-MYC is also involved in the tumorigenic signal of many types of cancer 
of non-neuronal origin (18-22). This disparity in understanding the cell signaling of the 
two oncogenes is evident when comparing the number of phosphorylation sites currently 
described in NMYC (6 sites) and those described in c-MYC (27 sites)(23).  
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Because several of the c-MYC phosphorylation sites have been directly linked to 
function in cancer and even selected as therapeutic targets(24), a similar scenario may 
hold for NMYC where many other phosphorylation sites may be present in the protein 
with potential function in the tumorigenicity of neuronal cancers.   
In this paper, we describe the identification of eleven phosphorylation sites in 
endogenously expressed NMYC using five high risk neuroblastoma cell lines. This more 
than doubles the number of known phosphorylation sites for NMYC. All of the novel 
sites located next to MYC family functional domains, and some sites have a direct 
homolog in c-MYC with known oncogenic signaling involvement. The increase in 
phosphorylation detection was accomplished through the use of immunoaffinity 
purification (IP) followed by in-gel trypsin digestion (TD) and phosphopeptide 
enrichment (TiO2) before LC-MS/MS. We further conducted the identification of a series 
of kinases with the capability of phosphorylating the novel NMYC sites using two 
computational models and then experimentally confirmed the phosphorylation events 
using in vitro kinase assays.  
5.3 Materials and Methods 
Cell culture and reagents - High risk neuroblastoma cell lines CHP134 and Kelly 
were purchased from Sigma Aldrich.  SK-N-BE(2), IMR-32 and SK-N-DZ were 
purchased from ATCC. Cells were grown in either RPMI or DMEM (Life Technologies) 
supplemented with 10% Fetal Bovine Serum (Hyclone) according to cell repository 
instructions. All cells were maintained in a humidified atmosphere at 37°C in 5% CO2.  
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The anti-NMYC rabbit antibody used for immunoprecipitation was purchased from Santa 
Cruz Biotechnology, Inc.  
Immuno-affinity purification (IP) - for each experiment, high risk neuroblastoma 
cells were plated in eight 145 cm2 plates, grown to 90% confluency and lysed using 2mL 
of cold RIPA buffer supplemented with EDTA-free HALT protease and phosphatase 
inhibitor (Thermo Scientific). The cell lysate was collected and centrifuged at 11,000 x g 
for 15 minutes at 4°C and the pellet discarded before the IP. For a single 
immunoprecipitation experiment, 30-50 mg of total protein were regularly utilized. This 
amount or protein was extracted routinely from 8 plates of cells. For the 
immunoprecipitation, 600ug of antibody was immobilized in 1 mL of protein-G 
dynabeads (Invitrogen) according to manufacturer instructions. Antibody conjugates 
beads were then added to the clarified lysates and incubated overnight at 4°C. Target 
proteins were eluted from the beads using 4x SDS and resolved via SDS-PAGE on 4-
20% Tris/Glycine gels (Bio-rad) and stained with Commassie protein stain following 
manufacturer instruction (Invitrogen). NMYC bands were photographed and then cut 
inside of a laminar flow cabinet following standard practices for MS sample preparation.  
MS sample processing - Target protein bands (which typically comprised two 
bands, one of slightly slower migration than the other around 50 KDa) were de-stained in 
20% ethanol overnight, washed for 2 hours and diced into small 1 mm3 gel fragments. In-
gel protein digestion was performed according to the classic Shevchenko method 
modified by Mann et al(25). Briefly, samples were dehydrated in acetonitrile, incubated 
in 10mM dithiothreitol (Bio-Rad) in 100mM ammonium bicarbonate, acetylated with 
55mM Iodoacetamide (Sigma Aldrich) and digested overnight in 13ng/ul trypsin in 
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10mM ammonium bicarbonate+10% acetonitrile. Digested peptides were extracted using 
a solution of formic acid 5% and acetonitrile in a 1:2 ratio. Peptide solution was 
evaporated to dryness in a vacuum concentrator (Eppendorf) and peptides either analyzed 
as is using LC-MS/MS or further processed with titanium oxide (TiO2). 
TiO2 phosphopeptide enrichment - Titansphere centrifuge pipette tips (3mg, 
200uL) were purchased from GL Sciences. Tips were conditioned according to 
manufacturer instructions using Buffer A (TFA 2% and acetonitrile 1:4 ratio) and Buffer 
B (Solution B + Buffer A 1:3 ratio). Dehydrated peptides from the previous step were re-
suspended in Buffer B and re-circulated inside the tip three times using a benchtop 
centrifuge (Beckman Coulter) at slow speed (~1500 rpm) for 12 minutes. The tips were 
washed once in Buffer B and three times in Buffer A. Elution was performed in three 
steps using 1%NH4OH in water, 1% NH4OH in acetonitrile and 5% pyrrolidine in water. 
The purpose of each step was to elute hydrophilic, hydrophobic and poly phosphorylated 
peptides from the TiO2 column.  The three elutions were pooled together and neutralized 
with acetic acid 50% before evaporating to dryness in a vacuum concentrator for 4 hrs. 
LC-MS/MS Analysis of phosphopeptides - MS analyses of phosphopeptides were 
performed by Michael Ford Ph.D. from MS Bioworks (Ann Arbor, Michigan). In brief, 
samples were solubilized in 70 uL of 0.01% trifluoroacetic acid (TFA) in water. Each gel 
digest was analyzed by nano LC-MS/MS in a Waters NanoAcquity HPLC system 
interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and 
eluted over a 75μm analytical column at 350nL/min. Both columns were packed with 
Jupiter Proteo resin (Phenomenex), and the injection volume was 30μL. The mass 
spectrometer was operated in data dependent mode, with the Orbitrap operating at 60,000 
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FWHM and 17,500 FWHM for MS and MS/MS respectively. The fifteen most abundant 
ions were selected for MS/MS. 
MS Data Processing - Data were searched using a local copy of Mascot with the 
following parameters:  Enzyme: Trypsin/P, Database: SwissProt Human, Fixed 
modification: Carbamidomethyl (C), Variable modifications: Oxidation (M), Acetyl (N-
term), Deamidation (N,Q), Phospho (S,T,Y), Mass values: Monoisotopic, Peptide Mass 
Tolerance: 10 ppm, Fragment Mass Tolerance: 0.02 Da, Max Missed Cleavages: 3. 
Mascot DAT files were parsed into Scaffold software for validation, filtering and to 
create a non-redundant list per sample. For protein identification, the data were filtered 
using a minimum protein value of 90%, a minimum peptide value of 50% (Prophet 
scores) and requiring at least two unique peptides per protein. Ascore-derived PTM site 
localizations were calculated and the fragmentation spectra alignments were manually 
inspected using the Scaffold PTM software v 2.0 (Proteome Software). 
Identification of kinase substrate motifs - A bioinformatics analysis was 
performed to correlate the sequence of the novel phosphorylation sites with known kinase 
substrate motifs using two independent algorithms (26, 27).  A series of eleven kinases 
were identified using both methods. NMYC peptide sequence and kinase motifs are 
presented together in Table 5.1. The list of kinase candidates was further analyzed using 
an exhaustive literature search for the terms “kinase name” and “neuroblastoma” in 
PubMed and SciFinder (April 2014). Results were parsed looking for papers describing a 
correlation between the kinase protein expression levels or kinase inhibition and 
neuroblastoma invasion, proliferation or growth. From the original list of 11 kinases, 
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several kinases were identified as linked to cancer but only three were linked specifically 
to high risk neuroblastoma.  
 
Table 5.1. Identification of kinase motifs correlating with the novel NMYC sites. 
 
 
In-vitro kinase assays - NMYC protein expression plasmid was acquired from 
the DNASU plasmid repository(28) (http://www.dnasu.org). The NMYC gene was 
located inside the pLP-DS3xFlag vector for in-vitro transcription and translation (IVTT) 
with mammalian extract. The plasmid also contains a C-terminal 3xFlag tag for 
immunoprecipitation. IVTT reaction was performed using the 1-step coupled Human IVT 
Protein Expression Kit (Thermo Scientific) according to manufacturer instructions. 
Proper expression of the full-length protein was characterized by western blot with both 
a-Flag antibody (Sigma-Aldrich) and a-NMYC (cell signaling) antibodies (Figure 5.1). 
Kinase aa site NMYC peptide kinase substrate motif Notes
AMP-PK s352 IKSEAsPRPL [M/V/L/I/F][R/K/H]XXX[pS/pT]XXX[M/V/L/I/F]
CaMKII S131,S315 LERAVsEK, RAQs [M/V/L/I/F]X[R/K]XX[pS/pT]XX, RXXpS
CaMKIV S131 LERAVs [M/I/L/V/F/Y]XRXX[pS/pT], 
CK1
T142, T149, 
S352, S371 tAGS, tAQs, SEAS, sPRNS [pS/pT]XX[S/T], pSPXX[pS*/pT*] linked to NB (REF)
CK2
T142, T149, 
S315, S352, 
S375 tAGS, tAQS, sSE, sEAS, sDS
[pS/pT]XX[E/D/pS*/pY*], pSX[E/pS*/pT*], 
pSXX[E/pS*/pT*], pSX[E/pS*/pT*]
linked to Cancer 
(REFs)
Chk1 S131 LERAVs [M/I/L/V]X[R/K]XX[pS/pT] linked to NB (REF)
DNA-PK T142 PtA P[pS/pT]X
ERK1, ERK2, 
T149, S355, 
S371 sP pSP
GRK1 
(RHOK)
S131, T142, 
S315, S352, 
S371, S375, 
S371
AVsE, PtAGST, QSsE, IKsE, 
LsPRNS, SDsE, sPR
XX[pS/pT]E, X[pS/pT]XXX[A/P/S/T], 
XX[pS/pT]E, XX[pS/pT]E, 
X[pS/pT]XXX[A/P/S/T],                XX[pS/pT]E, 
[pS/pT]P[R/K]
GSK3 T149, S371 sTAQS, sPRNS pSXXXpS*
MAPKAPK2 T149,S371 sTAQs, sPRNs pSXXX[pS/pT]
PKA S131,S315,S352,S355,S371,S375
RAVs, RAQs, KKIKs, sPR, 
RNs RXXpS, KXXX[pS/pT], [pS/pT]X[R/K], RXpS
PKC S131,S315,S352,S371,S375RAVs, RAQs, KIKs, sPR, RNs [R/K]XX[pS/pT], [pS/pT]X[R/K], [R/K]X[pS/pT] linked to NB (REF)
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NMYC-Flag protein was immunoprecipitated using a-Flag antibody (Sigma-Aldrich) 
immobilized in protein-G magnetic beads (Invitrogen).  The Protein-antibody-bead 
complex was washed in PBTS 0.2% and incubated with a solution of Lambda Protein 
Phosphatase (New England Biolabs) for 1 hr at 30⁰C to remove non-specific 
phosphorylations occurring during the IVTT reaction. De-phosphorylated NMYC was 
then incubated with a solution of Chk1, CK1 or CK2 active kinases (Millipore) in kinase 
buffer containing 200uM of ATP. The concentration of each kinase was adjusted 
according to the activity plot provided by the manufacturer. Mixtures were incubated for 
1 hour at 30⁰C and washed intensively with TBS buffer. Phosphorylated NMYC was 
eluted using 4x SDS sample solution, resolved using a SDS-PAGE gel and the NMYC 
band cut and processed for MS/MS using the same protocol previously described.  
 
 
Figure 5.1. Characterization of correct NMYC-Flag expression using western blots. 
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5.4 Results  
5.4.1 Isolation of Endogenous NMYC from High Risk Neuroblastoma Cell Lines 
To analyze the phosphorylations of endogenously expressed NMYC in detail, we 
grew five different high-risk neuroblastoma cell lines (CHP134, Kelly, SK-N-BE(2) , 
IMR-32 and SK-N-DZ), all of which expressed high levels of NMYC (Figure 5.2). Eight 
90% confluent plates of each cell line were required to generate enough material for the 
immunoprecipitation and subsequent phosphorylation analysis.  IP was performed in 30-
50mg of total protein (cell lysate), and NMYC was eluted from the beads and loaded into 
a SDS-PAGE gel. Figure 5.3 shows the purified NMYC protein stained with Coomassie 
dye.  The SDS gel was run inside the electrophoretic chamber for a few minutes, which 
was just enough time to resolve most of the proteins while allowing the two bands 
corresponding to the phosphorylated NMYC to run together. NMYC protein bands were 
then processed as described in material and methods. 
 
 
Figure 5.2. NMYC expression in 4 HR-NB cell lines and 1 negative control. 
  
Nmyc
Actin
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Figure 5.3. SDS gel stained with Coomassie dye showing the Immunoprecipitation of a 
large amount of NMYC protein. 
 
5.4.2 Identification of Novel NMYC Phosphorylation Sites Using a 3-Step Approach 
Liquid Mass Chromatography tandem mass spectrometry (LC-MS/MS) is the 
most common method used to identify novel post-translational modifications including 
phosphorylations. A well-known limitation of this technology is the difficulty to detect 
less abundant analytes in the presence of more abundant proteins that can mask the 
signals from the first, which can be compared to finding the mythical needle in the 
haystack where phosphopeptides are the needle and the non-phosphorylated peptides of 
both target and non-target proteins are the haystack. This problem has been addressed by 
separating complex mixtures of proteins (i.e., whole cell lysate) into fractions of lesser 
complexity. This is accomplished by isoelectric point separation, organelle specific 
isolation or other similar techniques. However, the problem still remains for the analysis 
of protein phosphorylation because most cell signaling proteins are not only low in 
abundance, but only a fraction of them are modified. This scarcity within a scarcity (a 
haystack inside of another haystack) makes the analysis of protein phosphorylation very 
challenging.  
Other groups have previously approached this problem using different methods 
(29-34). Here, we used a 3-step approach to sequentially immunoprecipitate (IP) NMYC 
from cells, produce tryptica digests (TD), and finally, enrich for only the phosphorylated 
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peptides (Ser, Thr and Tyr) using titanium dioxide (TiO2). Using a combination of these 
methods (IP-TD-TiO2), we increased the number of total phosphopeptides identified in 
the target protein up to 4-fold. Figure 5.4a and Figure 5.4b show the difference between a 
standard LC-MS/MS run (A) and the IP-TD-TiO2 approach (B). It is noticeable that 
although the protein coverage of sample A was large, only few phosphorylation sites 
were identified. In contrast, in sample B the protein coverage was much lower, but the 
number of phosphorylations identified was 4 times higher. This significant difference 
resulted from the addition of a phosphopeptide enrichment step in sample B which 
eliminated the non-phosphorylated peptides from the tryptic digest and allowed only the 
phosphorylated species to reach the MS detector. The phosphopeptide enrichment step 
resulted in a decrease of overall coverage (non-phosphorylated peptides), but also an 
increase of phosphopeptide concentration and a subsequent increase in phosphorylation 
site detection.  
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Figure 5.4. a) The application of a standard LC-MS/MS run resulted in 81% protein 
coverage, however only four phosphorylations were identified. b) A similar MS analysis 
conducted after Immunoprecipitation, in-gel trypsin digestion and TiO2 phospho 
enrichment (IP-TD-TiO) resulted in 21% protein coverage and fourteen S,T and Y 
phosphorylation sites were identified. c) The same process applied to NMYC extracted 
from 5 high risk neuroblastoma cells resulted in the identification of 11 phosphorylation 
sites including 8 novel sites. Amino acid protein sequences are represented with letters, 
MS identified peptides are highlighted in yellow, posttranslational modifications are 
labeled in green, phosphorylation sites are highlighted in red. 
 
a
b
c
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5.4.3 LC-MS/MS Identification and Assignment of Novel NMYC Phosphorylation 
Sites 
Using the IP-TD-TiO2 approach, we identified eight novel and three of the six 
reported phosphorylation sites in endogenous NMYC expressed in SK-N-BE high risk 
neuroblastoma cells (Figure 5.4c). The three most highly documented sites, T58, S62 and 
S156, were all observed with our approach; however, S64, S261 and S263, which have 
been only seen in few studies, were not observed. All identified sites were evaluated by 
Ascore and confirmed manually before confidently assigning the modification to the site. 
To eliminate potential phosphorylation artifacts because of the use of only one cell line, 
we confirmed the novel phosphorylations in five independently established high risk 
neuroblastoma cell lines: SK-N-BE(2), SK-N-DZ, IMR-32, Kelly and CHP-134 cells. 
Table 5.2 shows the sites that were identified in each cell line and confirms that most of 
the novel sites were present in multiple lines. A representative spectrum for each novel 
phosphorylation site is presented in Figure 5.5, and the best Ascore values for each 
peptide are presented in Table 5.3.  
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Table 5.2. NMYC phosphorylation sites identified in 5 high risk neuroblastoma cells 
using LC-MS/MS.  The table shows the phosphorylations sites identified in each cell line 
in blue (known sites) and red (novel sites). 
 
 
high risk 
NB cell 
line
Kelly SK-N-DZ IMR-32 CHP-134 SKNBE
T58 Y Y Y Y Y
S62 Y Y Y Y Y
S131 Y Y Y Y Y
T142 - Y - - -
S149 Y Y Y Y Y
S156 Y Y Y Y Y
S315 Y Y - - Y
S352 Y - - - -
S355 Y - Y - Y
S371 Y Y - Y Y
S375 Y Y - Y Y
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Figure 5.5. Representative MS/MS spectra of NMYC novel phosphorylation sites. 
Peptides prepared from IP-TD-TiO2 were subject to nano LC-MS/MS using a Waters 
NanoAcquity HPLC system interfaced to a Thermo Fisher Q Exactive as described in 
experimental procedures. Shown are representative examples of tandem mass spectra for 
each novel phosphorylation site displaying all PTM-bearing peptides fragment ion 
assignments. 
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Table 5.3. Novel phosphorylation sites identified in endogenous NMYC from high risk 
neuroblastoma cell lines.  The table shows the phosphorylation site, best Ascores for each 
site, localization probability and peptide sequence. 
 
 
5.4.4 Identification of Kinase Substrate Motifs Correlating with Novel NMYC 
Phosphorylation Sites 
Using two independent literature-curated databases of kinase substrates, The 
Human Protein Reference Database- motif finder (26) and Phosida-motif finder (27), we 
searched for serine or threonine kinases with substrate motives correlating with the novel 
phosphorylation sites identified in NMYC. In both databases, we identified 11 kinases 
with motifs matching the sequence of the novel sites as depicted in Table 5.4. After an 
exhaustive literature search with this list of kinases, three of them stand out as significant: 
Chk1, Ck1 and CK2 have been linked directly to high risk neuroblastoma tumorigenicity 
(35, 36)_ENREF_27 (37, 38). Chk1 is particularly interesting because we identified its 
substrate motif (NMYC-Ser131) in all five neuroblastoma cell lines and because Cole K. 
Site Modification
Best 
Ascore*
Localization 
Probability
Peptide Sequence Start Stop
Peptide 
Score
Charge Actual Mass
T58 Phospho 102.07 100% KFELLPtPPLsPSR 52 65 136.47 3 1740.825942
S62 Phospho 27.96 100% KFELLPTPPLsPSR 52 65 178.52 2 1660.858008
S131 Phospho 1,000.00 100% AVsEKLQHGR 129 138 141.74 2 1203.577248
T142 Phospho 21.44 98% GPPtAGSTAQSPGAGAASPAGR 139 160 127.99 4 1944.869096
S149 Phospho 112.12 100% GPPTAGSTAQsPGAGAASPAGR 139 160 395.49 2 1944.874128
S156 Phospho 238.84 100% GPPTAGSTAQsPGAGAAsPAGR 139 160 261.45 3 2024.840112
S315 Phospho 53.98 100% AQsSELILK 313 321 189.22 2 1067.530488
S352 Phospho 1,000.00 100% IKsEAsPRPLK 350 360 58.51 3 1384.648002
S355 Phospho 1,000.00 100% IKsEAsPRPLK 350 360 58.51 3 1384.648002
S371 Phospho 50.19 100% SLsPRnSDSEDSER 369 382 213.97 3 1658.646582
S375 Phospho 70.16 100% SLsPRNsDSEDSER 369 382 180.94 3 1737.621792
*Note that an Ascore of 1,000.00 means that there is no uncertainty in the position of the modification. 
 This happens when there is only one amino acid where the modification could go
  149 
et al (35) found that Chk1 inhibition had the strongest inhibitory effect on high risk 
neuroblastoma cell survival from a panel of 529 kinases shRNAs. 
 
Table 5.4. In-vitro phosphorylation of novel NMYC sites by CK1, Ck2 and Chk1. 
 
 
5.4.5 In-Vitro Kinase Assay 
To further characterize the effect of ChK1, CK1 and CK2 in the phosphorylation 
of NMYC, we conducted a series of in vitro kinase assays. We cloned NMYC into an in 
vitro translation vector and expressed the Flag tagged NMYC using a human IVT protein 
expression system. We immunoprecipitated NMYC and removed the non-specific 
phosphorylations occurring during the IVTT reaction using a protein phosphatase. The 
non-phosphorylated protein was then incubated with active Chk1, Ck1 or Ck2 in 
presence of ATP for 1h at 30˚C. The phosphorylated NMYC was eluted and further 
analyze by LC-MS/MS as previously described. The NMYC phosphorylation identified 
at each step of the IVT process are reported in Table 5.4. It is noticeable that each kinase 
induced the phosphorylation of a slightly different subset of sites. According to the 
bioinformatics analysis we performed and previous publications, CK2 was the only 
NMYC + + + + + +
Pptase - + + + + +
Kinase - - CK1 CK2 Chk1 Grk1
131 Y - Y Y Y Y
142 Y - Y Y Y Y
149 Y - Y Y Y Y
315 Y Y Y Y Y Y
352 - - Y Y Y Y
355 Y - Y - - Y
371 - - Y Y Y Y
375 Y - - Y - -n
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kinase capable of phosphorylating S375, and CK1 was the only kinase capable of 
phosphorylating S355 which was confirmed experimentally. However, the remaining 6 
novel sites were phosphorylated in a similar manner by all three kinases.   
5.5 Discussion  
Despite being one of the most common solid tumors in children and accounting 
for ~1 of 7 of pediatric cancer deaths, neuroblastoma treatment still relies on cytotoxic 
agents. To date, the monoclonal antibody Ch14.18, which targets GD2, is the only 
neuroblastoma-specific agent used in clinics. New therapeutic agents that target high risk 
disease are especially needed because of the poor success even after intensive therapy. 
Targeting abnormal cell signaling in cancer has proven highly successful, especially 
targeting kinases; however, many of the neuroblastoma-specific phosphorylations are still 
unknown. In this paper, we utilized a combination of techniques to describe in detail the 
phosphorylations of the most important neuroblastoma onco-protein: the transcription 
factor NMYC. Our analysis identified eight novel phosphorylation sites next to key 
functional domains of the MYC family of proteins (MBII, MBIV, and BR). Furthermore, 
several of these NMYC sites are homologous to oncogenic regulatory phosphorylations 
in the c-MYC oncoprotein. 
5.5.1 NMYC Novel Phosphorylation Sites Have Homologous Positions in c-MYC 
Based on its selective expression, NMYC is considered the neuronal counterpart 
of its famous sibling, the proto-oncogene c-MYC. Both proteins belong to the same 
family of transcription factors, are 47% homologous to each other and share the same 
functional domains. However, they are expressed in different subsets of cells as NMYC 
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is predominantly present in neuronal cells (39) whereas c-MYC is expressed 
ubiquitously. The cell signaling pathways mediated by c-MYC have been studied 
extensively; to–date, 27 phosphorylation sites have been described in c-MYC. However, 
only 6 phosphorylation sites are currently known for NMYC. Using a phosphorylation-
targeted approach, we increased the identification of NMYC phosphorylation sites to 14 
sites.  Most of the new identified sites have either a direct sequence or a relative position 
homologous in c-MYC. Figure 5.6 shows the homology comparison between the novel 
NMYC sites and the previously described sites in c-MYC. The figure also shows that 
some of the c-MYC homologous sites have been previously linked to an increment of c-
MYC turn over (A), an increase in c-MYC stabilization (B) and an increase in cell 
transformation and tumorigenicity (B and C).  
 
  152 
 
Figure 5.6. Homology comparison of novel (red) and known (blue) phosphorylations 
sites identified in NMYC and the protein family member c-NMYC. Novel sites were 
confirmed in five high risk neuroblastoma cell lines. 
 
5.5.2 Novel NMYC Phosphorylation Sites Are Located Next to Functional MYC 
Domains 
It is remarkable that the novel phosphorylation sites we identified in NMYC are 
situated next to well-described functional domains of the MYC family: The Myc 
Homology Box II and IV (MBII and MBIV) and the Basic Region (BR).  In c-MYC, 
MBII is necessary for interaction with the transactivation/transformation associated 
protein (TRRAP) and other co-factors involved in cancer transformation. MBIV and BR 
are also key for transformation of primary and immortal cells, especially the latter 
through its interaction with c-MYC binding partner MAX(40).  As shown in Figure 5.6 
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X,Y and Z, the novel NMYC sites S131 and T142 are located next to the MBII, S352, 
S355 are next to MBIV, and S371 and S375 are next to the BR domain. All these sites 
have homologous sites in similar positions in c-MYC as described in Figure 5.6 A, B and 
C. Some of those sites have even more remarkable similarities as described below.  
5.5.3 Novel NMYC Sites Are Homologous to Known c-MYC Sites Regulating Cell 
Transformation 
Using Clustal Omega(41), a multiple sequence alignment program for proteins, 
we aligned the amino acid sequences of NMYC and c-MYC. As reported, the homology 
between both proteins was 47%. Using the analysis software Jalview2(42), we visualized 
the alignment of both proteins side-by-side to compare the novel phosphorylation sites 
identified in NMYC against the analogous sites in c-MYC. The side-by-side comparison 
can be appreciated in the Figure 5.7. From this analysis, we observe that NMYC novel 
sites S371 and S375 have an almost identical sequence homology to c-MYC sites S344 
and S348. These two c-MYC sites were recently identified by Wasylishen et al (24) as 
two regulators of cellular transformation in MCF10A cells and SH-EP cells. Their study 
utilized anchorage independent growth in combination with gene expression profiling to 
evaluate the role of several c-MYC phosphorylation site mutants. The investigation 
concluded that S344 and S348 together with other two sites modulate MCF10A 
transformation through transcriptional regulation of c-MYC as they increase the protein 
binding to selected promoters. Within that list, genes involved in non-coding RNA 
processing and metabolism were significantly enriched. Because of the similarity in both 
protein sequence and relative position to functional domains, it is conceivable that S371 
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and S375 in NMYC may also affect cellular transformation and anchorage independent 
growth – a hypothesis that should be evaluated by site directed mutagenesis studies. 
 
 
Figure 5.7. Sequence homology comparison between c-MYC (top) and NMYC (bottom). 
Novel NMYC phosphorylation sites are highlighted in red, c-MYC analogous sites are 
highlighted in blue (phosphorylation) and green (acetylation). 
S131S146
S293
T142 S149
S315 S352 S355S329 S371 S375S344 S348
K143 K148 K157
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5.5.4 Novel NMYC Sites Are Homologous to Known c-MYC Site Regulating Protein 
Stability 
The novel NMYC sites S352 and S355 are also remarkably similar to Serine 329 
in c-MYC. They share the same relative position next to the functional MBIV domain 
(Figure 5.6) and share analogous amino acid vicinity as depicted in Figure 5.7.  Serine 
329 in c-MYC has also been well characterized, and phosphorylation in this position has 
been linked to increased c-MYC stability in B-cell lymphoma. Zhang et al (43) 
previously reported that phosphorylation of S329 regulates c-MYC endogenous levels by 
stabilizing c-MYC in vivo. This group also showed that the mutant S329D, which mimics 
the phosphorylation state of S329, was much more stable than wild type c-MYC and 
produced a large number of colonies during anchorage independent growth assays. In 
contrast the c-MYC mutant S329A, which cannot be phosphorylated, was less stable 
when transfected into cells and produced fewer colonies than wild type c-MYC. The 
combination of these results point to the relevance of c-MYC phosphorylation at S329 to 
c-MYC stability and induced tumorigenicity. Because the novel NMYC phosphorylation 
sites S352 and S355 share a similar relative position and peptide sequence to S329 in c-
MYC, both of these sites may play a role in stabilizing NMYC. It is not clear if there is 
an advantage to having two possible phosphorylation sites in the corresponding position 
where c-MYC has only one site.  Could this imply a possible redundant mechanism 
related to stabilizing NMYC? 
  156 
5.5.5 Novel NMYC Sites Surround Homologous c-MYC Stabilization Sequence 
Regulated By Acetylation 
As depicted in the Figure 5.7, the novel NMYC phosphorylations at S131, T142 
and S149 are located adjacent to the functional domain MBII. This area comprising 25 
amino acids has a sequence homolog in c-MYC (KL-SEKL--YQA-RK) that is also 
flanked by 3 lysines (K143, K148 and K157). Martinez and colleagues reported that the 
acetyl transferases P300 and GCN5 regulate c-MYC abundance through acetylation of 
these lysines (44-46).  Faiola et al described the mechanism of this system, which 
involves the acetylation of the three residues reducing c-MYC turnover through the 
proteasome, and they proposed that acetylation of the three sites may compete with c-
MYC ubiquitination and ubiquitination-mediated proteosomal degradation. This 
interpretation is consistent with the identification of ubiquitinated K143, K148 and K157 
on multiple proteome-wide MS analyses (47-49). In our study with NMYC, we identified 
that this regulatory sequence was flanked by three novel phosphorylations at S131, T142 
and S149, all of them within a close range of the same segment. Phosphorylation has 
been also documented as a plausible competitor of ubiquitin by means of steric hindrance 
of the E3 ligase responsible of the ubiquitination(50-52).  It is therefore plausible that 
these phosphorylations in NMYC may play a similar role to the prior mentioned 
acetylations in c-MYC, acting as a negative regulator of ubiquitination in NMYC and 
thus eluding NMYC proteosomal degradation, but the confirmation of this model would 
require further testing. 
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5.5.6 CK1, CK2 and ChK1 Phosphorylate Novel Sites During In Vitro Assays 
Using two different literature curated databases of kinase motifs, we identified 
several kinases with the potential to phosphorylate the novel sites identified in NMYC. 
Using in vitro kinase assays we verified that these kinases can phosphorylate the novel 
sites in different combinations. It is noticeable that two of the novel sites identified in 
NMYC (S371 and S375) have direct contiguous homologous sites in c-MYC (S344 and 
S348). For c-Myc, it has been reported that only S348 is phosphorylated by CK2.  
Similarly, we found during our in vitro kinase assays with NMYC that only S375 but not 
S371 was phosphorylated by CK2(53). When using an in silico approach, we identified 
that S352 and S355 in NMYC are also plausible targets of CK2, and we conducted an in 
vitro kinase assay to show that was the case. Using the same method, we identified that 
the other novel phosphorylation sites we identified in NMYC were plausible targets of 
the Chk1 and CK1 kinases. The in vitro assays conducted with those kinases again 
showed the phosphorylation of several of the novel sites. This observation is interesting 
in light of the observation that both ChK1 and CK1 kinases have been directly linked to 
high risk neuroblastoma tumorigenicity in two separate studies where inhibition of each 
kinase caused a significant decrease in NMYC amplified neuroblastoma cell survival(35, 
36). 
Check point kinase 1 (ChK1) was recently identified as a novel therapeutic target 
in neuroblastoma. This protein, which is highly expressed in some neuroblastoma cells, 
was the top hit of a recent high through put RNAi kinome screening to identify 
therapeutic neuroblastoma targets(35). The study also highlighted that Chk1 expression 
was significantly higher in NMYC amplified cells and that the effect of Chk1 inhibition 
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directly correlates with the total expression level of NMYC. It is therefore possible that 
Chk1 and NMYC modulate each other through a direct mechanism. Because we observed 
the in vitro phosphorylation of NMYC by Chk1, it is plausible that this modulation may 
take place through a phosphorylation mediated process; however, the characterization of 
this mechanism and its relationship to neuroblastoma tumorigenicity is still to be tested.  
Casein Kinase 1 (CK1) is also overexpressed in NMYC amplified neuroblastoma 
cells(54). It has been reported that the inhibition of CK1 either by siRNA or kinase 
inhibitors (IC261) prevents the growth of NMYC amplified xenografts and that a double 
KO of CK1 and NMYC is synthetically lethal for NMYC amplified cells (36). The 
precise relationship between CK1 and NMYC has not been yet characterized. In this 
paper, we identified NMYC as a substrate of CK1 in vitro and showed that several of the 
novel sites we identified in NMYC can be phosphorylated by CK1, which opens the 
possibility that this relationship may take place via phosphorylation.  
5.6 Conclusions 
The novel phosphorylation sites identified in NMYC are summarized in Figure 
5.6. In this diagram the analogous c-MYC sites and their known biological activity is also 
shown.  We conducted a homology comparison between the sequence of NMYC and c-
MYC and concluded that the position and sequence of the novel NMYC 
phosphorylations closely resembles known c-MYC active sites involved in abnormal 
protein stability, increased protein turn over and regulation of tumorigenicity. Therefore, 
we speculate that the novel NMYC phosphorylations will play a similar role in NMYC 
mediated cancers like neuroblastoma, where NMYC is overexpressed and plays a critical 
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role in tumorigenicity. This proposed model, which is shown in Figure 5.6, is presented 
to create testable scenarios to evaluate each novel phosphorylation site through site 
directed mutagenesis or site-specific antibodies.  
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CHAPTER 6 
PHOSPHORYLATION TARGETED MS ANALYSIS OF NMYC AND SHCC, 
TWO KEY ONCOPROTEINS HIGHLY EXPRESSED IN HIGH RISK 
NEUROBLASTOMA 
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6.1 Abstract 
Phosphorylation is one of the most important protein post-translational 
modifications involved in cell regulation. The analysis of phosphorylated proteins is 
fundamental to understand abnormal cell processes like cancer. However, because of the 
low abundance and low stoichiometry of phosphorylated proteins, their analysis is still 
challenging. This paper describes an alternative method to increase phosphorylation 
identification using LC-MS/MS using a combination of immunoaffinity, SDS 
purification, in-gel trypsin digestion and TiO2 phosphoenrichment. This sequential 
methodology decreased the complexity of biological mixtures at a protein level and at a 
peptide level and brought out phosphopeptide information not previously available.  The 
process was successfully used to analyze two key neuroblastoma oncoproteins, the 
scaffold protein ShcC and the transcription factor NMYC. Using cells and human tissue 
samples, we applied our methodology to identify 5 and 8 novel phosphorylation sites in 
ShcC and NMYC respectively. Many of the novel sites were located in functional protein 
domains or were homologous to known active sites in other protein family members.  
6.2 Introduction 
Serine, Threonine and Tyrosine phosphorylations are one of the most important 
mechanisms that eukaryotic cells utilize to regulate cell signaling. In diseases 
characterized by abnormal cell signaling like cancer, the analysis of the phosphorylation 
events in key tumorigenic proteins is an important step in understanding the mechanism 
and dynamics of such proteins in the context of the disease. Presently, the amino acid 
position of phosphorylation events is identified mainly through the use of tandem mass 
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spectrometry (MS/MS).  The execution of such analyses is, however, a challenging task 
limited by the low abundance and low stoichiometry of phosphoproteins as well as other 
sample-specific considerations.   
The primary difficulty presented by phosphoproteins participating in cell 
signaling is the relatively low abundance in comparison with structural or house-keeping 
proteins within the cell. This unfavorable ratio, which resembles a needle 
(phosphoprotein) within a haystack (structural proteins), makes the discrimination of 
phosphoproteins signals very challenging even for the most powerful mass spectrometers. 
This is further complicated by the standard MS sample processing in which 
phosphoproteins are digested into peptides suitable for MS analysis using proteolytic 
enzymes. For a single phosphoprotein, this process renders a mixture of phosphorylated 
and non-phosphorylated peptide digests. Because the number of modified sites in most 
phosphoproteins is usually small, the ratio of phosphorylated to non-phosphorylated 
peptides is in most cases unfavorable for the MS detection of this modification. 
Previously, techniques or combinations of techniques such as isoelectric point 
separation, immunoprecipitation or phopho-specific antibodies have been successfully 
used to identify phosphorylation sites in large sets of samples.(1-6) These methods, 
however, have not achieved in-depth phosphorylation site identification of individual 
proteins because of the difficulties to detect low abundant phosphopeptides in a large 
number of proteins simultaneously.  In the present work, we report the application of 
immunoaffinity purification, SDS electrophoresis, in-gel digestion and titanium oxide 
(TiO2) phosphopeptide enrichment to sequentially protein purify, digest and enrich the 
phosphopeptides of two key neuroblastoma proteins, ShcC and NMYC. By using a 
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combination of four methodologies we were able to detect a significant increase in the 
identification of phosphorylation sites, which included several novel phosphorylation 
sites, in ShcC and NMYC. The methodology was tested in endogenous protein expressed 
in cells and in clinical human tissue samples.  
Two neuroblastoma oncoproteins were selected for the application of this study 
because of their relevance to abnormal cell processes. (Src homology 2 domain 
containing) transforming protein 3 (ShcC) is a modulator protein that has been 
documented as an important regulator in glioblastoma(7), ependymomas(8) and  
neuroblastoma(9, 10). It has been specifically linked to the persistent undifferentiated 
state and tumorigenicity of high-risk neuroblastoma cells. (9, 11) v-myc 
myelocytomatosis viral related oncogene (NMYC) is a transcription factor described as 
the most important neuroblastoma oncoprotein(12-14). Its amplification and expression is 
the single most important marker of neuroblastoma aggressiveness(15-17), and it is 
clinically utilized to stratify patients for treatment(18, 19). NMYC-amplified patients 
exhibit the most aggressive type of tumors and present the lowest survival rates. 
6.3 Experimental Section 
Cell culture and reagents - Neuroblastoma cell lines SK-N-BE(2) were 
purchased from ATCC. Cells were grown in RPMI (Life Technologies) supplemented 
with 10% Fetal Bovine Serum (Hyclone). Cells were maintained in a humidified 
atmosphere at 37°C in 5% CO2. The rabbit antibodies NMYC (sc-53993) ShcC (sc-
28833) used for immunoprecipitation were purchased from Santa Cruz Biotechnology. 
Eight plates of neuroblastoma cells were plated in 145 cm2 plates (5663-9160Q, USA 
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Scientific), grown to 90% confluence and lysed using cold RIPA buffer containing Tris-
HCl 50 mM, NaCl 150 mM, Igepal CA 630 1% and 1/100 EDTA-free HALT protease 
and phosphatase inhibitor (Thermo Scientific). Cells were washed twice with 1x PBS and 
placed on an ice bath. 2 mL of RIPA buffer was added for 3 minutes before mechanically 
disrupting the cell layer using a plastic spatula. The cell lysate was collected and 
centrifuged at 11,000 xg for 15 minutes at 4°C, and the cell pellet was discarded.  
Human frozen tissue samples collection - IRB approval from Arizona State 
University and the Phoenix Children’s Hospital was obtained. Annual continuing reports 
were submitted and approved by both IRBs in a timely manner. Frozen tissue samples 
were obtained from the Hospital historical repository and transported frozen in large 
amounts of dry ice. The average tissue size was 230 mg. Patient information was blinded 
by a hospital representative and only unidentified sample information provided including: 
individual sample code, tissue anatomic source, patient gender, age at collection, 
collection year, storage temperature, tissue weight and tissue time lapse to processing. 
Samples were stored in liquid nitrogen vapor until lyses. 
Human frozen tissue samples processing - Tissue samples were placed on a dry 
ice cooled metal surface and cut to small 1mm2 pieces with a cold blade. 1 mL of cold 
RIPA buffer supplemented with inhibitors was used for each 10mg of tissue. Lysis was 
conducted inside a 30 mL Dounce Tissue Homogenizer (DTH) equipped with a PTFE 
head (89026-388, VWR). Homogenization was conducted at 700 rpm in 10 strokes of 30 
seconds each. Using these conditions, a yield of 70-150 ug of protein/mg of tissue was 
routinely obtained. After lysis, homogenates were centrifuged at 11,000 x g for 15 
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minutes at 4⁰C. The resulting pellets were discarded and the supernatants retained and 
stored at -80⁰C until used. Any subsequent sample preparation was performed at 4⁰C. 
Protein and phosphorylation stability - Protein integrity and the degree of 
phosphorylation was measured by western blots.  Antibodies of species different to those 
used for immuno-affinity purification (IP) were purchased for NMYC (9405S, Cell 
signaling) and ShcC (610642, BD Biosciences) and used at 1:1000 dilution for all 
western blots.  
 Immuno-affinity purification (IP) -. For a single immunoprecipitation 
experiment, ~40 mg of total protein extracted from cells or tissue lysate were regularly 
utilized. This amount of protein was obtained routinely from 8 plates of cells or 230 mg 
of tissue. For the immunoprecipitation, 600 ug of antibody were incubated together with 
1 mL of protein-G magnetic dynabeads (100-04D, Invitrogen) in 5 mL of PBST 0.02% 
and spun for 1 hr at room temperature. Antibody-bead conjugates were washed 3 times in 
PBST 0.02% and added to the clarified lysates for overnight incubation at 4°C. The next 
day, beads were separated from the lysate using a magnet and washed with RIPA buffer, 
PBST 0.02% and PBS. Immunoprecipitated proteins were eluted using 4x SDS sample 
buffer and resolved via SDS-PAGE on a Criterion TGX 4-20% Tris/Glycine gel (567-
1093, Bio-rad). Proteins were stained using Commassie protein stain following 
manufacturer instruction (LC6065, Invitrogen). ShcC bands were photographed and then 
cut inside of a laminar flow cabinet following standard practices for MS sample 
preparation.  
MS sample processing - Target protein bands were de-stained in 20% ethanol 
overnight, washed for 2 hours in water and diced into small 1 mm3 gel fragments. In-gel 
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protein digestion was performed as previously described(20). Briefly, samples were 
dehydrated in acetonitrile for 10 minutes, incubated in 10 mM dithiothreitol (Bio-Rad) in 
100 mM ammonium bicarbonate for 30 min at 56⁰C. Samples were dehydrated again and 
then acetylated with 55 mM Iodoacetamide (Sigma Aldrich) for 20 min at RT and 
digested overnight in 13 ng/ul trypsin in 10 mM ammonium bicarbonate+10% 
acetonitrile. Digested peptides were extracted from the gel using a solution of formic acid 
5% in acetonitrile in a 1:2 ratio. The peptide solution was evaporated  in a vacuum 
concentrator (Eppendorf) until dry and peptides were analyzed either as is using LC-
MS/MS (QExactive, Thermo-Fisher) or further processed with titanium oxide (TiO2). 
TiO2 phosphopeptide enrichment - Titansphere centrifuge pipette tips (3mg, 
200uL) were purchased from GL Sciences. Tips were primed using Buffer A (TFA 2% 
and acetonitrile 1:4 ratio) and Buffer B (manufacture’s Solution B + Buffer A 1:3 ratio). 
Dehydrated peptides from the previous step were re-suspended in Buffer B, added to the 
tip and centrifuged at slow speed (~1500 rpm) for 12 minutes using a benchtop centrifuge 
(Beckman Coulter). To wash out the non-phosphorylated peptides, tips were washed once 
in Buffer B and three times in 50 uL Buffer A.  Elution of phospho peptides was 
performed in three steps using 25 uL of 1%NH4OH in water, 25 uL of 1% NH4OH in 
acetonitrile and 50 uL of 5% pyrrolidine in water. The purpose of each step was to elute 
hydrophilic, hydrophobic and poly phosphorylated peptides from the TiO2 column.  The 
three elutions were pooled together and neutralized with acetic acid 50% before 
evaporating in a vacuum concentrator for 4 hrs until dry. 
LC-MS/MS Analysis of phosphopeptides - MS analyses of phosphopeptides was 
performed by Michael Ford Ph.D. from MS Bioworks (Ann Arbor, Michigan). In brief, 
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samples were solubilized in 70 uL of 0.01% trifluoroacetic acid (TFA) in water. Each gel 
digest was analyzed by nano LC-MS/MS in a Waters NanoAcquity HPLC system 
interfaced to a ThermoFisher Q Exactive. Peptides were loaded on a trapping column and 
eluted over a 75μm analytical column at 350nL/min. Both columns were packed with 
Jupiter Proteo resin (Phenomenex), and the injection volume was 30μL. The mass 
spectrometer was operated in data dependent mode, with the Orbitrap operating at 60,000 
FWHM and 17,500 FWHM for MS and MS/MS respectively. The fifteen most abundant 
ions were selected for MS/MS. 
MS Data Processing - Data were searched using a local copy of Mascot with the 
following parameters:  Enzyme: Trypsin/P, Database: SwissProt Human; Fixed 
modification: Carbamidomethyl (C), Variable modifications: Oxidation (M), Acetyl (N-
term), Deamidation (N,Q), Phospho (S,T,Y); Mass values: Monoisotopic, Peptide Mass 
Tolerance: 10 ppm; Fragment Mass Tolerance: 0.02 Da; Max Missed Cleavages: 3. 
Mascot DAT files were parsed into Scaffold software for validation, filtering and to 
create a non-redundant list per sample. For protein identification, the data were filtered 
using a minimum protein value of 90%, a minimum peptide value of 50% (Prophet 
scores) and requiring at least two unique peptides per protein. Ascore-derived PTM site 
localizations were calculated and the fragmentation spectra alignments were manually 
inspected using the Scaffold PTM software v 2.0 (Proteome Software). 
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6.4 Results 
6.4.1 Isolation of Target Proteins from High Risk Neuroblastoma Cells  
We initially attempted to identify novel phosphorylation sites in two key 
neuroblastoma proteins using standard Liquid Chromatography tandem mass 
spectrometry (LC-MS/MS) directly on whole neuroblastoma cell lysate. The lysate was 
fractionated using Immobilized pH gradient strips. Then, individual fractions were 
digested and phosphopeptides were concentrated using TiO2 columns. From the list of 
578 proteins identified (data not shown), neither ShcC, NMYC, ALK, BCL-2 nor any 
other of the major neuroblastoma oncoproteins were present. This was surprising 
especially for proteins like NMYC, which are not only amplified but also overexpressed 
in high risk neuroblastoma cells. Instead, our list was mostly occupied by several families 
of structural and housekeeping proteins. In a second approach, both proteins were 
immunoprecipitated using protein specific antibodies before analyzing them by LC-
MS/MS. Approximately 40 mg of high risk neuroblastoma cell lysate was utilized to 
immunoprecipitate either the ShcC or NMYC protein as described in experimental 
methods. The target proteins were then run in a SDS gel and stained with Coomassie dye 
for 1 hr. Using a dilution series of BSA protein standard along the gel, it was estimated 
that between 5-10 ug of protein was obtained from this amount of lysate (Figure 6.1). 
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Figure 6.1. SDS-PAGE stained with Coomassie dye showing the immunoprecipitation of 
ShcC (a) and NMYC. The concentration of the precipitated fraction was calculated 
between 5-10 ug using an FBS standard. 
 
6.4.2 Characterization of Phosphorylation Sites in Key Neuroblastoma Proteins 
Using this methodology, 63 unique spectra from 38 exclusive ShcC peptides were 
identified. The peptides accounted for 71% coverage of the ShcC sequence with a False 
Discovery Rate of 1.0% (Figure 6.2a). The result, although encouraging, seemed 
incomplete as only 3 phosphopeptides containing 4 putative phosphorylation sites were 
identified (Figure 6.2b). This number was much lower than the number of 
phosphorylation sites previously identified in other members of the Shc family. For 
example, the analysis of ShcA (the prototypical protein of this family) identified 14 
phosphorylation sites, eight of which has been found functional for protein 
stabilization(21), apoptosis induction(22-24), apoptosis inhibition(25, 26) and abnormal 
cell proliferation(27-29).  This disparity between ShcA and ShcC phosphorylation 
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inspired us to look for technical improvements to further increase phosphorylation 
detection. The problem was addressed by the use of titanium oxide columns which, under 
acidic conditions, hold a positive charge that selectively binds to phosphorylated species. 
Therefore, our next approach was conducted using a combination of 
immunoprecipitation, SDS gel separation, in-gel digestion and TiO2. The method 
resulted in the overall reduction in protein coverage of ShcC to 24%; however, the total 
number of phosphorylation sites identified increased to 15 putative phosphorylations sites 
(Figure 6.2c).  
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Figure 6.2. (a) Protein coverage of ShcC scaffold protein isolated from high risk 
neuroblastoma cells by immunoprecipitation and analyzed by MS/MS. 63 unique spectra 
belonging to 38 exclusive peptides were identified. From those, only 3 phosphopeptides 
were identified as presented in (b). (c) After using a combination of IP, SDS gel 
purification, in-gel digestion and titanium oxide, the ShcC protein coverage decreased to 
a  
b  
c  
d  
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24%; however, all 12 identified peptides were phosphorylated and included several 
putative phosphorylation sites. (d) Using the same methodology on endogenous NMYC 
isolated from high risk neuroblastoma cells, a total of 10 unique peptides were identified 
containing 12 putative phosphorylation sites.  
 
To unambiguously assign the phosphorylation modification to specific sites, we 
relied on the Ascore algorithm developed by Beausoleil(30). This method measures the 
probability of correct phosphorylation site localization based on the presence and 
intensity of site-determining ions in MS/MS spectra. An Ascore value ≥19 was 
considered localized with near certainty of >99%. Peptides containing unambiguous 
phosphorylation assignment (i.e. only one site in the peptide can be phosphorylated) hold 
a score of 1,000. We calculated the Ascores for all the putative sites and filtered out the 
peptides with low localization probability.  The validated phosphopeptides and their 
calculated Ascores are presented in   
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Table 6.1. A total of eight phosphorylation sites were assigned with confidence 
for endogenous ShcC in cells, including 3 phosphorylation sites that have never been 
previously reported.  
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Table 6.1. Summary of the Ascore validated ShcC phosphorylation sites identified in 
high risk neuroblastoma cells. The table indicates the position of the validated 
phosphorylation sites, the Ascore of the best peptide, the localization probability and the 
novelty of the identified site.  
Protein 
Accession 
Protein 
Name 
Site Modif 
Best 
Ascore 
Localization 
Probability 
Novelty 
sp|Q92529| 
SHC3_ 
HUMAN 
SHC-
transformin
g protein 3 
(ShcC) 
OS=Homo 
sapiens 
GN=SHC3 
PE=1 SV=1 
S171 Phospho 73.91 100% novel 
S402 Phospho 32.22 100% novel 
S470 Phospho 1,000.00 100% novel 
S474 Phospho 1,000.00 100% known 
S479 Phospho 1,000.00 100% known 
S482 Phospho 1,000.00 100% known 
Y308 Phospho 47.92 100% known 
Y406 Phospho 27.45 100% known 
 
The same approach was utilized to precipitate and analyze the transcription factor 
NMYC, also from high risk neuroblastoma cells. For this protein, 11 Ascore-validated 
phosphorylations were identified including 8 novel sites (  
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Table 6.2). This number accounts for almost twice the number of sites that have 
been previously identified for NMYC.  
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Table 6.2. Summary of the Ascore validated NMYC phosphorylation sites identified in 
high risk neuroblastoma cells.  
Protein 
Accession 
Protein 
Name 
Site Modif 
Best 
Ascore 
Localization 
Probability 
Novelty 
sp|P04198| 
MYCN_ 
HUMAN 
N-myc 
proto-
oncogene 
protein 
(NMYC) 
OS=Homo 
sapiens 
GN=MYCN 
PE=1 SV=2 
S62 Phospho 29.21 100% known 
T58 Phospho 95.01 100% known  
S156 Phospho 233.41 100% known 
S355 Phospho 101.21 100% novel 
S131 Phospho 1,000.00 100% novel 
S315 Phospho 32.22 100% novel 
S371 Phospho 43.67 100% novel 
S375 Phospho 21.44 99% novel 
S149 Phospho 69.09 100% novel 
 
6.4.3 Identification of ShcC Phosphorylation Sites in Human Brain Frozen Tissue 
Samples 
Eight phosphorylation sites in endogenous expressed ShcC were identified in high 
risk neuroblastoma cells. Because phosphorylations are a reversible modification that can 
be modified by several biological or artificial factors including cell culture methods or 
specific media growth factor, we decided to verify the presence of the previously 
identified phosphorylation sites in human frozen tissue samples(31). The ShcC protein is 
reported to be expressed in only a small subset of tissues, from which brain tissue is the 
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one showing the most prominent expression. After obtaining all the required IRB 
permissions, our collaborators from Phoenix Children’s Hospital provided us ten samples 
of brain human tissue from epilepsy biopsies to conduct our analysis in ShcC. We 
purified the protein from ~230 mg of tissue and conducted the analysis of ShcC as 
detailed in material and methods. The ten samples were analyzed using LC-MS/MS, and 
the phosphorylation sites were identified. Figure 6.3 shows the protein expression levels 
of ShcC and the overall tyrosine phosphorylation levels of all the samples provided. It 
was noticeable that sample one in the 2nd batch contained low detectable levels of 
tyrosine phosphorylation and ShcC protein.  This sample had the longest tissue 
processing time (TPT>3 hours). TPT accounts for the time lapse that passed since the 
tissue was removed from the patient until it was stored in liquid nitrogen for long time 
storage. Because phosphorylations are labile modifications that can be removed by 
intrinsic tissue phosphatases that remain active while the sample is not frozen, it is likely 
that this sample lost many of its phosphorylations during the long tissue processing time. 
This loss was also reflected on the MS analysis, which shows less phosphopeptides in 
this sample (Figure 6.4, top right). 
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Figure 6.3. Western blots showing the protein levels of ShcC and overall phosphotyrosine 
phosphorylation in 10 human brain tissue samples and high risk neuroblastoma cells as 
controls. The samples were processed in two batches of five samples each. 
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Figure 6.4. Sequence coverage and phosphorylation sites identified in ShcC protein 
extracted from 10 human brain tissue samples. 
 
The protein coverage and the schemes of the entire putative phosphorylation sites 
for all the samples are presented in Figure 6.4. All the phosphorylation sites were then 
evaluated using Ascore and manual validation before assigning the phosphorylation to 
the site with certainty. Table 6.3shows the compilation of all the Ascore verified 
phosphorylation sites in human tissue samples. A total of nine phosphorylation sites were 
identified in ShcC in brain tissues, and from those Y406, S474, S479 and S482 have been 
    Batch 1       Batch 2 
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previously seen in MS shotgun analyses. S171, S402, S470, T526 and S530 have never 
been reported before. Two phosphorylations, T526 and S530, were present in the C-
terminal region of ShcC, which is especially interesting because they were present only in 
the tissue samples but not in the cell lysates. This may indicate that those modifications 
may be triggered by biological conditions present in the tissue but absent in the cells, 
such as microenvironment elements or extracellular matrix interactions.   
 
Table 6.3. Summary of the Ascore validated ShcC phosphorylation sites identified in 
human brain tissues. The table indicates the position of the validated phosphorylation 
sites, the Ascore of the best peptide, the localization probability and the novelty of the 
identified site. 
Protein 
Accession 
Protein 
Name 
Site Modif 
Best 
Ascore 
Localization 
Probability 
Novelty 
sp|Q92529| 
SHC3_ 
HUMAN 
SHC-
transforming 
protein 3 
(ShcC) 
OS=Homo 
sapiens 
GN=SHC3 
PE=1 SV=1 
S171 Phospho 122.47 100% novel 
S402 Phospho 32.22 100% novel 
Y406 Phospho 29.21 100% known 
S470 Phospho 1,000.00 100% novel 
S474 Phospho 1,000.00 100% known 
S479 Phospho 1,000.00 100% known 
S482 Phospho 1,000.00 100% known 
T526 Phospho 30.46 100% novel 
S530 Phospho 21.44 100% novel  
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6.4.4 Attempt to Identify Phosphorylations in High-Risk Neuroblastoma Human Frozen 
Tissue Samples 
In an attempt to follow up the experiments conducted in brain tissue, we 
performed a series of experiments in a second set of tissues containing seven human 
frozen tissues of pathology confirmed high risk neuroblastoma tumors. These tissues 
hypothetically contain high levels of NMYC and ShcC proteins, or at least NMYC 
which, by definition, is over-expressed in high risk neuroblastoma.  After conducting the 
proteins extraction using our optimized protocol for tissue samples we obtained a good 
protein yield ranging from 50 to 93 ug protein/mg of tissue; however, the western blot 
analysis revealed that neither proteins were present in detectable levels in any of the eight 
tissue samples (Figure 6.5).  This observation was extremely disappointing because the 
lack of the endogenous target proteins did not allow us to complete our phosphorylation 
analysis in neuroblastoma tissue. Rather than being caused by a failure in our protocol, 
the lack of target proteins is most likely related to difficulties inherent to the samples 
analyzed, including high homogeneity of the tissue samples and long processing times. It 
is well known that neuroblastoma produces very heterogeneous type of tumors(32-36); 
therefore, it is possible that the analyzed samples contained a larger amount of stroma or 
other connecting tissue that decreased the net amount of tumor tissue in the samples. It 
was also noticeable that some of the tissue containing low levels of phosphorylations 
which may have been caused by sample temperature variations. This incidence, although 
not present in all of the samples, may have decreased the net phosphorylations in the 
affected tissues.  
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Figure 6.5. Western blots showing the protein levels of ShcC, NMYC and overall 
phosphotyrosine phosphorylations in 7 human high risk neuroblastoma tissues and high 
risk neuroblastoma cells as controls. 
 
6.5 Discussion  
6.5.1  Biological Role of the Novel ShcC and NMYC Phosphorylation Sites  
The method described above was utilized to identify several novel 
phosphorylation is two key high risk neuroblastoma oncoproteins. Both targets belong to 
well defined protein families: ShcC is part of the ‘SHC’ family of scaffold proteins, 
composed of 4 members (ShcA, ShcB, ShcC and ShcD). NMYC is part of the “MYC” 
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family of transcription factors constituted by the 3 members c-MYC, NMYC and 
MYCL1. It is remarkable that for both proteins, ShcC and NMYC are the predominant 
member of their families being expressed in the central nervous system (CNS) while 
other members are expressed in other tissues. It is also noteworthy that the two proteins 
are homologues to well described oncoproteins also within their families. ShcC is 47% 
identical to ShcA (aka Shc), a well-defined protein involved in the cell signaling of 
breast(37, 38), prostate cancers(22, 28), B-cell lymphoma(39). NMYC also shares 47% 
exact homology to c-MYC (aka MYC), one of the first described proto-oncogenes that is 
a key participant in the cell signaling of breast, prostate, liver and other types of cancer 
(40-44). To hypothesize the role of the novel phosphorylation sites identified in ShcC and 
NMYC we used homology studies to compare the amino acid sequence of the novel sites 
with their well-defined homologues ShcA and c-MYC.  
6.5.2  Key Functional Domains of Shc Family of Proteins  
The Shc family is a group of adaptor proteins that mediate the transduction of cell 
signals by providing a scaffold to recruit multiple signaling components.  ShcA and ShcC 
share a 47% exact sequence homology and contain the same functional domains; 
however, they are both expressed in a different subset of tissues. ShcA is found 
ubiquitously with the exception of the CNS where ShcC is primary found. ShcA has been 
identified as a central component in the transduction of several cell signals, from which 
RAS/MAPK, PI3K/ALK and RTKs are the most relevant. ShcA holds four protein 
domains which are shared with ShcC: an N-terminal Collagen rich domain (CH2), a 
Phospho Tyrosine Binding domain (PTB), another Collagen rich domain (CH1) and a Src 
Homology2 (SH2) domain. This unique structure (CH2-PTB-CH1-SH2) allows these 
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proteins to interact simultaneously with a large subset of proteins and act as a 
convergence point in several cell signals by facilitating the contact of other way-
independent proteins. 
 
 
Figure 6.6. (a) Phosphorylation sites identified in ShcC neuroblastoma cells and brain 
tissue samples are localized in functional domains of the SHC family of proteins. S171 is 
located in the46-207 active pocked of PTB domain. S470, S479 and S482 are located 
inside two PXXP sequences responsible for SH3 binding partner recognition. S526 and 
S530 are located in the middle of SH2 domain responsible for binding to several Tyrosine 
Receptor Kinases. (b) Phosphorylation sites identified in NMYC neuroblastoma cells 
homologous to known active phosphorylation sites in the canonical c-MYC proto-
oncogene. The sites regulate protein stabilization and/or cell transformation. 
 
As shown in Figure 6.6a, the novel phosphorylation at Serine 171 is located inside 
the PTB domain, which is the most important domain in regulating its binding events. 
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This serine is also located in the  pocket comprising the amino acids 46-207, which has 
been identified as critical for the regulation of Shc-PTB binding to partners(45).    Serines 
402, 470, 474, 479, 482 and Tyrosine 406 are located inside the CH1 domain. This area, 
rich in glycine and proline, moderates the Shc binding to multiple proteins through its 
interaction with their Src Homology 3 domain (SH3). The interaction of Shc-Ch1 and 
SH3 is in turn regulated by the Pro-X-X-Pro motifs that bind to the SH3 domains of 
multiple kinases such as Src, Fyn, Lyn and others(45). The phosphorylation sites S470, 
S474, S479, and S482 that we identified in neuroblastoma cells are located inside of two 
out of the four P-X-X-P domains of the CH1 domain of ShcC. Therefore, it is possible 
that those sites may regulate the interaction of ShcC with other kinases. Also within CH1 
domain, tyrosine 406 was identified. This phosphorylation site is part of a canonical try-
X-Asp-X binding pocket for the RAS/MAPK signal member Grb2. Finally, the two novel 
T526 and S530 phosphorylation sites were located inside the SH2 domain, a 
phosphotyrosine recognition domain that is known to interact with the receptor tyrosine 
kinases family (RTKs).  
All the phosphorylation sites identified in ShcC using cells and tissues were 
located in functional domains of the Shc family, and some of them are surrounded by 
amino acids sequences linked to specific protein interactions. It is thus possible that the 
identified sites may also play a role in the regulation of ShcC-mediated cell signals.  
6.5.3 Key Functional Phosphorylation Sites of c-MYC Are Homologous to Novel 
NMYC Phosphorylations 
NMYC is the neuronal counterpart of c-MYC, one of the most well-known proto-
oncogenes in the cancer field. Both proteins have 47% exact homology and perform 
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similar functions in distinctive tissue sub-types. C-MYC is ubiquitously expressed while 
NMYC is mainly expressed in the tissues of the CNS. C-MYC has been studied in great 
detail: to-date, 27 phosphorylation sites have been described in c-MYC.  In striking 
contrast, only 6 sites for NMYC are currently known.  Using our methodology, we 
increased the NMYC phosphorylation coverage by detecting 8 novel phosphorylation 
sites. Several of the novel identified sites share a close homology to previously active 
identified sites in c-MYC.  
c-Myc Serines 344 and 348 have been reported as two sites that regulate the cell 
transformation of SH-EP and MCF10A cells in soft agar(46). As shown in Figure 6.6b, 
the two sites are homologous to the novel NMYC sites S371 and S375 we identified in 
NMYC. The c-MYC site S329 has been shown to increase c-MYC protein stability and 
through that an increase in the tumorigenicity of B-cell lymphoma cells.(39) This 
position is homologous to the NMYC sequence where the novel sites S352 and S355 
were located.  Lastly, the S131, T142 and S149 of NMYC share a close homology to a 
regulatory sequence in c-MYC that undergoes ubiquitination and as a result regulates 
proteosomal c-myc degradation and protein stability. This sequence was found acetylated 
in c-MYC mediated cancers at positions K143, K147 and K148 as a mechanism to avoid 
ubiquitination and resulting protein degradation(47-49). In our analysis, we found that 
NMYC was heavily phosphorylated in the same sequence, which may indicate an 
alternate mechanism to avoid ubiquitination via phosphorylation in neuroblastoma cells.   
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6.6 Conclusions 
In this work a series of purification steps were utilized to increase the 
phosphorylation detection of two key neuroblastoma proteins. This protocol directly 
addressed the problem of an in-depth analysis of the phosphorylation sites of key proteins 
in complex biological mixtures. The method was proved to be efficient for analyzing 
target proteins in cell and human tissue lysates. Immunoprecipitation and SDS gel were 
first utilized to separate the target proteins from the more abundant components of the 
cell. Then, the proteins were in-gel digested with trypsin, and phosphorylated peptides 
were further concentrated using TiO2 beads. This methodology was tested in endogenous 
proteins extracted from cells and human tissue samples and showed good results when 
target proteins are expressed in samples. Results showed a considerable increase in 
phosphorylation site detection for both proteins. For NMYC, 11 sites were identified and 
unambiguously assigned. 8 of these sites have not been previously reported. For ShcC a 
total of 9 sites were identified, 4 of which were novel. All of the novel sites were present 
in either functional protein domains or known homologous active sequences in both 
proteins. The above system suggests that a combination of two protein purification 
methods followed by a specific phospho peptide enrichment step is an attractive way to 
identify novel phosphorylation sites in low abundance proteins concealed in complex 
mixtures of cells or tissue lysates.  
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CONCLUDING REMARKS 
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7.1 Abstract 
The work presented in the preceding chapters describes the study of two post 
translational modifications. Chapters 2, 3 and 4 focus in general on the study of 
glycosylation and specifically on the development of a method to label bacterial glycans 
with fluorescent nano-particles. These chapters also address the application of the 
fluorescent probes to study the interaction of glycans and peptides in a microarray format.  
Chapters 5 and 6 focus on the study of phosphorylation with a specific focus on 
the identification of novel phosphorylations sites in two key neuroblastoma proteins.  
The conclusions for each investigation are summarized here. 
7.2 Conclusions 
The research described in Chapters 2 and 4 sought to create a novel fluorescent 
conjugate of bacterial lipopolysaccharide (LPS) and Quantum Dots (QDots). This 
construction was achieved by means of a ternary solvent system of Water – Chloroform – 
Methanol. The mixture of the three solvents allowed the hydrophobic QDots and the 
hydrophilic LPS to co-exist in a single phase. The novel conjugates readily dissolved in 
water, which allowed us to use them in physiological conditions. This research was the 
first to synthesize a QDot-LPS conjugate and to use them to label live cells. After 
publication, different groups utilized the method successfully. One interesting example 
was the use of QDot-LPS conjugates to follow the TLR2 response in live mice using 
biophotonic imaging.(1) 
Chapter 3 described the use of the QDots-LPS conjugates to interrogate a 10,000 
peptide microarray. The objective of the experiment was to explore the capabilities of the 
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array to bind a series of LPS of divergent glycan composition. Using this technique we 
identified a list of peptides that bound to LPS. The interaction between the peptides and 
the LPS was then validated using three orthogonal methods: SPR, ITC and flow 
cytometry. These analyses showed that the peptides bind to the LPS not only on the 
surface of the array but also in solution with a Kd of 1.75uM. A value comparable to 
natural occurring LPS binding peptides such as human lactoferrin (Kd=1.5uM) and 
polymyxin (Kd=1.1-5.8uM). Using flow cytometry, it was also noticed that the peptides 
had the capability to bind to the natural occurring LPS directly on the surface of bacteria. 
Something interesting and unexpected that it’s worth nothing is that some of the selected 
LPS binding peptides presented antimicrobial activity. We conducted a series of growth 
inhibitory assays to show that 8 of the 16 LPS binding peptides inhibited bacterial 
growth. This effect was traced down to the amino acid composition of these peptides rich 
in amino acids of positive change that resembled the sequence of some natural occurring 
antimicrobial peptides. These observations were noted in the publication resulted of this 
work. (2) 
The research in Chapter 6 sought to create a MS methodology to identify the 
phosphorylation sites of two selected neuroblastoma oncoproteins. In a first approach, we 
digested the entire proteome of a selected neuroblastoma cell lines into peptides. Then, 
we repeated the approach using titanium dioxide enriched for the phosphorylated species. 
From the 578 phospho-proteins identified, none of the key neuroblastoma proteins was 
found. This result supported the notion of utilizing a target-specific approach to achieve 
our goal. Using immune affinity purification before the MS, we were able to identify our 
target proteins; however, the phosphorylation identification was still poor. The problem 
  204 
was approached by combining two protein purification steps, followed by titanium 
dioxide enrichment. This methodology resulted in a massive increase in phosphopeptide 
detection. A total of 9 and 11 phosphorylation sites were identified in both proteins from 
which 5 and 8 were novel sites.  
Chapter 5 expands respectively on this results for one of the proteins, the 
transcription factor NMYC. Previously only 6 phosphorylation sites were known in 
NMYC. With our methodology this number increased to 14. Remarkably, several of the 
novel sites were homologous to active phosphorylation sites in c-MYC, a member of the 
same family of proteins that is also amplified in cancer cells. Using homology studies, we 
showed that the phosphorylation sites of both proteins correlate in position and in amino 
acid sequence. This supports the possibility that the novel NMYC sites may be also 
active in cancer.  
Additionally, using computational studies we predicted a series of kinases that 
potentially phosphorylate the novel NMYC sites. Using in vitro kinase assays we showed 
that Chk1, Ck1 and Ck2 had the capability of phosphorylate NMYC in vitro. 
7.3 Future Directions 
The results in Chapter 3 showed the capability of the 10,000 peptide microarray to 
discriminate glycan differences in selected lipopolysaccharides. It was also shown that 
the identified peptides not only bound to LPS but presented antimicrobial activity. These 
two observations open a large number of possibilities to explore. The glycan recognition 
capabilities of the approach can be further used to explore glycan diversity. For example, 
other glycan conjugates not only from bacteria but from other organism can be tested in 
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an attempt to identify peptides binding profiles of glycans. These profiles can potentially 
be utilized in a similar way to the current lectin microarrays technologies but without the 
protein instability limitations that characterize them. The capability of this method to 
identify potential antimicrobial peptides is also a very interesting area of exploration. 
Glycans from other bacterial species can be potentially utilized in a similar fashion to the 
method described here. Teichoic acid from Gram negative bacteria or trehalose 
conjugates from mycobacteria are other potential targets for this approach.  
The results in Chapter 5 and 6 showed the identification of several novel 
phosphorylation sites in NMYC and ShcC. It was also shown that those sites are 
homologous to active phosphorylation sites in proteins of the same family or were locates 
in the midst of active domains. Further characterization of those sites is required to define 
their role in protein function and neuroblastoma tumorigenicity. We already initiate this 
process by utilizing site directed mutagenesis to mutate each of the phosphorylation sites 
to alanine or glutamic acid.  These two amino acids resemble the negative and positive 
phosphorylation site of the mutated residue. The next step would be to test these mutants 
in the context of a molecular or cellular model that allow us to quantify the effect of each 
site in the protein activity. This can be accomplished for examples, using a cellular knock 
in model, were each mutant is transfected into a mammal cells and phenotypical changes 
are measured. The results of these experiments would provide detailed information of the 
mechanism of NMYC and ShcC and have the potential to uncover the underlying 
mechanism regulating the role of these two molecules in the tumorigenicity of high risk 
neuroblastoma. 
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conditions. These terms and conditions, together with CCC's Billing and Payment terms and 
conditions(which are incorporated herein), comprise the entire agreement between you and 
publisher (and CCC) concerning this licensing transaction. In the event of any conflict between 
your obligations established by these terms and conditions and those established by CCC's 
Billing and Payment terms and conditions, these terms and conditions shall control.  
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions 
described in this License at their sole discretion, for any reason or no reason, with a full refund 
payable to you. Notice of such denial will be made using the contact information provided by 
you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier 
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage 
incurred by you as a result of a denial of your permission request, other than a refund of the 
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.  
LIMITED LICENSE  
The following terms and conditions apply only to specific license types:  
15. Translation: This permission is granted for non-exclusive world English rights only 
unless your license was granted for translation rights. If you licensed translation rights you may 
only translate this content into the languages you requested. A professional translator must 
perform all translations and reproduce the content word for word preserving the integrity of the 
article. If this license is tore-use 1 or 2 figures then permission is granted for non-exclusive 
world rights in all languages.  
16. Posting licensed content on any Website: The following terms and conditions apply 
as follows: Licensing material from an Elsevier journal: All content posted to the web site must 
maintain the copyright informationline [sic] on the bottom of each image; A hyper-text must be 
included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a 
scanned version of the material to be stored in a central repository such as that provided by 
Heron/XanEdu.  
Licensing material from an Elsevier book: A hyper-text link must be included to the 
Elsevier homepage at http://www.elsevier.com . All content posted to the web site must maintain 
the copyright information line on the bottom of each image.  
Posting licensed content on Electronic reserve: In addition to the above the following 
clauses are applicable: The web site must be password-protected and made available only to 
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bona fide students registered on a relevant course. This permission is granted for 1 year only. 
You may obtain a new license for future website posting.  
For journal authors: the following clauses are applicable i n addition to the above: 
Permission granted is limited to the author accepted manuscript version* of your paper.  
*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript 
(AAM) is the author’s version of the manuscript of an article that has been accepted for 
publication and which may include any author-incorporated changes suggested through the 
processes of submission processing, peer review, and editor-author communications. AAMs do 
not include other publisher value-added contributions such as copy-editing, formatting, technical 
enhancements and (if relevant) pagination.  
You are not allowed to download and post the published journal article (whether PDF or 
HTML, proof or final version), nor may you scan the printed edition to create an electronic 
version. A hyper-text must be included to the Homepage of the journal from which you are 
licensing at http://www.sciencedirect.com/science/journal/xxxxx. As part of our normal 
production process, you will receive an e-mail notice when your article appears on Elsevier’s 
online service ScienceDirect(www.sciencedirect.com). That e-mail will include the article’s 
Digital Object Identifier (DOI). This number provides the electronic link to the published article 
and should be included in the posting of your personal version. We ask that you wait until you 
receive this e-mail and have the DOI to do any posting.  
Posting to a repository: Authors may post their AAM immediately to their employer’s 
institutional repository for internal use only and may make their manuscript publically available 
after the journal-specific embargo period has ended. Please also refer to Elsevier's Article 
Posting Policy for further information.  
18. For book authors the following clauses are applicable in addition to the above: 
Authors are permitted to place a brief summary of their work online only.. You are not allowed 
to download and post the published electronic version of your chapter, nor may you scan the 
printed edition to create an electronic version. Posting to a repository: Authors are permitted to 
post a summary of their chapter only in their institution’s repository. 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may 
be submitted to your institution in either print or electronic form. Should your thesis be published 
commercially, please reapply for permission. These requirements include permission for the 
Library and Archives of Canada to supply single copies, on demand, of the complete thesis and 
include permission for UMI to supply single copies, on demand, ofthe complete thesis. Should 
your thesis be published commercially, please reapply for permission.  
Elsevier Open Access Terms and Conditions  
Elsevier publishes Open Access articles in both its Open Access journals and via its Open 
Access articles option in subscription journals.  
Authors publishing in an Open Access journal or who choose to make their article Open 
Access in an Elsevier subscription journal select one of the following Creative Commons user 
licenses, which define how a reader may reuse their work: Creative Commons Attribution 
License (CC BY), Creative Commons Attribution – Non Commercial - ShareAlike (CC BY 
NCSA) and Creative Commons Attribution – Non Commercial – No Derivatives (CC BYNC 
ND)  
Terms & Conditions applicable to all Elsevier Open Access articles:  
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Any reuse of the article must not represent the author as endorsing the adaptation of the 
article nor should the article be modified in such a way as to damage the author’s honour or 
reputation.  
The author(s) must be appropriately credited.  
If any part of the material to be used (for example, figures) has appeared in our 
publication with credit or acknowledgement to another source it is the responsibility of the user 
to ensure their reuse complies with the terms and conditions determined by the rights holder.  
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: You may distribute and copy the article, create extracts, abstracts, and other 
revised versions, adaptations or derivative works of or from an article (such as a translation),to 
include in a collective work (such as an anthology), to text or data mine the article, including for 
commercial purposes without permission from Elsevier  
CC BY NC SA: For non-commercial purposes you may distribute and copy the article, 
create extracts, abstracts and other revised versions, adaptations or derivative works of or from 
an article (such as a translation), to include in a collective work (such as an anthology), to text 
and data mine the article and license new adaptations or creations under identical terms without 
permission from Elsevier  
CC BY NC ND: For non-commercial purposes you may distribute and copy the article 
and include it in a collective work (such as an anthology), provided you do not alter or modify 
the article, without permission from Elsevier  
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC 
BY NC ND license requires permission from Elsevier and will be subject to a fee.  
Commercial reuse includes:  
· Promotional purposes (advertising or marketing) 
 · Commercial exploitation ( e.g. a product for sale or loan) 
 · Systematic distribution (for a fee or free of charge)  
Please refer to Elsevier's Open Access Policy for further information.  
21. Other Conditions:  
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John Wiley & Sons, Inc. 
TERMS AND CONDITIONS  
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. 
or one of its group companies (each a "Wiley Company") or a society for whom a Wiley 
Company has exclusive publishing rights in relation to a particular journal (collectively 
"WILEY"). By clicking "accept" in connection with completing this licensing transaction, you 
agree that the following terms and conditions apply to this transaction (along with the billing and 
payment terms and conditions established by the Copyright Clearance Center Inc., ("CCC's 
Billing and Payment terms and conditions"), at the time that you opened your RightsLink 
account (these are available at any time at http://myaccount.copyright.com).  
Terms and Conditions  
1. The materials you have requested permission to reproduce (the "Materials") are 
protected by copyright.  
2.You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, 
worldwide, limited license to reproduce the Materials for the purpose specified in the licensing 
process. This license is for a one-time use only with a maximum distribution equal to the number 
that you identified in the licensing process. Any form of republication granted by this license 
must be completed within two years of the date of the grant of this license (although copies 
prepared before may be distributed thereafter). The Materials shall not be used in any other 
manner or for any other purpose. Permission is granted subject to an appropriate 
acknowledgement given to the author, title of the material/book/journal and the publisher. You 
shall also duplicate the copyright notice that appears in the Wiley publication in your use of the 
Material. Permission is also granted on the understanding that nowhere in the text is a previously 
published source acknowledged for all or part of this Material. Any third party material is 
expressly excluded from this permission.  
3. With respect to the Materials, all rights are reserved. Except as expressly granted by 
the terms of the license, no part of the Materials may be copied, modified, adapted (except for 
minor reformatting required by the new Publication), translated, reproduced, transferred or 
distributed, in any form or by any means, and no derivative works may be made based on the 
Materials without the prior permission of the respective copyright owner. You may not alter, 
remove or suppress in any manner any copyright, trademark or other notices displayed by the 
Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign 
the Materials, or any of the rights granted to you hereunder to any other person.  
4. The Materials and all of the intellectual property rights therein shall at all times remain 
the exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or 
their respective licensors, and your interest therein is only that of having possession of and the 
right to reproduce the Materials pursuant to Section 2 herein during the continuance of this 
Agreement. You agree that you own no right, title or interest in or to the Materials or any of the 
intellectual property rights therein. You shall have no rights hereunder other than the license as 
provided for above in Section 2. No right, license or interest to any trademark, trade name, 
service mark or other branding ("Marks") of WILEY or its licensors is granted hereunder, and 
you agree that you shall not assert any such right, license or interest with respect thereto.  
5. NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR 
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, 
IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE ACCURACY 
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OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT 
LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY, 
SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, 
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES ARE 
HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.  
6. WILEY shall have the right to terminate this Agreement immediately upon breach of 
this Agreement by you.  
7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their 
respective directors, officers, agents and employees, from and against any actual or threatened 
claims, demands, causes of action or proceedings arising from any breach of this Agreement by 
you.  
8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR 
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, 
CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, 
HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE 
DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS 
REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, 
BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE 
(INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, 
DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND 
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH 
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY FAILURE 
OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.  
9. Should any provision of this Agreement be held by a court of competent jurisdiction to 
be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly 
as possible the same economic effect as the original provision, and the legality, validity and 
enforceability of the remaining provisions of this Agreement shall not be affected or impaired 
thereby.  
10. The failure of either party to enforce any term or condition of this Agreement shall 
not constitute a waiver of either party's right to enforce each and every term and condition of this 
Agreement. No breach under this agreement shall be deemed waived or excused by either party 
unless such waiver or consent is in writing signed by the party granting such waiver or consent. 
The waiver by or consent of a party to a breach of any provision of this Agreement shall not 
operate or be construed as a waiver of or consent to any other or subsequent breach by such other 
party.  
11. This Agreement may not be assigned (including by operation of law or otherwise) by 
you without WILEY's prior written consent.  
12. Any fee required for this permission shall be non-refundable after thirty (30) days 
from receipt  
13. These terms and conditions together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between you and WILEY 
concerning this licensing transaction and (in the absence of fraud) supersedes all prior 
agreements and representations of the parties, oral or written. This Agreement may not be 
amended except in writing signed by both parties. This Agreement shall be binding upon and 
inure to the benefit of the parties' successors, legal representatives, and authorized assigns.  
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14. In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC's Billing and Payment terms and conditions, these 
terms and conditions shall prevail.  
15. WILEY expressly reserves all rights not specifically granted in the combination of (i) 
the license details provided by you and accepted in the course of this licensing transaction, (ii) 
these terms and conditions and (iii) CCC's Billing and Payment terms and conditions.  
16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor 
Type was misrepresented during the licensing process.  
17. This Agreement shall be governed by and construed in accordance with the laws of 
the State of New York, USA, without regards to such state's conflict of law rules. Any legal 
action, suit or proceeding arising out of or relating to these Terms and Conditions or the breach 
thereof shall be instituted in a court of competent jurisdiction in New York County in the State of 
New York in the United States of America and each party hereby consents and submits to the 
personal jurisdiction of such court, waives any objection to venue in such court and consents to 
service of process by registered or certified mail, return receipt requested, at the last known 
address of such party.  
Wiley Open Access Terms and Conditions  
Wiley publishes Open Access articles in both its Wiley Open Access Journals program 
[http://www.wileyopenaccess.com/view/index.html] and as Online Open articles in its 
subscription journals. The majority of Wiley Open Access Journals have adopted the Creative 
Commons Attribution License (CC BY) which permits the unrestricted use, distribution, 
reproduction, adaptation and commercial exploitation of the article in any medium. No 
permission is required to use the article in this way provided that the article is properly cited and 
other license terms are observed. A small number of Wiley Open Access journals have retained 
the Creative Commons Attribution Non Commercial License (CC BY-NC), which permits use, 
distribution and reproduction in any medium, provided the original work is properly cited and is 
not used for commercial purposes.  
Online Open articles - Authors selecting Online Open are, unless particular exceptions 
apply, offered a choice of Creative Commons licenses. They may therefore select from the CC 
BY, the CC BY-NC and the Attribution-NoDerivatives (CC BY-NC-ND). The CC BY-NC-ND 
is more restrictive than the CC BY-NC as it does not permit adaptations or modifications without 
rights holder consent.  
Wiley Open Access articles are protected by copyright and are posted to repositories and 
websites in accordance with the terms of the applicable Creative Commons license referenced on 
the article. At the time of deposit, Wiley Open Access articles include all changes made during 
peer review, copyediting, and publishing. Repositories and websites that host the article are 
responsible for incorporating any publisher-supplied amendments or retractions issued 
subsequently.  
Wiley Open Access articles are also available without charge on Wiley's publishing 
platform, Wiley Online Library or any successor sites.  
Conditions applicable to all Wiley Open Access articles:  
 The authors' moral rights must not be compromised. These rights include the right 
of "paternity" (also known as "attribution" - the right for the author to be 
identified as such) and "integrity" (the right for the author not to have the work 
altered in such a way that the author's reputation or integrity may be damaged).  
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 Where content in the article is identified as belonging to a third party, it is the 
obligation of the user to ensure that any reuse complies with the copyright 
policies of the owner of that content.  
 If article content is copied, downloaded or otherwise reused for research and other 
purposes as permitted, a link to the appropriate bibliographic citation (authors, 
journal, article title, volume, issue, page numbers, DOI and the link to the 
definitive published version on Wiley Online Library) should be maintained. 
Copyright notices and disclaimers must not be deleted. Creative Commons 
licenses are copyright licenses and do not confer any other rights, including but 
not limited to trademark or patent rights.  
 Any translations, for which a prior translation agreement with Wiley has not been 
agreed, must prominently display the statement: "This is an unofficial translation 
of an article that appeared in a Wiley publication. The publisher has not endorsed 
this translation."  
Conditions applicable to non-commercial licenses (CC BY-NC and CC BY-NC-ND)  
For non-commercial and non-promotional purposes individual non-commercial users 
may access, download, copy, display and redistribute to colleagues Wiley Open Access articles. 
In addition, articles adopting the CC BY-NC may be adapted, translated, and text- and data-
mined subject to the conditions above.  
Use by commercial "for-profit" organizations  
 Use of non-commercial Wiley Open Access articles for commercial, promotional, 
or marketing purposes requires further explicit permission from Wiley and will be 
subject to a fee. Commercial purposes include: 
 Copying or downloading of articles, or linking to such articles for further 
redistribution, sale or licensing; 
 Copying, downloading or posting by a site or service that incorporates advertising 
with such content;  
 The inclusion or incorporation of article content in other works or services (other 
than normal quotations with an appropriate citation) that is then available for sale 
or licensing, for a fee (for example, a compilation produced for marketing 
purposes, inclusion in a sales pack)  
 Use of article content (other than normal quotations with appropriate citation) by 
for-profit organizations for promotional purposes  
 Linking to article content in e-mails redistributed for promotional, marketing or 
educational purposes;  
 Use for the purposes of monetary reward by means of sale, resale, license, loan, 
transfer or other form of commercial exploitation such as marketing products 
 Print reprints of Wiley Open Access articles can be purchased from: 
corporatesales@wiley.com  
The modification or adaptation for any purpose of an article referencing the CC BY-NC-
ND License requires consent which can be requested from RightsLink@wiley.com .  
Other Terms and Conditions:  
BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE THAT YOU 
HAVE READ AND FULLY UNDERSTAND EACH OF THE SECTIONS OF AND 
PROVISIONS SET FORTH IN THIS AGREEMENT AND THAT YOU ARE IN 
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AGREEMENT WITH AND ARE WILLING TO ACCEPT ALL OF YOUR OBLIGATIONS 
AS SET FORTH IN THIS AGREEMENT.  
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Springer Science + Business Media 
Introduction  
The publisher for this copyrighted material is Springer Science + Business Media. By 
clicking "accept" in connection with completing this licensing transaction, you agree that the 
following terms and conditions apply to this transaction (along with the Billing and Payment 
terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that 
you opened your Rightslink account and that are available at any time at 
http://myaccount.copyright.com).  
Limited License  
With reference to your request to reprint in your thesis material on which Springer 
Science and Business Media control the copyright, permission is granted, free of charge, for the 
use indicated in your enquiry.  
Licenses are for one-time use only with a maximum distribution equal to the number that 
you identified in the licensing process.  
This License includes use in an electronic form, provided its password protected or on the 
university’s intranet or repository, including UMI (according to the definition at the Sherpa 
website: http://www.sherpa.ac.uk/romeo/). For any other electronic use, please contact Springer 
at (permissions.dordrecht@springer.com or permissions.heidelberg@springer.com).  
The material can only be used for the purpose of defending your thesis, and with a 
maximum of 100 extra copies in paper.  
Although Springer holds copyright to the material and is entitled to negotiate on rights, 
this license is only valid, subject to a courtesy information to the author (address is given with 
the article/chapter) and provided it concerns original material which does not carry references to 
other sources (if material in question appears with credit to another source, authorization from 
that source is required as well).  
Permission free of charge on this occasion does not prejudice any rights we might have to 
charge for reproduction of our copyrighted material in the future.  
Altering/Modifying Material: Not Permitted  
You may not alter or modify the material in any manner. Abbreviations, additions, 
deletions and/or any other alterations shall be made only with prior written authorization of the 
author(s) and/or Springer Science + Business Media. (Please contact Springer at 
(permissions.dordrecht@springer.com or permissions.heidelberg@springer.com)  
Reservation of Rights  
Springer Science + Business Media reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of this licensing 
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and 
conditions.  
Copyright Notice:Disclaimer  
You must include the following copyright and permission notice in connection with any 
reproduction of the licensed material: "Springer and the original publisher /journal title, volume, 
year of publication, page, chapter/article title, name(s) of author(s), figure number(s), original 
copyright notice) is given to the publication in which the material was originally published, by 
adding; with kind permission from Springer Science and Business Media"  
Warranties: None  
  256 
Example 1: Springer Science + Business Media makes no representations or warranties 
with respect to the licensed material.  
Example 2: Springer Science + Business Media makes no representations or warranties 
with respect to the licensed material and adopts on its own behalf the limitations and disclaimers 
established by CCC on its behalf in its Billing and Payment terms and conditions for this 
licensing transaction.  
Indemnity  
You hereby indemnify and agree to hold harmless Springer Science + Business Media 
and CCC, and their respective officers, directors, employees and agents, from and against any 
and all claims arising out of your use of the licensed material other than as specifically 
authorized pursuant to this license.  
No Transfer of License  
This license is personal to you and may not be sublicensed, assigned, or transferred by 
you to any other person without Springer Science + Business Media's written permission. No 
Amendment Except in Writing This license may not be amended except in a writing signed by 
both parties (or, in the case of Springer Science + Business Media, by CCC on Springer Science 
+ Business Media's behalf).  
Objection to Contrary Terms  
Springer Science + Business Media hereby objects to any terms contained in any 
purchase order, acknowledgment, check endorsement or other writing prepared by you, which 
terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and 
conditions. These terms and conditions, together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein), comprise the entire agreement between you and 
Springer Science + Business Media (and CCC) concerning this licensing transaction. In the event 
of any conflict between your obligations established by these terms and conditions and those 
established by CCC's Billing and Payment terms and conditions, these terms and conditions shall 
control.  
Jurisdiction  
All disputes that may arise in connection with this present License, or the breach thereof, 
shall be settled exclusively by arbitration, to be held in The Netherlands, in accordance with 
Dutch law, and to be conducted under the Rules of the 'Netherlands Arbitrage Instituut' 
(Netherlands Institute of Arbitration).OR:  
All disputes that may arise in connection with this present License, or the breach thereof, 
shall be settled exclusively by arbitration, to be held in the Federal Republic of Germany, in 
accordance with German law.  
Other terms and conditions:  
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